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Abstract 
Oestrogen plays a major role in the development and progression of oestrogen 
receptor-positive breast cancers. Previously, a set of nineteen oestrogen-regulated 
genes was identified in oestrogen-responsive breast cancer cells. Seventeen were 
upregulated and two were downregulated. Oestrogen altered the expression of 
genes that encode proteins involved in the regulation of ion transport. SLC12A2 
encodes NKCC1, a Na+-K+-Cl- co-transporter. PDZK1 encodes the scaffolding 
protein NHERF3 and SCNNIB encodes the β-subunit of the epithelial Na+ channel 
(ENaC). Expression of the oestrogen-regulated gene SLC12A2 decreased whilst 
PDZK1 and SCNNIB expression increased.   
The purpose of this study is to investigate the oestrogen regulation of NKCC1, 
NHERF3 and ENaC-β protein expression in oestrogen-responsive breast cancer 
cells by western transfer analysis. NKCC1 expression decreased whereas the 
expression of NHERF3 and ENaC-β increased in response to oestrogen in all three 
cell lines MCF-7, EFM-19 and EFF-3. Immunofluorescence data confirmed the 
localisation of NKCC1 to the cell membrane. NHERF3 and ENaC-β were located 
mainly in the cytoplasm and there was evidence for vesicular localisation.  
Functional activity of NKCC1, assessed by 86Rb+ (K+) influx, revealed low activity of 
NKCC1 which was then enhanced by hypertonicity. NKCC1 activity was decreased 
more by oestrogen treatment in EFM-19 cells than in MCF-7. Intracellular pH was 
measured with a pH-sensitive dye BCECF-AM to evaluate Na+/H+ exchange. 
Oestrogen increased the capacity of EFM-19 cells to regulate pHi.    
The oestrogenic and anti-oestrogenic effects of several anti-oestrogens were 
assessed. Notably, bazedoxifene was agonistic for NKCC1 expression. Tamoxifen, 
4-hydroxytamoxifen, toremifene and lasofoxifene were partially agonistic for 
NHERF3. The antagonistic activities of the anti-oestrogens were more complex and 
varied between cell lines for all three proteins. Fulvestrant was unable to reverse 
the oestrogen-induced expression of ENaC-β.      
In conclusion, this study confirmed that oestrogen alters the expression and activity 
of proteins involved in ion transport. Modification of this cell phenotype may favour 
breast cancer progression. 
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Chapter 1.    Introduction 
 
1.1 Breast Cancer 
1.1.1 Normal breast structure 
The human breast contains epithelial ducts and lobules. The lobules are the 
glands that produce breast milk and the ducts carry the milk produced by the 
lobules to the nipple. A network of small ducts connects to larger ducts which 
then join to one main duct that transports milk to the nipple. The lobules and 
ducts of the breast are surrounded by stroma consisting of adipose tissue, 
fibrous connective tissue, lymphatics and blood capillaries. The ducts and 
lobules are lined by two cell layers of epithelium: the inner layer of ductal or 
lobular epithelial cells and the non-continuous outer layer of myoepithelial cells. 
These epithelia are supported by a basement membrane, hence separating 
them from the surrounding stroma (Figure 1.1). The epithelial cells of ducts and 
lobules within the breast are responsive to circulating hormones such as 
oestrogen. Breasts undergo structural changes during puberty and further 
development occurs during pregnancy and lactation.  
 
Figure 1.1 Components of normal breast tissue. The lobular and ductal epithelia along with 
the myoepithelial cells are supported by a basement membrane. The surrounding stroma 
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consists of capillaries, fibroblasts and extracellular matrix (ECM). Figure taken from (Kalluri and 
Zeisberg, 2006). 
1.1.2 Breast cancer - Incidence and mortality 
Breast cancer is the most common cancer in females in the UK, accounting for 
about 30% of all cases diagnosed. In women, the lifetime risk of developing 
breast cancer is 1 in 8 (Sasieni et al., 2011). Approximately 49,900 females and 
350 males were diagnosed with breast cancer in the UK in 2011 (Cancer 
Statistics, CRUK, 2014). The incidence rates of breast cancer in females in the 
UK continue to rise. This increase could possibly be due to early detection 
through current effective breast screening and awareness programmes running 
across the UK.         
In 2012, over 522,000 women died from breast cancer worldwide. Currently, 
breast cancer is the second leading cause of death from cancer in females after 
lung cancer, and accounts for 15% of cancer-related deaths (Figure 1.2). In the 
UK, almost 11,600 women and 75 men died from breast cancer in 2012 
(Cancer Statistics, CRUK, 2014). The mortality rates have dropped markedly 
due to improvements in diagnosis and treatment. The survival rates have been 
increasing and presently more than 8 in 10 women survive breast cancer 
beyond 5 years.  
 
Figure 1.2 Most common causes of cancer death. Lung cancer, followed by breast and 
bowel cancers are the main causes of female cancer-related mortality. Figure obtained from 
(Cancer Statistics, CRUK, 2014). 
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1.1.3 Breast cancer - Risk factors 
Several key risk factors have been associated with increased probability of 
developing breast cancer. The details of these risk factors are outlined in the 
following sub-sections.   
1.1.3.1 Gender 
The highest risk factor for developing breast cancer is being female. Worldwide 
about 1.7 million women were diagnosed with breast cancer in year 2012 
(GLOBOCAN, 2012). Men have about a 100-fold decreased risk of developing 
breast cancer than females. In 2011, the incidence rates for males were less 
than 1% of all breast cancer cases reported.   
1.1.3.2 Age 
Age is one of the stronger risk factors. The likelihood of being diagnosed with 
breast cancer increases with age in both women and men. Women over the age 
of 50 are diagnosed most commonly, whereas most men are over the age of 75 
when diagnosed with breast cancer (Cancer Statistics, CRUK, 2014). Between 
year 2009 and 2011, over 80% of breast cancer cases arose in women over 50 
years of age (Figure 1.3A). For men approximately 36% of cases occurred over 
the age of 75 (Figure 1.3B). Females up to the ages of 20, 49 and 69 have an 
estimated risk of 1 in 2000, 1 in 50 and 1 in 13 respectively, of developing 
breast cancer.    
 
Figure 1.3 Age specific incidence for females and males in the UK. The risk of developing 
breast cancer increases with age and the majority is over the age of 50 and 75 for women and 
men, respectively. Figure obtained from (Cancer Statistics, CRUK, 2014).    
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1.1.3.3 Reproduction 
There are several reproductive factors that increase or decrease the chances of 
developing breast cancer. Child bearing and breast feeding lowers the risk 
whereas early age at menarche and late menopause tend to increase the risk. 
As the parity of a woman increases, there is a decrease in the probability of 
developing breast cancer. Breastfeeding is a well known protective factor, and 
is shown to reduce the risk by 4.3% if a child is breastfed for at least 12 months 
(Parkin, 2011). Breast cancer incidence is more common in the developed 
world, than in developing countries. One of the possible explanations for this 
increase in risk is that women in developed countries have fewer children and 
breast feed for a shorter period of time compared to women in developing 
countries. Early menarche before the age of 12 years and late menopause on 
or after 50 years increase the risk, primarily due to the prolonged exposure to 
the actions of endogenous oestrogens (Pike et al., 1993). 
1.1.3.4 Hormones 
Exogenous hormonal factors such as oral contraceptive use and hormone 
replacement therapy have been associated with increased risk of breast cancer. 
Oral contraceptives usage and the development of breast cancer remain 
controversial. For current users of oral contraceptives, there is an increased risk 
compared to never-users, whilst the risk is reduced the longer the duration of 
discontinued use (CGHFBC, 1996). Studies have shown that the age at first 
oral contraceptive use is correlated positively with the age at diagnosis with 
breast cancer. This suggests that there is an increased risk of developing breast 
cancer earlier in life, if a female has started to use oral contraceptive at a 
younger age (Imkampe and Bates, 2012). Increased duration of hormone 
replacement therapy use seems to cause an increase in the risk of being 
diagnosed with breast cancer. Current users of combined oestrogen and 
progestin hormone replacement therapy have a greater risk than users of drugs 
consisting of oestrogen alone (Rossouw et al., 2002; Beral, 2003).            
Higher levels of endogenous hormones such as oestrogen and progesterone 
may also play a role in increasing breast cancer risk. Although pre-menopausal 
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women with high concentrations of circulating oestrogen do not show an 
association with increased risk, post-menopausal women with high oestrogens 
levels have a 2-3 times higher risk of developing breast cancer than those with 
low levels of endogenous oestrogen (Key et al., 2002; Walker et al., 2011). The 
development of oestrogen receptor-α positive (ERα+) tumours have been 
associated with exposure to other circulating hormones such as insulin. Insulin-
like growth factor 1 (IGF-1) and insulin have been implicated with the 
development of breast cancer in pre-menopausal and post-menopausal women. 
Also obesity and type 2 diabetes mellitus have been correlated with an increase 
in breast cancer risk. Higher circulating levels of insulin increases the risk of 
developing breast cancer in obese women with diabetes (Gunter et al., 2009; 
Liao et al., 2011).     
1.1.3.5 Hereditary factors and family history 
Hereditary factors contribute to a small proportion of breast cancer; the vast 
majority of breast cancers arise sporadically. Hereditary mutations account for 
about 5-10% of all cancer cases reported (Deng, 2006). Mutations in hereditary 
tumour suppressor genes BRCA1 and BRCA2 are implicated as breast cancer 
causative genes and contribute to an increase in risk of developing breast 
cancer. BRCA1 and BRCA2 are involved in homologous recombination and 
DNA double strand break repair. Women carrying a germ-line mutation in either 
BRCA1 or BRCA2 genes have a 45% to 65% risk of developing breast cancer 
by the age of 70 (Antoniou et al., 2003). The presence of mutations in other 
genes such as p53, ATM and PTEN confers an increase in breast cancer risk 
(Elledge and Allred, 1998; Inskip et al., 1999).  
Genome wide association studies (GWAS) have led to the discovery of low 
penetrance alleles that contribute to the familial risk of breast cancer. Several 
studies have reported the identification of new breast cancer susceptibility loci 
that were associated significantly with breast cancer risk (Easton et al., 2007; 
Hunter et al., 2007; Stacey et al., 2007). These susceptibility loci are single 
nucleotide polymorphisms (SNPs) within FGFR2, TNRC9, CASC8, CASC16, 
CASC21 and LSP1. The genes have two alleles with SNPs, one of which is a 
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high-risk allele and the other a low-risk allele. The SNPs in intron 2 of the 
FGFR2 gene were the most significantly associated with risk. The FGFR2 gene 
encodes a receptor tyrosine kinase that belongs to the Fibroblast Growth Factor 
Receptor family. The relative-risk per allele is 1.26 and 1.20 for FGFR2 and 
TNRC9, respectively (Easton et al., 2007). The FGFR2 SNPs were associated 
only with oestrogen receptor positive cancers, whereas TNRC9 was observed 
to be associated with both oestrogen receptor positive and oestrogen receptor 
negative tumours. More recently, another 78 loci have been discovered through 
GWAS. Most of these loci were associated with risk of oestrogen receptor 
positive tumours. In contrast, TERT, RALY, MDM4, LGR6 and FTO were largely 
associated with risk of oestrogen receptor negative tumours (Haiman et al., 
2011; Siddiq et al., 2012; Couch et al., 2013; Garcia-Closas et al., 2013). 
BABAM1 and ANKLE1 were more commonly associated with risk of triple 
negative breast cancers (Antoniou et al., 2010). Ghoussaini et al. (2012) 
identified three new susceptibility loci at 12p11, 12q24 and 21q21 which were 
associated with breast cancer risk. The 12p11 and 12q24 loci contained the 
genes PTHLH and TBX3, respectively, both of which are known to play a role in 
the development of mammary glands (Wysolmerski and Stewart, 1998; 
Davenport et al., 2003). The 21q21 locus was closest to the gene NRIP1 which 
acts as a repressor of ERα activity and inhibits cell growth. 
Familial breast cancer is another important factor, as the risk doubles if there is 
one first-degree relative such as mother or sister who is affected by breast 
cancer. In women, with an affected first-degree relative the breast cancer 
incidence rate is 5.5%, whereas if there are two or more first-degree relatives 
affected the incidence rate increases to 13.3% (CGHFBC, 2001).   
1.1.3.6 Lifestyle  
Diet, smoking, alcohol consumption, exercise and obesity are included in this 
broad category of lifestyle factors. They are considered potentially avoidable 
risk factors. The consumption of alcohol and smoking increases the risk of 
developing breast cancer. In comparison to women who do not smoke, cigarette 
smoking women conveys a 10-20% increased risk (Xue et al., 2011). Alcohol 
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consumption is associated with approximately 6% of breast cancers in women 
in the UK. The risk of breast cancer has been shown to increase by 12% for 
every additional 10 g increase in the daily intake of alcohol (Allen et al., 2009). 
Despite inadequate evidence, some studies suggest a direct link between 
dietary saturated fat intake and breast cancer (Boyd et al., 2003; Sieri et al., 
2008). Another risk factor for developing breast cancer is obesity. In overweight 
and obese post-menopausal women the risk is estimated to increase by 10-20% 
and 30%, respectively (Parkin and Boyd, 2011). This increase in risk is 
correlated directly to increased synthesis of oestrogen in excess adipose tissue 
(Lorincz and Sukumar, 2006). Other harmful factors contributing to an increase 
in breast cancer risk include exposure to mutagenic agents such as ionising 
radiation. In the UK, approximately 1% of breast cancers occur due to exposure 
to x-rays or gamma radiation (Parkin and Darby, 2011). Carcinogenic ionising 
radiation causes damage to DNA which may be repaired aberrantly leading to 
mutations that predispose to increased risk of breast cancer.   
Other factors such as appropriately controlled diet and exercise are beneficial, 
and may reduce an individual’s risk of breast cancer. Post-menopausal women 
who tend to be more physically active have a reduction in breast cancer risk by 
15-20% (Monninkhof et al., 2007). This decrease in risk may be associated to 
active post-menopausal women having lower concentrations of circulating 
hormones such as oestrogen in blood, than the less active post-menopausal 
women.    
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1.1.4 Breast cancer - Types 
Breast cancer is broadly categorised into two main groups according to its 
histological appearance and invasion of the stroma. Invasive carcinoma and 
non-invasive carcinoma are these two main groups (Fabbri, 2008). 
Adenocarcinomas of the breast cancer arise from epithelial cells lining the ducts 
or lobules within the breast.  
Invasive or infiltrating carcinomas are malignant tumours that have the ability to 
break through the myoepithelial cell layer, and invade into the surrounding 
tissue. Such invasive adenocarcinomas are either invasive ductal (IDC) which is 
the most common type of breast cancer, or invasive lobular (ILC) which 
comprises about 15% of all breast cancers (Kumar V, 2004). Invasive 
carcinomas have the potential to metastasise through the blood circulation and 
lymphatic system, into other parts of the body. IDC of no special type (IDC NST), 
also known as IDC not otherwise specified (IDC NOS) accounts for the majority 
of 80% of breast carcinomas diagnosed.  
Non-invasive or carcinoma in-situ stay in the place of origin and do not invade 
into adjacent tissue stroma. These carcinomas include ductal carcinoma in situ 
(DCIS) or lobular carcinomas in situ (LCIS) (Kumar V, 2004; Fabbri, 2008). In-
situ carcinomas do not infiltrate into surrounding breast tissue and instead 
remain within an intact myoepithelial cell layer. Because both DCIS and LCIS 
do not have the capacity to break through the myoepithelium they do not 
metastasise into other parts of the body.  
 
1.1.5 Breast cancer - Classification 
1.1.5.1 Molecular classification 
In addition to the aforementioned histological classification, breast tumours are 
further classified according to their molecular receptor expression. Breast 
cancer cells can express the oestrogen receptor (ER), the progesterone 
receptor (PgR) and the human epidermal growth factor receptor 2 (EGFR2, 
HER2 or neu). 
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Tumours that express the oestrogen receptor-α are referred to as “oestrogen 
receptor-α-positive” or ERα+, whereas breast cancers that express 
progesterone receptor are identified as “progesterone receptor-positive” or 
PgR+. Tumours which overexpress HER2 are termed “HER2-positive”. 
Additionally tumours that do not express any of these three receptors are known 
as “triple-negative” breast cancers. 
Breast cancer is widely considered as a highly heterogeneous disease. 
Therefore more recently, extensive molecular and genetic profiling had been 
investigated to determine detailed analysis of prognosis and to predict response 
to treatments. Analyses of gene expression arrays have identified five distinct 
molecular subtypes of breast cancer (Perou et al., 2000; Sorlie et al., 2003).  
These subdivisions include luminal A, luminal B, HER2 enriched, basal-like and 
normal-like tumours. The luminal A subtype express ER and have a low 
proliferation rate, whilst luminal B subtype also express the ER, but have higher 
rate of proliferation. Luminal A has a better prognosis than luminal B. The HER2 
enriched breast cancers have HER2 gene amplification and overexpress HER2, 
but test negative for ER and PgR. Basal-like tumours are triple-negative and do 
not express ER, PgR or HER2. Such cancers are highly proliferative and have 
worst prognosis. The normal-like breast cancers often relate to gene clusters of 
normal breast cells. These normal-like tumours express genes that are 
distinctive of basal epithelial cells. 
A recent study based on integrated analysis of genome and transcriptome data 
has led to the identification of ten novel molecular subtypes of breast cancer 
(Curtis et al., 2012). In this study, 2000 breast tumours were analysed by joint 
clustering of data from gene expression and copy number data. The 10 
subgroups were categorised as Integrative Cluster (IntClust) 1-10. The IntClust 
2 subtype are high risk oestrogen receptor positive breast cancers that have 
amplifications of known driver genes such as CCND1 and EMSY. The IntClust 3 
and IntClust 4 subgroups generally had tumours with good prognosis. The 
IntClust 3 comprised oestrogen receptor positive cases, whilst IntClust 4 had 
both oestrogen receptor positive and oestrogen receptor negative cases. The 
IntClust 4 subgroup was also called the “CNA-devoid” subgroup, due to the lack 
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of copy number aberrations. IntClust 1, 6, and 9 consisted mostly of oestrogen 
receptor positive tumours with intermediate prognosis. Moreover, the IntClust 
10 subgroup comprised basal-like tumours, whereas the IntClust 5 consisted of 
HER2-enriched breast tumours. Each of the subtypes are associated with 
different prognosis and are proposed to require different therapeutic strategies.   
The cancer genome atlas (TCGA) network has analysed tumour and germline 
DNA samples from 825 patients, and combined data from different platforms. 
The platforms included exome sequencing, mRNA arrays, microRNA, DNA 
methylation, protein expression and copy number variant arrays (Cancer 
Genome Atlas, 2012). Four main classes of breast cancer were identified with a 
high degree of heterogeneity within each of the classes. The four groups were 
luminal A, luminal B, HER2 enriched and basal-like. The genes TP53, PIK3CA 
and GATA3 were mutated in 37 %, 36 % and 11 % of breast tumours, 
respectively. Mutations were more prevalent in luminal A and luminal B tumours 
than in HER2-enriched and basal-like groups. PIK3CA gene was mutated in 45 % 
of luminal A tumours and 29 % of luminal B tumours, making it one of the most 
frequently mutated genes in breast cancer. The TP53 gene was mutated in 12 % 
of luminal A and 29 % of luminal B tumours. The more frequently mutated 
genes were specific to the different subgroups. Mutations in the TP53 gene was 
observed in 72 % of HER2-enriched cases and in 80 % of basal-like tumours. 
MAP3K1 and MAP2K4 genes which encode proteins belonging to the 
serine/threonine kinase family, were amongst the more frequently mutated 
genes, particularly specific to luminal tumours. Additionally the TCGA identified 
several novel genes which were mutated significantly in the breast tumours 
analysed. The genes include RUNX1, PTPN22, NF1, CCND3, AFF2 and TBX3 
to name a few (Cancer Genome Atlas, 2012). 
1.1.5.2 TNM stage 
Clinical staging of breast cancer is based upon the tumour size (T), the spread 
to lymph nodes (N) and the presence of distant metastasis (M). This staging 
system is called the Tumour, lymph Node and Metastases (TNM) staging 
(Edge, 2010). This TNM staging system guides the clinician through 
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classification of the breast tumour to determine the best treatment options for 
individuals.  
 The T (tumour) stage 
This T staging system is grouped into six main categories: TX, T0, T1, T2, T3 
and T4. The inability to assess the primary tumour is specified by the TX 
notation. If there is no evidence of a primary tumour it is designated as T0. 
Additionally, T1 classifies, breast tumours that are less than 2 cm in size and 
includes further subdivisions T1mi, T1a, T1b and T1c. T1mi signifies a tumour 
less than 0.1 cm, whilst T1a and T1b tumours are larger than 0.1 cm and 0.5 
cm, respectively. T1c tumours are larger than 1 cm but smaller than 2 cm. 
Tumours larger than 2 cm but no more than 5 cm across are grouped as T2, 
whereas T3 cancers are more than 5 cm across in their greatest dimension. 
Any tumours that have spread directly to the chest wall or into the skin are 
designated as T4.      
 The N (nodes) stage  
The nodal stage assesses whether the tumour has extended to the lymph 
nodes and is classified into five groups namely, NX, N0, N1, N2 and N3 (Edge, 
2010). In the case where lymph nodes have been removed previously or are 
inaccessible, the cancer is specified as NX. N0 stands for cancers that have not 
spread to any lymph nodes nearby. The presence of cancerous cells in 1-3 
axillary nodes of the underarm or in the internal mammary lymph nodes are 
indicated as N1. N2 signifies that the tumours have spread to one or more 
mammary lymph nodes and to at least 4-9 lymph nodes in the underarm. N2 
has two subdivisions, in which N2a denotes tumours present in the axillary 
lymph nodes which are attached to surrounding tissues. N2b stands for any 
cancer cells that are not present in the axillary lymph nodes, but present in the 
internal mammary lymph nodes behind the sternum. N3 consists of three 
subgroups namely; N3a, N3b and N3c. tumours that are classified as N3a have 
either spread to 10 or more axillary lymph nodes and also to the infraclavicular 
lymph nodes beneath the collar bone. Cancerous cells present in both internal 
mammary lymph nodes and axillary lymph nodes are categorised as N3b. in 
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contrast to N3a, any tumour metastasis detected in the supraclavicular lymph 
nodes above the collar bone are referred to as N3c. 
 The M (metastasis) stage 
This stage is the simplest to classify as it contains only two groups: M0 and M1. 
No distant metastasis exhibited by clinical or radiographic signs are indicated as 
M0. If any distant metastasis that is metastases in other parts of the body other 
than the breast and surrounding lymph nodes is observed, then the tumour is 
designated as M1 (Edge, 2010).  
 
1.1.6 Breast cancer - Therapy 
Patients with breast cancer are treated dependent upon the clinical stage and 
prognosis of their breast cancer type. The choice of treatment depends also on 
the receptor status of the cancer cells, that is whether they express any of the 
following receptors: ER, PgR or HER2/neu. Treatment of breast cancer consists 
of a single or combination of treatment procedures. 
1.1.6.1 Surgical treatment 
Surgical resection is still the most widely used mode of treatment. Several 
pathological factors including size and grade of tumour, involvement of the 
lymph nodes and invasion to lymphatics, are taken into account when making a 
decision about surgical treatment. Surgery may involve complete removal of the 
breast in which case it is termed “total mastectomy”, or breast conserving 
surgeries such as removal of small tumour lumps and parts of the breast where 
the procedure is known as “lumpectomy” or “wide local excision” (Sabel, 2009). 
Depending on the degree of invasiveness and metastasis of the tumour, lymph 
nodes may also be removed surgically. Patients may be treated with 
neoadjuvant therapies such as radiation therapy and chemotherapy, prior to 
surgical resection. These neoadjuvant therapies will aid in the shrinkage of the 
tumour and potentially allow for breast conservation surgery.     
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1.1.6.2 Radiotherapy 
Following breast conservation surgery, patients are often treated with radiation 
therapy. Radiotherapy involves the use of radiation such as X-rays to kill tumour 
cells, in residual breast tissue (Lin and Tripuraneni, 2011). Irradiation is usually 
used as an adjuvant therapy, which refers to any treatment administered post-
operatively. Radiotherapy is also used to successfully prevent or treat tumour 
metastases. A recent report highlighted that post-surgical radiation therapy 
reduces greatly the risk of disease recurrence (Early Breast Cancer Trialists' 
Collaborative et al., 2011a).  
1.1.6.3 Chemotherapy 
Chemotherapy is the use of cytotoxic drugs to kill or prevent the growth and 
division of cancer cells. Chemotherapeutic agents are used as neoadjuvant and 
adjuvant breast cancer treatments. Neoadjuvant chemotherapy may induce 
tumour shrinkage, prior to surgery. Cyclophosphamide, epirubicin and 
doxorubicin are examples of chemotherapeutic drugs, which target and destroy 
fast replicating cancer cells (Tabuchi et al., 2009). These drugs induce DNA 
damage by intercalating with DNA. Other agents such as docetaxel and 
paclitaxel inhibit polymerisation of microtubules, thus preventing cell division. 
They then promote apoptosis. Chemotherapy has potential adverse effects, as 
it does not only target fast-growing cancer cells, but also fast-growing normal 
cells. The resulting side effects are fatigue, hair loss and nausea.               
1.1.6.4 Endocrine therapy 
Hormones such as oestrogen are responsible for both the pathogenesis and the 
progression of breast cancer. Another form of systemic therapy in addition to 
chemotherapy is endocrine therapy. Breast cancers that express the oestrogen 
receptor and/or progesterone receptor are treated with endocrine receptor-
based therapy. Endocrine therapy is considered the most effective form of 
systemic treatment and has led to improvements in patient recovery from breast 
cancer (Pritchard, 2005). Hormonal therapy includes potential 
chemopreventative agents that either inhibit the production of oestrogens or 
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block the functional oestrogen receptor. Anti-oestrogenic drugs such as 
tamoxifen and fulvestrant have been administered widely to patients with 
oestrogen receptor-positive tumours mainly due to their specificity of action.     
Tamoxifen 
Anti-oestrogens such as tamoxifen target and compete with oestrogen and 
block their mode of action, thus inhibiting oestrogen receptor activity. Because 
oestrogen induces the expression of genes that promote cell growth and 
proliferation, tamoxifen treatment thereby, leads to an arrest of cell proliferation. 
The cell cycle is blocked at the G1 phase, in cells treated with tamoxifen (Dalvai 
and Bystricky, 2010). 
Adjuvant treatment with tamoxifen for 5-years reduces the relative risk of 
recurrence and prolongs the disease-free survival particularly in pre-
menopausal women with ER-positive breast cancer (Early Breast Cancer 
Trialists' Collaborative, 2001). However, the extensive use of tamoxifen has 
both its advantages and disadvantages. Tamoxifen has oestrogenic actions on 
bones, which is advantageous because it prevents osteoporosis. Conversely, 
the use of tamoxifen causes side effects such as fatigue, hot flushes, sweating 
and lowering of serum cholesterol levels. Other disadvantages include the 
increased risk of developing endometrial cancer because tamoxifen has partial 
agonist activity in the endometrium. Tamoxifen has been in use for the past 4 
decades. Alternative drugs that have greater anti-oestrogenic effects on 
tumours than tamoxifen have been developed. Hormonal treatment agents that 
do not cross the blood brain barrier, hence proven not to induce hot flushes 
were established (O'Regan and Jordan, 2001).   
4-hydroxytamoxifen 
4-hydroxytamoxifen is one of the active metabolites of tamoxifen. It has a 25-
100 fold stronger binding affinity for ER than tamoxifen (Favoni and de Cupis, 
1998). The binding affinity of 4-hydroxytamoxifen to ER is similar to that of 17β-
oestradiol.  
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Fulvestrant 
A more selective anti-oestrogen is fulvestrant also known as ICI 182,780 or 
Faslodex. It is a pure anti-oestrogen and does not induce any oestrogen-like 
activity in the uterus or in bones (Platet et al., 2004). Fulvestrant is a steroidal 
anti-oestrogen and as shown in Figure 1.4, its structure is quite similar to that of 
17β-oestradiol, apart from the additional long-chain alkyl moiety at the 7-alpha 
position. Fulvestrant has an ER binding affinity which is about 100 times more 
than that of tamoxifen (Howell et al., 2004). Its mechanism of action involves 
rapid degradation of the ER and it has been termed a selective oestrogen 
receptor downregulator (SERD). It has minimal side effects, but has been 
shown to be effective treatment for prevention of breast cancer recurrence. In 
comparison to tamoxifen, fulvestrant does not cross the blood brain barrier 
hence does not induce hot flushes. 
Raloxifene 
Raloxifene is a benzothiophene that causes blockage of the ER. It is a second 
generation selective oestrogen receptor modulator (SERM). Raloxifene exerts 
anti-oestrogenic effects on breast tissue and displays weak antagonism in the 
endometrium. Similar to tamoxifen, raloxifene is capable of preventing 
osteoporosis, as it increases the density of bones (Ettinger et al., 1999).  
Bazedoxifene 
Another anti-oestrogen bazedoxifene belongs to the 3rd generation of partial 
anti-oestrogens and was developed using raloxifene as a template. The 
chemical structures of raloxifene and bazedoxifene are quite similar. The 
benzothiophene group (C8H6S) of raloxifene highlighted in green in Figure 1.4, 
is substituted with an indole ring (C8H7N). Bazedoxifene inhibits growth and 
proliferation of oestrogen-stimulated breast cancer cells MCF-7 and T47D 
(Komm et al., 2005; Lewis-Wambi et al., 2011). Bazedoxifene also increases 
the degradation of ER in MCF-7 cells. Bazedoxifene is a ‘raloxifene-like’ drug 
and has been shown to increase bone density (Miller et al., 2008). 
Bazedoxifene is used widely in the clinic as a treatment and prevention of 
osteoporosis. Unlike other anti-oestrogens, bazedoxifene did not induce hot 
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flushes, and also showed beneficial antagonistic effects in ovarian, endometrial 
and breast tissue (Ronkin et al., 2005; Archer et al., 2009).   
Toremifene 
Toremifene is an analogue of tamoxifen, and is very similar in structure apart 
from the chlorine (Cl) atom at the 4th position (circled in red in Figure 1.4). The 
binding affinity of toremifene for the ER is also similar to tamoxifen. Toremifene 
inhibited the growth of oestrogen responsive cell lines and is currently used in 
the clinic as a treatment for advanced metastatic breast cancer (Robinson and 
Jordan, 1989; Pyrhonen et al., 1999). The agonist activity of toremifene on bone 
was similar to that of tamoxifen (Saarto et al., 2001).  
Lasofoxifene  
Lasofoxifene is a third generation anti-oestrogen used in the treatment of 
osteoporosis and vaginal atrophy. It exerts antagonistic effects in breast and 
uterine tissue (Rosati et al., 1998). Clinical studies have shown a 65-85% 
reduction in relative risk of developing breast cancer in patients to whom 
lasofoxifene was administered (Gennari et al., 2010). Compared to raloxifene, 
lasofoxifene exerts an additional benefit of decreasing the risk of coronary heart 
disease (Cummings et al., 2010). A substantial reduction in cholesterol levels 
contribute to this decrease in risk.    
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Figure 1.4 Chemical structures of oestrogen receptor ligands. The structure of oestradiol, 
tamoxifen, 4-hydroxytamoxifen, fulvestrant, bazedoxifene, toremifene, raloxifene and 
lasofoxifene are shown. Red circles highlight structural differences between tamoxifen and 
toremifene. Green circles highlight structural differences between raloxifene and bazedoxifene. 
Figure modified from (Burris et al., 2013).  
 
Another form of endocrine therapy is the use of steroidal and non-steroidal 
aromatase inhibitors. Aromatase also known as oestrogen synthase is the 
enzyme that converts androgens to oestrogens. Aromatase belongs to the 
cytochrome P450 superfamily and is expressed in many tissues, including 
ovaries, breast, liver, placenta and adipose tissue (Brueggemeier et al., 2005; 
Bhatnagar, 2007). High levels of aromatase are detected in endometrial and 
breast cancers. There are two types of aromatase inhibitors: steroidal and 
nonsteroidal (Lonning, 2011). The steroidal aromatase inhibitors bind to the 
aromatase enzyme irreversibly. In contrast, the nonsteroidal aromatase 
inhibitors bind to aromatase reversibly and are more potent than the steroidal 
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aromatase inhibitors (Miller and Dixon, 2000). Third generation steroidal 
aromatase inhibitor exemestane and non-steroidal aromatase inhibitors 
anastrozole and letrozole inhibit the enzyme aromatase and hence prevent the 
biosynthesis of oestrogen. This inhibition of aromatisation leads to a minimal 
production of oestrogen. Aromatase inhibitors are used as an adjuvant 
treatment for oestrogen receptor-positive breast cancers mainly in post-
menopausal women and have been reported to prevent reappearance of 
disease (Winer et al., 2005).  
1.1.6.5 Other targeted therapy 
Breast cancer is a highly heterogeneous disease and it is of vital importance to 
identify the receptor status of an individual’s cancer. There is a greater need to 
target cancer cells in a specific manner, without harming normal cells. One way 
this specificity can be achieved is by using molecular targeted therapy. Such 
targeted therapies could either be in the form of monoclonal antibodies or of 
tyrosine kinase inhibitors. Better systemic actions are provided for by these 
selective inhibitors as they have a precise and more efficient mode of action. 
These molecular targeted inhibitors tend to block growth and proliferation of 
cancer cells and prevent tumour cell metastasis.    
Endocrine therapy is administered to patients with ER and PgR expressive 
cancers, whereas HER2 over-expressive cancers are treated with trastuzumab 
(Herceptin) (Spector and Blackwell, 2009). Trastuzumab is a humanised 
monoclonal antibody against the HER2 receptor and is generally administered 
in combination with chemotherapy. Pertuzumab is another monoclonal antibody 
against the HER2 receptor that is used in the treatment of metastatic breast 
cancer (Perez and Spano, 2012). Selective inhibitors that target different 
members of the epidermal growth factor receptor family (EGFR) are lapatinib 
and gefitinib, both of which are tyrosine kinase inhibitors. 
Current research focus is on identifying other suitable targets. Other potential 
receptors that could be targeted include the vascular endothelial growth factor 
receptor (VEGF) and insulin-like growth factor receptor. The monoclonal 
antibody, Bevacizumab targets the vascular endothelial growth factor and 
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blocks tumour angiogenesis (Hampton, 2005). Several recently developed 
antibodies and inhibitor molecules are undergoing clinical trials.  
Currently, there are several other targeted agents that interfere with signal 
transduction pathways such as PI3K/AKT/mTOR and Ras/Raf/MAPK. It is 
proposed that these targeted therapies will be particularly effective in the 
treatment of oestrogen receptor positive breast cancers. The PIK3CA gene that 
encodes the catalytic subunit of PI3K have been shown to be mutated 
commonly in oestrogen receptor positive breast cancers (Cancer Genome Atlas, 
2012). This observation suggest that inhibitors that target PI3K would be 
effective to treat cancer progression and resistance to current treatment 
regimes in oestrogen receptor positive breast cancer. Pictilisib is a selective 
inhibitor of PI3K, which was evaluated in combination with fulvestrant in a 
randomised phase II study. Results indicated that the progression-free survival 
of patients in the combination arm was not significantly different to that of the 
fulvestrant alone arm. mTOR inhibitors such as everolimus have been 
combined with exemestane, an aromatase inhibitor, and have been proven 
successful at improving progression-free survival compared to patients treated 
with exemestane alone (Piccart et al., 2014). Everolimus is usually administered 
to postmenopausal women with advanced breast cancer. 
Resistance to endocrine therapy has been reported to develop through 
activation of the Ras/MEK/MAPK pathway. MEK inhibitors such as selumetinib 
have been combined with fulvestrant to test their effectiveness in the treatment 
of patients with advanced breast cancers that developed after endocrine 
therapy with aromatase inhibitors (Zaman et al., 2015). The combination 
treatment did not improve overall survival and resulted in several adverse 
events such as vomiting, skin disorders and oedema. Another MEK inhibitor, 
trametinib has been tested in combination with an AKT inhibitor, afuresertib in a 
phase I study (Tolcher et al., 2015).   
Drugs that target CDK4/6 prevent cell cycle progression from G1 to S phase. A 
CDK4/6 inhibitor palbociclib has been shown to be effective at inhibiting growth 
of oestrogen receptor positive, HER2-negative breast cancers (Turner et al., 
2015). Other CDK4/6 inhibitors, abemaciclib and ribociclib are undergoing 
20 
 
clinical trials and will be tested in combination with fulvestrant or aromatase 
inhibitors such as anastrozole and letrozole (Lu, 2015). 
 
1.2 Role of oestrogen in the development of breast cancer 
Steroid hormones such as oestrogens are crucial for the regulation of lipid 
metabolism, neuronal homeostasis, female and male fertility, bone development 
and also for efficient functioning of the cardiovascular system (Shao and Brown, 
2004). Normal breast tissue development does not occur in aromatase-deficient 
women who have lower levels of circulating oestrogens. However, normal pre- 
and post- pubertal breast growth and development take place when these 
women were treated with oestrogen therapy. This observation illustrates the 
importance of oestrogen for the normal development of the breast. The roles 
played by oestrogen is not limited to the breast, but extend to the uterus, liver, 
ovary and bones. Oestrogen is known to stimulate growth and proliferation of 
breast cancer cells and plays an extensive role in facilitating the progression 
and metastasis of breast cancer. Because oestrogens mediate their action via 
interaction with the oestrogen receptor, anti-oestrogenic drugs that target the 
oestrogen receptor are beneficial in the treatment of breast cancer.      
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Figure 1.5 Different forms of oestrogen. Oestrone, oestradiol and oestriol consist of one, two 
and three hydroxyl (OH) groups respectively. Oestrone can be inter-converted to 17β-oestradiol 
by the enzyme 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). Oestrone can be broken 
down further into oestriol and 2-hydroxyestrone. The hydroxylation of oestrone to 2-
hydroxyestrone is catalysed by a member of cytochrome P450 family, CYP2C19. 2-
hydroxyestrone is methylated to 2-methoxyestrone by catechol-o-methyltransferase (COMT). 
Figure adapted from (Ackerman and Carr, 2002). 
 
There are three different types of endogenous oestrogens: oestrone (E1), 17β-
oestradiol (E2) and oestriol (E3), which contain one, two and three hydroxyl (OH) 
groups respectively (Figure 1.5). Out of the three oestrogens, 17β-oestradiol is 
the most biologically active and is produced primarily in the ovaries in pre-
menopausal women. In post-menopausal women oestradiol is produced in 
adipose tissue, bone, brain and in vascular endothelial cells. The enzyme 17β-
hydroxysteroid dehydrogenase type 1 (17β-HSD) aids the conversion of 
oestrone to oestradiol. The catechol metabolites 2-hydroxyestrone and 2-
methoxyestrone are catabolic degradation products of oestrogens. The 
oestrogens exert their actions by binding to oestrogen receptors.   
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1.2.1 Oestrogen Receptors 
Oestrogen receptors belong to the superfamily of nuclear receptors and are 
characterised as ligand-dependent-transcription factors (Platet et al., 2000; 
Huang et al., 2010). There are two different oestrogen receptors ERα and ERβ 
which have distinct functions (Osborne and Schiff, 2005). ERα is encoded by 
the gene ESR1 located on chromosome 6 and ERβ is encoded by the gene 
ESR2 which is located in chromosome 14. ERα was cloned in 1985, whereas 
ERβ was discovered later in 1996. The 66 kDa ERα consists of 595 amino acid 
residues and is larger than the ERβ which contains 530 amino acids and has a 
molecular weight of 59 kDa. It is well known that the expression of ERα in 
breast cancer cells is critical for the progression of the tumour. In contrast, the 
function of ERβ is understood poorly. Human tissues including the spleen, 
thymus, ovary and testis express ERβ (Mosselman et al., 1996). The binding 
affinity of oestradiol to oestrogen receptors is higher than that of oestrone and 
oestriol, therefore oestrone and oestriol are weaker agonists for the ER in 
comparison to oestradiol. Due to its high binding affinity, 17β-oestradiol 
concentrations of less than 10-9 M can activate both ERα and ERβ. Yet ERβ 
requires a higher 10-10 M concentration of 17β oestradiol to reach half maximal 
activity, in comparison to the 10-11 M oestradiol concentration required by ERα 
(Mosselman et al., 1996).    
 
Figure 1.6 Organisation of the functional domains of oestrogen receptors: ERα and ERβ. 
The five different domains are indicated. NTD refers to the amino terminal domain (red), DBD is 
the DNA binding domain (green), hinge region (blue), LBD is the ligand binding domain (yellow) 
and the F-region located at the C-terminal end (grey). The numbers indicate the amino acid 
sequence position for each domain. Figure taken from (Kumar et al., 2011) . 
 
As shown in Figure 1.6, both oestrogen receptors are organized into five distinct 
regions. They are amino terminal domain (NTD), DNA binding domain (DBD), 
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hinge region, ligand binding domain (LBD) and the F-region which is located at 
the C-terminal end. The NTD contains the transcriptional activation function 
domain AF-1, which is a regulator of transcription. The NTD is considered to be 
in a dynamic structural state that is intrinsically disordered which allows in 
recognition and providing a surface that encourages binding of specific target 
molecules (Warnmark et al., 2001). Upon binding of the interaction complexes, 
the molecules will rearrange themselves into the correct conformation. The 
DNA-binding domain binds to short palindromic sequences of DNA known as 
oestrogen response elements (EREs). The binding affinity of the oestrogen 
receptor is regulated by the DBD. It also assists in the recruitment and direction 
of co-activators to the transcription site. The hinge region acts as a flexible 
connector between the DBD and the LBD. Binding of ligands such as oestrogen 
exposes the nuclear localisation signal present in the hinge region (Kumar et al., 
2011). The LBD also known as the “E” domain follows the hinge region. This 
LBD is the key region which determines the activity of the oestrogen receptor 
and its ligand. This functional domain comprises of a ligand binding cavity and 
impacts binding of co-activators and co-repressors. The LBD is made up of 12 
helices, of which helices 10 and 11 are involved in the formation of dimers. The 
dimer interaction surface formed allows the binding of agonistic and 
antagonistic ligands to the oestrogen receptor. The activation function domain 
AF-2 is located in the LBD. In comparison to the AF-1 situated in the NTD which 
is constitutively active, the AF-2 requires binding of hormone for it to be 
activated (Platet et al., 2000). The LBD of both ERα and ERβ share about 55% 
sequence homology. The “F” region within the C-terminus is known to regulate 
gene transcription and interaction with other proteins. In the presence of 17β-
oestradiol this F domain was shown to inhibit receptor dimerisation (Yang et al., 
2008). Complete deletion of the F region was required to remove the agonist 
activity of 4-hydroxytamoxifen which suggests a role in selective modulation of 
the oestrogen receptor (Koide et al., 2007).  
1.2.2 Mechanism of action 
Oestrogen exerts its actions via two pathways: one which is the classical 
pathway and the other non-classical pathway. The classical pathway is also 
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termed genomic pathway whereas the non-classical pathway is also known as 
non-genomic pathway. The effects of oestrogen via these pathways lead to a 
range of cellular processes including cell proliferation, survival, differentiation 
and apoptosis. The development and progression of oestrogen receptor positive 
breast cancers occur via the contribution of both these pathways. 
The binding of ligands such as oestrogen to the oestrogen receptor causes its 
dissociation from the chaperone heat shock proteins. The induction of a 
conformational change causes homodimerisation of the ER, thus leading to an 
interaction between the EREs present in the promoter regions of the target 
genes and ER (Miyoshi et al., 2010). Phosphorylation of the serine residues in 
the AF-1 region of the NTD is essential for full activation of the ER. The dimeric 
receptor can bind either directly or indirectly. Formation of an active ER 
complex allows for and recruitment of coactivator complexes such as CBP, 
P300 to other DNA-bound transcription factors such as c-fos and c-jun, thus 
allowing transcription of oestrogen-responsive genes. The indirect binding of the 
activated ER occurs through different non-oestrogen-response-element (non-
ERE) sites of promoter regions such as the activator protein-1 (AP-1) and 
specificity protein-1 (SP-1) also lead to transcription of genes (Kushner et al., 
2000; Safe, 2001).    
Oestrogen may also mediate its actions via formation of cell membrane bound 
complexes. These oestrogen receptors may form complexes with other adaptor 
proteins such as focal adhesion kinase (FAK) and Src homology domain 
containing protein (SHC). Such non-genomic interactions may include actions 
mediated through receptors such as the type 1 IGF receptor and EGF receptor 
(Razandi et al., 2003; Song et al., 2004). The formation of macromolecular 
complexes activates the IGF and EGF receptors and sends signals further 
downstream. This signal transduction is reported to occur via stimulation of the 
mitogen-activated protein kinase (MAPK) pathway (Le Romancer et al., 2010). 
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1.3 Oestrogen stimulates cell proliferation and invasion 
Studies have shown that there is an increase in proliferation and invasion of 
cells in response to oestrogen as well as the presence of oestrogen receptor 
(Chalbos et al., 1982; Jakesz et al., 1984). Oestradiol was shown to increase 
invasiveness of MCF-7 cells in in vitro studies using Matrigel (Thompson et al., 
1988). Although the majority of studies have shown the stimulatory effects of 
oestrogen on cell proliferation and invasion, some studies have reported 
contradictory effects of oestrogen, indicating reduced metastatic potential and 
invasion ability of breast cancer cell lines. Several studies stated that high 
expression of ERα may lead to a reduction in invasion. Results from a study in 
MCF-7 cells indicated that there was an increase in cell migration and invasion 
in response to anti-oestrogens; tamoxifen and 4-hydroxytamoxifen. Despite the 
increase in cell migration, the addition of anti-oestrogens inhibited cell 
proliferation (Thompson et al., 1988). In addition to this, the presence of ERα 
and ERβ has been shown to reduce invasion by 3-fold and 2-fold, respectively 
in ERα-negative MDA-MB-231 cells cotransfected with an ERα expression 
vector (Platet et al., 2000).           
 
1.4 Genes regulated by oestrogen 
Oestrogen binding to the ER leads to altered transcription of a large number of 
genes that play a role in a number of cellular processes including growth, 
differentiation, angiogenesis and apoptosis. Oestrogen-regulated genes are 
crucial in causing breast tumourigenesis. The exact function of such oestrogen-
regulated genes is yet to be elucidated. Whole genome expression profiling led 
to the discovery of numerous oestrogen-regulated genes (Frasor et al., 2003). 
Expression analyses including those based on microarray technologies has 
identified a series of nineteen genes in oestrogen-responsive breast cancer 
cells. The genes were either upregulated or downregulated by oestrogen 
(Westley and May, 2006). However, the roles of about ten of these oestrogen-
regulated genes remain unclear.             
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1.5 Genes that regulate vesicle trafficking and exocytosis leading to 
tumourigenesis 
Many characteristics of cancer such as cell cycle regulation, angiogenesis, 
invasion and metastasis depend on changes in vesicle trafficking that occur in 
tumour cells (Steeg, 2005; Wright, 2008). The effects of oestradiol have been 
studied using scanning and transmission electron microscopy in MCF-7 cells in 
culture. The study indicated that oestrogen treatment of 2-11 days caused the 
formation of an extensive network of microvilli at the cell surface (Vic et al., 
1982). Upon treatment with oestrogen, there was an observable difference in 
cellular structures such as mitochondria, Golgi body and rough endoplasmic 
reticulum. The clear mitochondria, rough endoplasmic reticulum and Golgi 
complexes were detected initially in the cytoplasm, but as oestrogen treatment 
continued to about day 8, the cellular structures were located near the cell 
membrane. These changes in structure suggest that the breast cancer cells had 
acquired a secretory cell phenotype. There appears to be a link between the 
modulation of exocytosis and tumourigenesis (Chan and Weber, 2002). A gene 
expression study in breast cancer cells has identified a set of oestrogen-
regulated genes, out of which 5 genes involved in vesicle trafficking have been 
studied in greater detail (Wright et al., 2009). Expression microarray analyses 
identified 147 genes associated with vesicle trafficking including exocytosis. 
One of such oestrogen-regulated genes is SLC12A2 which encodes for the 
Na+-K+-Cl- co-transporter NKCC1. The mRNA levels of SLC12A2 were shown 
to decrease when oestrogen-responsive MCF-7, EFM-19 and EFF-3 cells were 
treated with oestrogen for 48 hours. 
 
1.6 Role of ion transporters in the development of cancer 
Ion transporters are specialised membrane proteins or signal transduction 
molecules that play a major role in a wide range of cellular activities including 
gene expression, secretion, solute transport, intercellular communication, 
hormone secretion, proliferation, cell volume regulation, migration and invasion 
(Fraser et al., 2005). Defects in ion transporter structure or function are 
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associated with the development of cancer and many other diseased states (Li 
and Xiong, 2011). Hallmarks of cancer pathogenesis including uncontrolled cell 
growth, invasion, angiogenesis, metastasis and reduction in apoptosis have 
been shown to be linked to aberrations of membrane ion transporters 
(Kunzelmann, 2005; Prevarskaya et al., 2010). The actions of ion transporters 
are known to stimulate motility and cell migration. Therefore malignant tumour 
cells that acquire such motility cause detrimental effects. Although the process 
through which cell motility occurs is not understood fully, it is thought to be 
mediated by changes in cytosolic Ca2+ activity. Movement of osmotically active 
ions Na+ and K+ is thought to encourage cell motility. Functional ion channels 
and exchangers are crucial for the regulation of cell volume. The movement of 
ions results in loss or gain of water by osmosis. This in turn leads either to cell 
swelling or cell shrinkage (Cuddapah and Sontheimer, 2011).   
This research project will focus on three proteins; NKCC1, a Na+-K+-Cl- co-
transporter that assists in the active transport of sodium, potassium and chloride 
ions into cells, a sodium hydrogen exchange regulatory factor, NHERF3 which 
is a PDZ-containing scaffold protein involved in the regulation of transporters 
such as sodium hydrogen exchangers at the plasma membrane, and finally 
ENaC which is an epithelial sodium channel.        
 
1.7 SLC12A2 (NKCC1) 
The electroneutral Na+-K+-Cl- co-transporter is a member of the solute carrier 12 
(SLC12) family of transporters. The gene SLC12A1 encodes the protein NKCC2, 
whereas the SLC12A2 gene encodes NKCC1. Both NKCC1 and NKCC2 belong 
to the Na+ dependent subgroup SLC12A gene family. In humans, the SLC12A2 
gene is located on chromosome 5, location 5q23.3 (Payne et al., 1995).  
NKCC1 is ubiquitously expressed in the basolateral membranes of many 
different secretory epithelial cells including airway, testes, breast, colon, inner 
ear, vascular smooth muscle and salivary gland (Xu et al., 1994; Payne et al., 
1995). NKCC1 is expressed in other cells such as glial cells which reside in 
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neural tissue. NKCC2 expression is limited to the apical surface of cells in the 
thick ascending limb of the loop of Henle in the kidney. NKCC1 corresponding 
to a transcript size of 7.4 kb is larger than NKCC2 and is made up of about 
1200 amino acid residues. The transcript size of NKCC2 is approximately 5.2 kb 
and it consists of 1000 amino acids. NKCC1 has a molecular mass of 195 kDa, 
and NKCC2 is of 121 kDa (Russell, 2000). The two NKCC proteins share 
approximately 58% identity.     
1.7.1 Structure  
Studies have shown that NKCC1 comprises 12 α-helical transmembrane 
spanning domains (Xu et al., 1994). It consists of three regions which include an 
amino-terminal region, a central hydrophobic region and a carboxy-terminal 
region as illustrated in Figure 1.7. Early studies recognised several N-
glycosylation sites. These potential extracellular hydrophilic segments of 
NKCC1 assist in glycan linkage and are located within the large extracellular 
loop between transmembrane (TM) 7 and TM8. The amino-terminal domain 
contains one phosphorylation site, whereas the carboxy-terminal region has 
multiple phosphorylation sites. Site-directed mutagenesis studies revealed that 
mutational changes that occur in TM2 cause changes in the binding affinity of 
cations. This suggested that TM2 is important for binding and transport of the 
cations Na+ and K+. TM4 and TM7 control the transport of the anion Cl- 
(Isenring et al., 1998). The stoichiometry at which NKCC transports the three 
types of ions is at 1 Na+: 1 K+: 2 Cl- (Geck et al., 1980).  
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Figure 1.7 Graphical representation of the structure of NKCC1. NKCC1 is divided into three 
main regions including an amino terminal domain, a central hydrophobic domain and a carboxy-
terminal domain. The central hydrophobic domain consists of 12 transmembrane spanning α-
helices (TM1 to TM12). The amino-terminal domain has one phosphorylation site, whereas the 
carboxy-terminal domain has multiple phosphorylation sites. The mutational changes that occur 
in TM2 have led to a change in the affinity of cations. The affinity to the anion chloride was 
affected by point mutations in TM4 to TM7. Figure taken from (Russell, 2000). 
1.7.2 Function 
The main functions of ion transporters such as NKCC1 are the maintenance of 
epithelial ion secretion and regulation of cell volume (Hebert et al., 2004). 
Activation of NKCC1 occurs by the accumulation of Cl- ions within the cell. By 
allowing ions into the cell, NKCC1 is responsible for the maintenance of an 
electrochemical gradient. This ionic gradient results in loss of water by osmosis 
and hence leads to cell shrinkage. The loss of water and cell shrinkage 
activates NKCC (Russell, 2000). This activation is thought to be mediated by 
the phosphorylation of serine and threonine residues (Lytle and Forbush, 1992). 
Dephosphorylation of SPS1-related proline/alanine-rich kinase (SPAK) / 
oxidative stress-responsive kinase 1 (OSR1) or an increase in intracellular Cl- 
concentration leads to the inactivation of NKCC (Breitwieser et al., 1990; Gillen 
and Forbush, 1999). Such effects of SPAK/OSR1 are mediated via the with no 
lysine kinase (WNK) signalling pathway in response to hypertonic stress 
(Thastrup et al., 2012). The migration of cells through narrow confined spaces is 
brought about by cell shrinkage. In human glioma cells, NKCC1 has been 
shown to assist in regaining cell volume subsequent to migration through 
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narrow spaces (Haas and Sontheimer, 2010). Loop diuretics such as 
bumetanide and furosemide inhibit NKCC1 (Figure 1.8). This inhibition is 
mediated by the binding of the loop diuretic to the transmembrane domains 
TM2 to TM7 and TM11 to TM12 at a stoichiometry of one inhibitory molecule 
per transporter protein (Isenring et al., 1998). The order of potency is 
bumetanide > piretanide > furosemide (Reyes and Leary, 1993).          
 
Figure 1.8 Chemical structures of loop diuretics. The structure of furosemide, bumetanide 
and piretanide are shown. 
 
The mammary gland is a highly metabolic tissue. It expresses a range of 
membrane-bound transporters such as NKCC1. In mammary ducts, NKCC1 
was expressed mainly at the plasma membrane. There was no expression 
observed in the cytoplasm of epithelial cells (Shillingford et al., 2002). NKCC1 
expressed in these ductal epithelial cells was shown to mediate Cl- ion secretion 
(Selvaraj et al., 2000). In rat mammary tissue, NKCC1 has been shown to be 
important in secretion and transport of milk constituents during lactation 
(Shennan, 1989; Shennan and McNeillie, 1990). The regulation of Cl- ion 
secretion and cell volume suggests that NKCC1 is important in ductal 
morphogenesis of the breast. NKCC1 plays a role in the development of ducts 
as evidence showed that actively dividing epithelial cells express less NKCC1 
(Shillingford et al., 2002). There could be a potential role of NKCC1 in the 
development of breast cancer.    
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1.8 PDZK1 (NHERF3) 
The oestrogen-responsive gene PDZK1 is located on chromosome 1, location 
1q21. This gene encodes the Na+-H+ exchange regulatory co-factor 3 
(NHERF3). Epithelial cells of proximal tubules of the kidney, pancreas, adrenal 
cortex, breast and gastrointestinal tract have been shown to express NHERF3 
(Kocher et al., 1998). The protein NHERF3 consists of 519 amino acids and has 
a molecular mass of 63 kDa. 
1.8.1 Structure  
NHERF3 consists of an N-terminal domain, four PDZ domains, namely, PDZ1, 
PDZ2, PDZ3 and PDZ4 and a C-terminal region (Figure 1.9). These PDZ 
domains can interact concurrently with other proteins. They can coordinate the 
interaction of several proteins which are present at the cell membrane such as 
the membrane-associated protein 17 (MAP17). The NHERF family has four 
members: NHERF1, NHERF2, NHERF3 and NHERF4. NHERF1 and NHERF2 
have two PDZ domains. The other two members NHERF3 and NHERF4 that 
belong to this family have four PDZ domains.   
 
Figure 1.9 Schematic model diagram of the NHERF3 protein. NHERF3 has a short N-
terminal domain, four PDZ domains named PDZ1, PDZ2, PDZ3 and PDZ4 followed by a C-
terminal region. Figure adapted from (Fenske et al., 2009). 
1.8.2 Function 
Proteins that belong to the PDZ family are known to regulate various cellular 
functions. These include ion transport, signal transduction, cell proliferation and 
differentiation. The NHERF proteins facilitate the organisation of membrane 
associated proteins at the cell membrane (Figure 1.10). Therefore NHERF 
proteins are termed scaffolding proteins. Within the gastrointestinal tract, 
NHERF3 and the other PDZ adaptor proteins NHERF1, NHERF2 and NHERF4 
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have been implicated in mediating ion transport and anion secretion (Lamprecht 
and Seidler, 2006).  
 
Figure 1.10 Schematic diagram of the formation of a complex. The interaction of the 
NHERF3-NHERF1-ezrin complex. The tail of NHERF3 binds to NHERF1, which in turn binds to 
ezrin. The carboxy-terminal of ezrin interacts with the cytoskeletal F-actin.   
 
Cancers that originate from epithelial cells tend to have an overexpression of 
NHERF3. The protein MAP17, which interacts with NHERF3, was 
overexpressed in several carcinomas including breast, colon, kidney and 
prostate (Guijarro et al., 2007). Oestrogen receptor positive breast cancers 
more commonly overexpressed NHERF3 in comparison to oestrogen receptor 
negative breast cancers (Ghosh et al., 2000). Some studies have shown the 
effects of oestradiol in the alternation of membrane structures such as microvilli. 
Therefore it could be speculated that the induction of NHERF3 plays a role in 
facilitating the response to oestrogen in ER positive breast cancers. A study 
confirmed that siRNA knockdown of PDZK1 inhibited the oestrogen-induced 
increase of both oestrogen receptors. These results further clarified that the 
actions mediated by oestrogen on NHERF3 acts through the ERα and ERβ 
receptors (Kim et al., 2012). In skin specimens taken from patients with 
melasma, oestrogen induced the expression of tyrosinase, which is an enzyme 
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that catalyses the oxidation of tyrosine along with the expression of NHERF3. 
Moreover, treatments with increasing concentrations of oestrogen from 10 nM 
to 100 nM, lead to an increase in expression of other NHERF3 interacting ion 
transporters such as the Na+-H+ exchanger (NHE) and cystic fibrosis 
transmembrane conductance regulator (CFTR).            
 
1.9 SCNN1B (ENaC-β) 
Epithelial sodium channels (ENaC) are expressed mainly on the apical surface 
of epithelial cells within the lung, colon and kidney (Garty and Palmer, 1997). In 
the mammalian kidney, ENaC is located primarily in the distal convoluted 
tubules and in the cortical collecting ducts (Gambling et al., 2004). Our gene of 
interest SCNN1B is situated on chromosome 16 location 16p12.2-p12.1 and 
encodes the β-subunit of ENaC. ENaC-β has a molecular mass of 
approximately 72 kDa.  
1.9.1 Structure  
ENaC consists of three different subunits named, ENaC-α, ENaC-β and ENaC-
γ. More recently, a fourth subunit ENaC-δ has been isolated (Yamamura et al., 
2008). Each of the three α, β and γ subunits comprises two transmembrane 
segments that span the apical membrane of epithelial cells (Figure 1.11). The 
amino-terminals and the carboxy-terminals of the subunits are located 
intracellularly.   
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Figure 1.11 Structure of the epithelial sodium channel (ENaC). It is made up of three 
heterotrimeric subunits named α, β and γ. Each subunit consists of two transmembrane helices. 
ENaC has an intracellular amino-terminal region followed by a transmembrane domain, a large 
extracellular loop, a second transmembrane segment and an intracellular carboxy-terminal tail. 
Figure adapted from (Gamper and Shapiro, 2007).    
1.9.2 Function 
The main function of ENaC is the maintenance of sodium homeostasis and also 
the regulation of blood volume and blood pressure (Rossier et al., 2002). 
Several hormones present in the kidney such as vasopressin, aldosterone, 
catecholamines and insulin control the activity of ENaC. They induce a rapid 
increase in Na+ transport by altering the subcellular localisation of ENaC to the 
plasma membrane (Loffing et al., 2001). These effects are facilitated by the 
secondary messengers: serum glucocorticoid kinase 1 (SGK), cyclic adenosine 
monophosphate (cAMP) and inositol-1,4,5 triphosphate (IP3). The mRNA levels 
of ENaC-α, ENaC-β and ENaC-γ are regulated by hormones such as 
aldosterone and vasopressin, with resulting changes in expression of the three 
ENaC subunits. Vasopressin has been shown to increase the expression of 
ENaC-β and ENaC-γ subunits mRNAs, in the lung and renal collecting ducts of 
rats (Nicco et al., 2001). This increase in expression led to an increase in 
vasopressin mediated Na+ transport. Hormones such as oestrogen and 
progesterone may play a role in modulating the renal handling of Na+ and assist 
in the retention of sodium and water. The role of hormones such as oestrogen 
was proposed based on studies that have observed that renal regulation of Na+ 
varies during the oestrous cycle of rats and humans (Hartley and Forsling, 2002; 
Pechere-Bertschi et al., 2002).  
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One of the key features of cancer pathogenesis is migration of cells. ENaC is 
involved in cell migration and regulation of cell volume. Cells lose volume and 
shrink in size in order to invade through narrow intercellular spaces. ENaC 
allows cells to regain cell volume after cell shrinkage. This increase in cell 
volume is termed “regulatory volume increase”. A study in human glioma cells 
has shown that one of the main roles of ENaC is to aid in the process of 
regulatory volume increase (Ross et al., 2007). Knockdown of ENaC-α and 
ENaC-γ inhibited the migration of glioma cells (Kapoor et al., 2009). This 
observation provides evidence of the potential relationship between cell 
migration and channels that transport ions.      
The amiloride-sensitive ENaC is responsible for the presence of the low Na+ ion 
concentration in milk. The role of ENaC in the mammary ductal epithelia has 
been demonstrated in studies of murine models. With the aid of Ussing 
chambers, in which planar sheets of bovine mammary epithelial cells were 
grown on permeable filter matrices which were clamped forming a barrier 
between two half-chambers, Quesnell et al confirmed that ENaC-β and ENaC-γ 
responded to glucocorticoids such as dexamethasone and cortisol. These 
actions were mediated via the glucocorticoid receptor (Quesnell et al., 2007b). 
The mammary epithelial cells under evaluation exhibited an increase in short 
circuit currents in the presence of cortisol and dexamethasone. The increase in 
short circuit current is a direct measure of net ion transport. In cells that were 
previously induced by corticosteroids, a decrease in short circuit current was 
observed when the apical membranes were exposed to 10 µM amiloride or 1 
µM Benzamil. Amiloride is an epithelial sodium channel blocker and benzamil is 
a sodium-calcium exchange blocker in addition to being a potent ENaC blocker.   
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The following Figure 1.12 shows a model diagram of the mediation of ion 
transport in a secretory mammary duct epithelial cell. NKCC1 located in the 
basolateral membrane transports Na+, K+ and 2 Cl- ions into the cell. A Na+ ion 
gradient is generated by the ATP-driven Na+/K+ pump, which pumps Na+ ions 
out and K+ ions into the cell, against their concentration gradients (Shennan and 
Peaker, 2000). A low Na+ ion concentration inside the cell is maintained by the 
ouabain-sensitive Na+/K+ ATPase which is located in the basolateral membrane 
of the cell (Kimura, 1969; Linzell and Peaker, 1971). NHERF3 facilitates 
organisation of membrane associated proteins such as the Na+/H+ exchangers 
(NHEs) (Thomson et al., 2005). The NHEs are responsible for regulation of 
intracellular pH and transports ions at a stoichiometry of 1 Na+ : 1 H+. The 
amiloride-sensitive ENaC is localised to the apical membrane and transports 
Na+ ions into the cell. In lactating tissue, secretion of milk constituents is 
dependent upon the polarised transport of ions determined by the transepithelial 
ionic concentration gradients.             
 
Figure 1.12 Schematic diagram of a mammary duct epithelial cell. NKCC1 is located in the 
basolateral membrane and transports Na+, K+ and 2Cl- ions. The epithelial Na+ channel (ENaC) 
that transports Na+ ions is located in the apical membrane. The Na+, K+ ATPase pumps 3 Na+ 
out and takes 2 K+ ions in. NHERF3 provides a scaffold to other membrane associated proteins 
such as the Na+/H+ exchanger (NHE). 
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1.10 Ion transporters as therapeutic targets 
It has been suggested that ion channels and transporters could be potential 
therapeutic targets for cancer (Li and Xiong, 2011). Inhibition of ion transporters 
could aid in preventing the progression of cancer. It has been proposed that 
gliomas including primary brain tumours could be treated with chlorotoxin, which 
is a peptide derived from the death-stalker scorpion (Soroceanu et al., 1998). 
Chlorotoxin is a Cl- channel inhibitor that binds specifically to glioma cells and 
cells in tumours originating from the neuroectoderm (Lyons et al., 2002).      
Another gene KCNK5 which is induced by oestradiol, encodes for a potassium 
channel known as TASK2. In oestrogen-responsive breast cancer cells MCF-7 
and T47D, this potassium channel played a role in the regulation of cell 
proliferation (Alvarez-Baron et al., 2011). Moreover, siRNA knockdown of 
KCNK5 resulted in attenuation of cell proliferation by cell cycle arrest at the 
G1/S phase. Inhibitors that have the ability to target TASK2 specifically would be 
beneficial in treatment of ER positive breast tumours.    
The association of molecules involved in organisation of transport proteins at 
the cell surface, or of transport proteins or ion channels in cancer cell function 
suggests that inhibitors or modulators of ion transporters such as NKCC1, 
ENaC and the scaffold protein NHERF3 could eventually lead to new breast 
tumour treatments. Although it is a long term prospect, this project will provide 
the initial basis. 
 
1.11 Hypothesis 
We hypothesise that oestrogen alters the expression of specific genes 
SLC12A2, SCNN1B and PDZK1 that encode proteins involved in ion transport. 
The alteration of protein expression induced by oestrogens, leads to polarised 
transport of ions. Modifications in membrane transporter abundance and to their 
polarised location will likely impact on cellular ion homeostasis. Ion transporters 
have been implicated in many pathophysiological processes of cancer such as 
uncontrolled growth, decreased apoptosis and increased migration and invasion. 
38 
 
The associated phenotypic changes in ion transport and any change in the 
polarised organisation of transport activity may favour breast cancer 
progression. We aim to understand how ion transporters and scaffolding 
proteins relate to each other in the context of altering the cell phenotype in 
response to oestrogen. 
1.12 Aims 
The main objectives of this project were to; 
 Measure the expression of oestrogen-regulated genes SLC12A2, PDZK1 
and SCNN1B in oestrogen-responsive cell lines MCF-7, EFM-19 and 
EFF-3. The protein expression of NKCC1, NHERF3 and ENaC-β was 
analysed by western transfer. 
 Study the oestrogen regulation of proteins NKCC1, NHERF3 and ENaC-
β. Steroid hormone withdrawal studies will enable study of the effects of 
oestrogen on breast cancer cells.   
 Evaluate expression of the proteins NKCC1, NHERF-3 and ENaC-β in 
the absence and presence of different anti-oestrogens such as 
tamoxifen, fulvestrant, 4-hydroxytamoxifen, raloxifene, toremifene etc.  
 Investigate the cellular localisation of membrane transporters and 
scaffolding proteins by immunofluorescence and confocal microscopy in 
polarised cell monolayers and determine the effects of oestrogens. 
 Determine the functional regulatory roles of the protein encoded by the 
oestrogen-regulated gene SLC12A2. The activity of NKCC1 was 
assessed with the 86Rb+ (K+) influx assay. Pharmacological agents such 
as ouabain and loop-diuretics furosemide and bumetanide which inhibit 
NKCC1 were used.   
 Test the importance of the NHERF3 protein in regulation of Na+/H+ 
exchange. This was assessed in the context of cellular control of pH 
using the pH-sensitive dye BCECF-AM. 
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Chapter 2.    Materials and Methods 
2.1 Tissue Culture 
2.1.1 Cell lines 
Human breast cancer cell lines were purchased from the American Type 
Culture Collection (ATCC). Cells were cultured in sterile tissue culture flasks 
(Corning, UK) of varying growth surface areas of 25 cm2, 75 cm2 and 175 cm2 
(T-25, T-75 and T-175). 
2.1.2 Routine cell culture 
Oestrogen responsive human breast cancer cell lines were MCF-7, EFM-19, 
EFF-3, BT-474, T-47D and ZR-75. Oestrogen non-responsive cell lines were 
MDA-MB-231, SKB-R3, BT-20, Hs578T and HBL-100. These cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10 % foetal 
calf serum (FCS) and 1 µg/ml (0.17 µM) insulin. Cell lines were incubated at 
37°C in a humidified 5% CO2 incubator and usually grown to 70 % confluence. 
Prior to trypsinisation, cells were washed twice with autoclaved phosphate 
buffered saline (PBS) comprising 0.14 M NaCl, 0.01 M PO4 buffer and 0.003 M 
KCl. Cells were detached from tissue culture flask surfaces with 50 mg/ml 
porcine trypsin and 20 mg/ml EDTA (1:3 trypsin/EDTA) solution diluted in PBS. 
Once detached, cells were centrifuged (Beckman Allegra X-12 R rotor SX 4750) 
for 5 minutes at 1500 rpm at room temperature, in sterile BD FalconTM tubes 
(BD Biosciences, UK). Cells were then seeded into fresh flasks at dilutions 
between 1:2 and 1:9 in fresh tissue culture medium. Cell lines were tested for 
mycoplasma contamination on a regular basis. 
2.1.3 Cryopreservation of cells 
As mentioned previously, once cells were trypsinised, they are resuspended in 
DMEM supplemented with 20% (v/v) foetal bovine serum and 10% (v/v) DMSO. 
The cell suspension was added to sterile polypropylene cryo-vials (Invitrogen 
Life Technologies, UK) in 0.5 ml aliquots. For short-term storage cells were kept 
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in a -70°C freezer and for long-term storage cells were transferred to liquid 
nitrogen.  
When required, cell aliquots were thawed rapidly and added to pre-warmed cell 
culture medium in T25 flasks. The medium was replaced 24 hours after seeding. 
2.1.4 Preparation of dextran-coated charcoal stripped serum (DCCS) 
Twenty grams of charcoal (Sigma, UK) and 0.2 g of dextran T70 (Pharmacia, 
UK) were mixed thoroughly and suspended in 250 ml of sterile distilled water. 
This was followed by 10 minute incubation at room temperature and 
centrifugation for 15 minutes at 7000 rpm at 4 oC (JA17 rotor, Beckman J2-21 
centrifuge). The supernatant was aspirated carefully and the process was 
repeated. The dextran-coated charcoal was resuspended in 200 ml of newborn 
calf serum (Invitrogen Life Technologies, UK). The contents were transferred to 
conical flasks and incubated at 55 oC in a shaking waterbath for 40 minutes. 
After incubation, the contents were centrifuged at 10,000 rpm at 4 oC for 30 
minutes. The serum was carefully transferred to clean centrifuge bottles and 
centrifuged at 10000 rpm at 4 oC for 30 minutes to remove any remaining 
charcoal. Then the dextran-coated charcoal stripped calf serum (DCC-CS) was 
filter sterilised through a 0.45 µm filter unit (Corning, UK) and was stored in a 
freezer at -20 oC. 
2.1.5 Withdrawal of cells 
Cells were plated onto 12-well or 24-well plates in routine culture medium and 
were allowed to attach for 24 hours. Withdrawal from steroids in the culture 
medium was by culture for 5 days in phenol red-free DMEM containing 1 µg/ml 
(0.17 µM) insulin and 10 % newborn calf serum which had been treated with 
dextran-coated charcoal. This medium is steroid depleted and does not 
contains any cytokines. Throughout the first 3 days of serum withdrawal, cells 
were washed twice with PBS and fresh steroid-depleted medium was added. 
During the next 2 days, medium was changed daily.   
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2.1.6 Treatment of cells 
Following the 5 day withdrawal of cells from steroids, cells were treated with 
oestrogen diluted to a concentration of 10-9 M in withdrawal media for 6 hours to 
10 days. Media were changed daily. For oestrogen concentration dependent 
experiments, different concentrations of oestrogen were used ranging from 10-7 
M to 10-13 M.  
For anti-oestrogen dependent experiments, several anti-oestrogens were used 
at the concentrations given below. 
Anti-oestrogen Concentration Manufacturer 
Tamoxifen 10-7 M 
5x10-6 M 
Sigma 
4-Hydroxytamoxifen 10-8 M Sigma 
Fulvestrant 10-8 M Sigma 
Bazedoxifene 10-7 M Cayman 
chemical 
Toremifene 10-7 M Santa Cruz 
Raloxifene 10-7 M Cayman 
chemical 
Lasofoxifene 10-8 M Santa Cruz 
 
Table 2.1 List of anti-oestrogens and concentrations. The anti-oestrogens and 
manufacturers are listed. 
 
2.2 Preparation of cell lysates 
2.2.1 Protein Extraction 
Cells were washed twice with ice-cold PBS. Cells were then lysed in 
radioimmunoprecipitation assay (RIPA) lysis buffer containing 150 mM NaCl, 50 
mM Tris pH 7.5, 1 mM EDTA, 1% NP-40 and 0.25% Sodium deoxycholate 
supplemented with the protease inhibitors 1 µg/ml aprotinin, 1 µg/ml leupeptin, 
1 µg/ml pepstatin, 2 mM sodium orthovanadate, 2 mM sodium fluoride and 2 
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mM phenyl methyl sulphonyl fluoride (PMSF) (Sigma, UK) on ice. Then cells 
were agitated for 30 minutes on ice and centrifuged at 14,000 rpm for 10 
minutes at 4oC to remove any insoluble cellular debris. Once centrifugation was 
complete, the supernatant was removed to a fresh eppendorf tube and labelled 
accordingly. These lysates were stored in a -20 oC freezer. Then the protein 
concentration was measured with bicinchoninic acid assay (Thermo Scientific, 
UK) using BSA as the standard. 
2.2.2 Measurement of protein concentration 
The protein concentrations of the cell lysates were measured using 
bicinchoninic acid (BCA) assay. BCA is a detergent based upon bicinchoninic 
and is used for quantification of total protein. BCA reagents A and B (Thermo 
Scientific, UK) were mixed at a ratio of 50:1 to produce a working dilution. 
Standards of 0, 0.025, 0.05, 0.1, 0.2, 0.5, 1 and 2 mg/ml bovine serum albumin 
(BSA) were prepared in a 1:10 dilution of RIPA buffer and made into aliquots of 
5 µl each. Cell lysate aliquots of 0.5 µl were diluted in a 1:10 ratio in 4.5 µl of 
SDW. Ninety five microliters of the BCA reagent mixture was added to 5 µl of 
each of the protein standards and diluted lysates. The samples were vortexed 
and incubated in a water bath at 37 oC for 30 minutes. 
This BCA assay uses a colorimetric detection system which shows a strong 
absorbance at 562 nm. The proteins present in an alkaline medium allows a 
biuret reaction to occur in which Cu2+ cations are reduced to Cu+ ions forming a 
coloured complex. This initial step forms a pale blue complex due to the 
chelation of copper with the protein. During the next step two molecules of the 
BCA react with the Cu+ ions formed initially, hence producing an intense purple-
colour. This complex is water soluble and exhibits an absorbance at 562 nm. 
The lysates were then placed immediately on ice to avoid further colour 
development. The optical density was determined spectrophotometrically at a 
wavelength of 562 nm (DU 640 series spectrophotometer) and a standard curve 
of the BSA standard serial dilutions is produced. The protein concentrations of 
the cell lysates were calculated based upon the BSA standard curve generated 
by the spectrophotometer. 
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2.3 Western transfer analysis 
2.3.1 Protein gel electrophoresis 
For sodium dodecyl sulphate polyacrylamide gel electrophoresis, the separating 
gels prepared had 12% acrylamide and the stacking gels had 3% acrylamide. 
For the separating gel the acrylamide to bisacrylamide ratio was 200:1 (w/w) 
and consisted of 12% polyacrylamide (v/v), 0.5 M Tris-HCl pH 8.8, 0.1% (w/v) 
SDS, 0.05% (w/v) ammonium persulphate (APS) and 0.1% (v/v) N, N, N’, N’-
tetramethylethylenediamine (TEMED). The stacking gel’s acrylamide to 
bisacrylamide ratio was 20:1 (w/w) and contained 3% polyacrylamide (v/v), 125 
mM Tris-HCl pH 6.8, 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulphate and 
0.5% (v/v) TEMED. 
The gels were cast in a Hoeffer mighty small 10 x 12 cm vertical gel apparatus. 
After the separating gel was added, it was overlayed with 200 µl of water 
saturated butan-2-ol (50% butan-2-ol and 50% SDW) in order to avoid 
meniscus formation, and the acrylamide was allowed to polymerise for 45 - 60 
minutes. After the separating gel had set, water saturated butan-2-ol was 
poured off and the 15-well or 20-well lane combs were inserted to cast the 
stacking gel. This was then left for 30 minutes to allow complete polymerisation. 
Protein samples of 10 µg were prepared by mixing the lysates samples diluted 
in RIPA buffer with 10 µl of 2 x SDS mix containing 0.125 M Tris-HCl, 25 mM 
EDTA, 4% SDS, 20% glycerol, 0.01% bromophenol blue and 10% β-
mercaptoethanol, pH 6.8 making up to a total volume of 20 µl. This sample 
mixture was vortexed and boiled for 10 minutes on a heat block at 95 oC. 
Samples were loaded into lanes within the stacking gel. Protein markers of full 
range known molecular mass (Rainbow marker, GE Life Sciences) were 
electrophoresed alongside the samples. The cassettes were placed and 
secured in electrophoresis chambers and were electrophoresed in running 
buffer containing 0.38 M glycine, 0.5 M Tris-HCl and 0.1% SDS at a constant 
current of 10 mA per gel. 
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2.3.2 Western transfer 
Proteins were separated by polyacrylamide gel electrophoresis and were 
transferred to 0.45 µM nitrocellulose membranes (VWR International, UK). A 
semi-dry transfer apparatus (S&S CarboGlas, Peqlab, PerfectBlue) was used. 
The transfer sandwich comprised of 2 sheets of 3 mm Whatman 
chromatography paper soaked in 0.3 M Tris, and 20% methanol (anode buffer 
1), one sheet soaked in 25 mM Tris and 20% methanol (anode buffer 2), a 
sheet of 0.45 µM nitrocellulose membrane pre-wet in SDW, and soaked in 
anode buffer 2, the polyacrylamide gel and 3 sheets of chromatography paper 
soaked in 25 mM Tris, 40 mM 6-amino-n-hexanoic acid pH 9.4 and 20% 
methanol (cathode buffer). The protein transfer from the polyacrylamide gel to 
the nitrocellulose membrane was at a constant current of 100 mA per gel for 45 
- 60 minutes. Following transfer the membranes were left to dry overnight at 
room temperature. 
2.3.3 Incubation with antibodies 
The membranes were blocked in 5% (w/v) milk containing 20 mM Tris-HCl, 140 
mM NaCl and 0.1% Tween 20 (TBS-Tween solution) for 1 hour at room 
temperature. Later the membranes were washed three times with TBS-Tween 
for 5 minutes each with gentle shaking. After the final wash, the membranes 
were incubated overnight at 4 oC with specific primary antibodies. The NKCC1 
antibody was a rabbit monoclonal raised against a synthetic peptide 
corresponding to residues surrounding Arg80 of the human NKCC1 protein 
detected a broad protein band around 160 - 200 kDa (1:5000-1:20000) (#8351; 
Cell Signalling Technology, UK). The NHERF3 antibody was a rabbit polyclonal 
immunogen detected NHERF3 at an apparent molecular mass of about 66 kDa 
(1:5000-1:10000) (HPA006155; Atlas antibodies, UK). The ENaC-β antibody 
was a mouse monoclonal synthetic peptide raised against residues of 271-460 
of human ENaC-β and detected a protein band at an apparent molecular mass 
of approximately 70 kDa (1:100-1:200) (sc25354; Santa Cruz Biotechnology, 
USA). The HRP-GAPDH, a rabbit polyclonal raised against amino acids 1-335 
representing the full length of human GAPDH (1:10000-1:50000) (sc-25778; 
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Santa Cruz Biotechnology, USA) followed by horseradish peroxidase 
conjugated anti-rabbit or anti-mouse secondary antibodies (1:5000-1:20000) 
(7074S and 7076S respectively; Cell Signalling, UK) diluted in Tris buffered 
saline tween / 5% milk for 1 hour at 37 oC. After incubation with the secondary 
antibodies, the membranes were washed three times with TBS-Tween and 
once with TBS.   
2.3.4 Development of filter 
Proteins were visualised by enhanced chemiluminescence with SuperSignal 
West Dura Extended Duration Substrate (Thermo Scientific, UK). The 
chemiluminescent solutions Luminol/Enhancer and peroxide buffer were mixed 
at a 1:1 ratio. The membranes were incubated with the mix for 5 minutes at 
room temperature. They were exposed to X-ray films (Fujifilm, SuperRX) and 
developed using the developer machine. 
2.3.5 Densitometric analysis 
Following development, the X-ray films were digitally scanned and the intensity 
of the signal was quantified by densitometric analysis using Lab Works 4.0 
software (Ultra Violet Products, UK). The background of the film was subtracted 
from the densitometry analysis. Data were normalised, by dividing the 
densitometry values of the protein of interest to the expression values of 
GAPDH. This would adjust for any variances in protein loading for each sample.  
 
2.4 Immunofluorescence 
2.4.1 Cell culture 
Coverslips 20 mm x 20 mm (VWR International Ltd, UK) were sterilized in 
ethanol for a few minutes. Using a needle and forceps each of the coverslips 
were then left standing by the side of each well in a 6-well plate and left to dry in 
a laminar flow hood. Cells were seeded at the required density onto a 6-well 
plate and incubated for 24 hours for attachment. 
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2.4.2 Fixation of cells 
Once the cells reached confluency, they were then washed with PBS once and 
fixed in methanol or ice-cold 4% paraformaldehyde at -20 oC or at room 
temperature, respectively. A fixative such as methanol dehydrates the cells, 
allowing easy access of antibodies to the protein of interest. But in some cases 
depending on the proteins analysed, dehydration might cause damage to cell 
morphology (Stadler et al., 2010). Therefore methanol fixation is widely used for 
evaluating cytoskeletal proteins. In contrast, paraformaldehyde allows 
conservation of soluble proteins without causing much damage to internal cell 
structures. Hence paraformaldehyde is commonly used in the analysis of 
soluble proteins within the cell. After fixation the cells were washed with PBS 
three times with each wash lasting 20 minutes. 
2.4.3 Blocking and permeabilisation of cells 
After fixation, cells were blocked in blocking buffer consisting of 1x PBS, 5% 
goat serum and 0.3% Triton X-100 for 1 hour at room temperature. Triton X-100 
of 0.3% was replaced with 0.2% Saponin depending on the primary antibody 
used. Triton is a mild detergent that causes irreversible permeabilisation of 
cellular membranes, whereas saponin preserves the membrane structures 
better and results in a reversible permeabilisation (Stadler et al., 2010). This 
permeabilisation step is crucial to allow antibodies to gain access to the inside 
of the cell.  
2.4.4 Incubation with antibodies 
The blocking buffer was aspirated and the appropriate primary antibody was 
added at different dilutions from 1:100 to 1:2000 and incubated overnight at 4 oC. 
The next day the primary antibody was aspirated and the coverslips were 
washed 3 times with PBS. The appropriate secondary antibody, Alexa fluor 488 
conjugated goat anti-rabbit IgG (A11034, Invitrogen, UK) or Alexa fluor 568 
conjugated goat anti-mouse IgG (A11004, Invitrogen, UK) was added at a 
dilution of 1:1000 and the plates were covered with foil as the secondary 
antibody is sensitive to light. The cells were incubated for 1 - 2 hours at room 
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temperature. As mentioned previously, cells were washed 3 times on a shaker 
whilst covered in foil. Mounting media with DAPI (H-1200, Vector Laboratories, 
UK) was added to the glass slides prior to placing the coverslip on the glass 
slide. DAPI intercalates with DNA and produces a blue fluorescence when 
bound to DNA. In some experiments, prior to mounting the coverslip on a glass 
slide, phalloidin (Alexa fluor 555 conjugated phalloidin, #8953; Cell Signalling 
Technology, UK) was added at a dilution of 1:100 for 15 minutes at room 
temperature. This was to selectively label the F-actin filaments of cells. The 
slides were then examined under the laser scanning spectral confocal 
microscope (Leica TCS SP2) or on the fluorescent microscope (Leica DMR). 
The confocal images were taken with a 63x oil immersion objective and 1.3x 
numerical aperture. Images were collected from 10 to 15 sections and all slices 
were stacked together to produce the final image.   
 
2.5 86Rb+ (K+) influx measurement as a functional assay for NKCC1 
2.5.1 Cell culture 
MCF-7 and EFM-19 cells were seeded to sub-confluency at a density of 10,000 
and 30,000 cells per well respectively, in 6-well plates (Corning, UK). Plates 
used for culturing MCF-7 cells in withdrawn media, were coated with rat-tail type 
1 collagen (#11179179001, Roche Applied Science, Germany) at a 
concentration of 5 µg/cm2 to enhance cell attachment. Cells were seeded at 
high density (1 – 2 million cells per filter) onto polycarbonate Transwell filter 
supports of pore size 0.4 µm, 12 mm diameter (#3401, Corning, UK) and at 
similar high density to collagen-coated polytetrafluoroethylene (PTFE) filter 
supports, pore size 0.4 µm, 12 mm diameter (#3493, Corning, UK). One milliliter 
of culture media was added to the upper compartment which is the inside of the 
transwell insert and 2 ml were added to the lower, plate well compartment. 
Media were changed daily.  
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2.5.2 Preparation of Krebs’s solution 
A modified Krebs’s solution consisting of 137 mM NaCl, 5.4 mM KCl, 2.8 mM 
CaCl2, 1.0 mM MgSO4, 0.3 mM KH2PO4, 0.3 mM NaH2PO4, 10 mM Glucose 
and 10 mM HEPES was prepared. The pH was adjusted to pH 7.4 by addition 
of Tris. 
2.5.3 Measurement of 86Rb+ (K+) influx  
Radioactive Rubidium, 86Rb+ provides an isotopic tracer of K+ ion movement 
(Simmons, 1984). The 86Rb+ (K+) influx assay allows assessment of the K+ influx 
through the Na+/K+ ATPase and NKCC1 in breast cancer cells. Since 42K+ has a 
short half-life of 12 hours, 86Rb+ with a half-life of approximately 19 days is used 
as a convenient alternative. The 86Rb+ tracer was added at 0.1 µCi/ml to 
experimental solutions in modified Krebs’s solution. Stock solutions of the 
inhibitors ouabain and furosemide were dissolved in distilled water at 10-3 M 
and 10-2 M respectively. Ouabain is a Na+K+ATPase inhibitor and used at a 
concentration of 10-5 M whereas furosemide is an NKCC1 inhibitor, used at a 
concentration of 10-4 M (Hannaert et al., 2002; Hamann et al., 2010). These two 
inhibitors are used alone and in combination. Cell monolayers were washed 
once with warm (37 oC) modified Krebs’ solution. The cells were incubated in 
Krebs’ solutions for different lengths of time to determine the optimum 
incubation time. Cell monolayers were then washed rapidly four times with ice 
cold Krebs’ solution to remove any extracellular radioactive tracer. Cells were 
lysed by incubation in 1 ml of distilled water. The 86Rb+ activity of the cell 
extracts was measured by counting its β-emissions in a liquid scintillation 
spectrometer in 2 ml of scintillation cocktail.  
2.5.4 Determination of cell number and calculation of influx 
A similar parallel plate of cells were treated with a trypsin solution (0.25% w/v) 
to form a cell suspension for determination of cell numbers per well.  
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The reading produced by the scintillation spectrometer is in counts per minute 
(CPM). Then the following equation was applied to convert measurements to 
molar terms.  
ܨ݈ݑݔ ൌ ሺܿ݋ݑ݊ݐݏ	݋݂	ݏܽ݉݌݈݁ െ ܾ݈ܽ݊݇ݏሻݔ	݊	ݔ	5.4ሺܿ݋ݑ݊ݐݏ	݋݂ݎܽ݀݅݋ܽܿݐ݅ݒ݁	݅ݏ݋ݐ݋݌݁ሻ	ݔ	5	ݔ	ሺ݈݈ܿ݁	ܿ݋ݑ݊ݐሻ	 
Where n=fraction of sample taken for counting and 5.4 is the K+ concentration 
in mM. Blanks are counts from a plate containing no cells, treated in the same 
way as plates containing cells, in order to eliminate non-specific radioactivity 
from the culture plate and to define cell dependent uptake. The cell count per 
well is expressed in 106 cells. The influx measurements are then multiplied by 
103 to be expressed in nanomoles/106 cells per 15 min. 
 
2.6 Measurement of pHi and regulation of Na+/H+ exchange    
2.6.1 Cell culture 
Different cell numbers ranging from 1000 – 10000 cells per well were seeded 
onto 96-well plates (#3598, Corning, UK) and left in an incubator. MCF-7 cells 
were cultured in steroid-depleted media and plated on collagen-coated 96-well 
plates to allow for better cell attachment. These plates were coated with rat-tail 
type 1 collagen (#11179179001, Roche Applied Science, Germany) at a 
concentration of 5 µg/cm2. 
2.6.2 Preparation of standards and bathing solution 
The high K+ buffers consisted of 110 mM K2HPO4 with 20 mM NaCl at pH 8.96 
(Solution A), and 135 mM KH2PO4 with 20 mM NaCl at pH 4.45 (Solution B). 
Standard pH buffers of pH 6.0, 6.2, 6.6, 7.0, 7.4 and 7.8 were prepared by 
titrating Solution A with Solution B. 
The bathing solution was Krebs’s Henseleit HEPES-buffered (KHH) media at 
pH 6.0 and pH 7.4, consisting of 140 mM NaCl, 3 mM KCl, 1 mM MgCl2, 1 mM 
CaCl2, 20 mM HEPES and 10 mM Glucose. The pH was adjusted to pH 7.4 by 
addition of Tris, whereas pH 6.0 was adjusted by addition of MES hydrate.  
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2.6.3 Measurement of pHi 
2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester 
(BCECF-AM, Invitrogen, UK) is a pH-sensitive indicator with a pKa of ~7.0. It 
has a dual excitation and single emission fluorescence. The excitation at ~490 
nm is pH-dependent whereas, the excitation at its isosbestic point of ~440 nm is 
pH-independent. The isosbestic point is the wavelength at which the 
absorbance remains constant. Emission is at ~535 nm. BCECF-AM is cell-
permeant thus enabling efficient measurement of changes in cytosolic pH. 
Intracellular esterases are involved in the hydrolytic conversion of non-
fluorescent BCECF-AM to fluorescent pH-sensitive BCECF.  
A stock solution of 1 mM BCECF-AM was prepared by dissolving BCECF-AM in 
anhydrous DMSO. Cells were washed with Krebs’s Henseleit HEPES-buffered 
(KHH) solution. BCECF-AM was added to the cells at a concentration of 10 µM 
and incubated for 15-30 minutes in an incubator at 37 oC. Cells were washed 
with KHH solution and the different pH buffers standards ranging from pH 6.0, 
6.2, 6.6, 7.0, 7.4, 7.8 containing 10 µM Nigericin (Invitrogen, UK) were added to 
the standard wells. Nigericin is a K+/H+ ionophore which transports K+ and H+ 
ions across the cell membrane to equilibrate the intracellular pH with the 
extracellular pH of the solution. This method is known as the high K+/Nigericin 
technique. KHH solution was added to the experimental cells. Additionally a set 
of blanks, consisting of unloaded cells (i.e. non BCECF-AM added), were later 
replaced with the standard pH buffers for pH 6.0, 6.2, 6.6, 7.0, 7.4, 7.8 
containing 10 µM Nigericin to allow for correction of fluorescent data cell 
autofluorescence.  
The fluorescent intensity was measured with a FLUOstar Omega plate reader 
(BMG Labtech Ltd., UK). The plate reader had excitation filters for 485 nm ± 10 
nm and 420 nm ± 10 nm and an emission filter for 520 nm ± 10 nm. A 
calibration curve was produced using the standards. This was linear over the 
given pH range. The pH of the experimental cells was determined from the 
fluorescence ratio of 485 nm / 420 nm of the standard curve. The ratio of 
fluorescent intensity was calculated using Microsoft Excel 2010 software. 
Calculations of the intracellular pH were performed by linear regression and 
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interpolating from the standard curve using the software GraphPad Prism 
version 6.0. 
2.7 Statistics 
The statistical significance of observed differences were tested using ANOVA 
generated by the software GraphPad Prism version 6.0. Error bars indicate 
standard errors of mean of replicates in each experiment. A p-value of <0.05 
was considered to be statistically significant.  
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Chapter 3.    SLC12A2 (NKCC1) 
3.1 Introduction 
The study of the function of genes regulated by oestrogen is crucial in 
understanding the underlying causes of breast tumourigenesis. One of the 
oestrogen-regulated genes identified from expression analyses is SLC12A2. 
The expression of SLC12A2 was found to be decreased by oestrogen in 
oestrogen-responsive breast cancer cells (Wright et al., 2009). This gene 
encodes the protein NKCC1.  
NKCC1 is a Na+-K+-Cl- co-transporter, that has 12 α-helical transmembrane 
spanning domains (Xu et al., 1994). It has three regions, an amino-terminal 
region, a central hydrophobic region and a carboxy-terminal. NKCC1 is located 
mainly in the basolateral membrane of many different epithelial cells including 
colon, salivary gland, testes and airway. NKCC1 transports the three types of 
ions with a stoichiometry of 1 Na+: 1 K+: 2 Cl- (Geck et al., 1980) and therefore 
is electroneutral. Ion transporters such as NKCC1 play an important role in the 
regulation of epithelial cell volume and in the maintenance of ion secretion. Ion 
transporters have functions in intercellular communication, secretion, migration 
and invasion. Alteration or defects in the structure and function of ion 
transporters contribute to a wide range of diseases including cancer (Li and 
Xiong, 2011). Such abnormalities in membrane ion transporters of tumour cells 
have been shown to be involved in promoting uncontrolled growth, proliferation 
and progression of cancer (Kunzelmann, 2005; Prevarskaya et al., 2010).    
Ion transporters have been implicated in promoting cell motility, however the 
exact process by which motility occurs is not understood fully. Cell motility is 
considered to involve movement of osmotically-active ions Na+ and K+ and 
changes in Ca2+ activities in the cytosol. NKCC1 maintains an ionic gradient 
across the cell membrane by allowing Na+, K+ and Cl- ions into the cell. The net 
flux is dependent on the sum of the chemical activity gradients for Na+, K+ and 
Cl- ions. NKCC1 plays a role in cell volume regulation and is activated in 
response to shrinkage of cells (Russell, 2000). The alteration of the net 
chemical gradient in response to an increased external osmolarity leads to an 
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accumulation of Na+, K+ and Cl- ions intracellularly (Hebert et al., 2004). Water 
follows into the cell osmotically allowing the cell to regain cell volume. 
3.1.1 Aim 
The aim of the experiments reported in this chapter is to investigate the 
expression, cellular localisation, regulation and function of NKCC1 in three 
oestrogen-responsive breast cancer cell lines MCF-7, EFM-19 and EFF-3.           
 
3.2 Expression of NKCC1 in breast cancer cells 
3.2.1 Expression of NKCC1 protein in breast cancer cell lines 
The expression of NKCC1 protein in breast cancer cell lines was investigated 
by western transfer analysis. Protein extracts were prepared from T75 flasks of 
breast cancer cells cultured in DMEM containing 10 % FCS and 1 µg/ml insulin. 
Equal amounts of 20 µg of protein were separated by polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membranes. The oestrogen 
responsive cell lines were MCF-7, EFM-19, EFF-3, BT-474, T47-D and ZR-75. 
The oestrogen unresponsive cells were MDA-MB-231, SKBR3, BT-20, Hs578T 
and HBL-100. A rabbit monoclonal antibody against NKCC1 detected NKCC1 
protein at an apparent molecular mass of around 160 - 200 kDa. As shown in 
Figure 3.1, ZR-75 and Hs578T had the highest levels of NKCC1 protein 
expression, followed by BT-474, EFF-3 and EFM-19 cells. MCF-7, MDA-MB-
231 and HBL-100 cells expressed similar amounts of NKCC1. Lower levels of 
NKCC1 protein were detected in SKBR3 and BT-20 cells. T47-D cells did not 
express any NKCC1 protein. 
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Figure 3.1 Expression of NKCC1 in breast cancer cells. Different breast cancer cell lines 
were cultured in routine culture medium in T75 flasks. Cells were lysed and protein extracts 
were prepared. Equal amounts of 20 µg of protein were separated by 12% polyacrylamide gel 
electrophoresis and then transferred to nitrocellulose membranes. The membranes were 
incubated with anti-NKCC1 antibody (1:10000 dilution) overnight at 4 oC, followed by 
horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 37 oC. 
Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A. The protein expression of NKCC1 was determined by Western 
transfer analysis in MCF-7, EFM-19, EFF-3, BT-474, T47-D, ZR-75, MDA-MB-231 (MDA-231), 
SKBR3, BT-20, Hs578T and HBL-100 cells. B. Densitometric quantification of NKCC1. The 
black bars ( ) represent oestrogen-responsive cell lines, whereas the grey bars ( ) indicate 
the oestrogen-unresponsive cell lines. Error bars indicate standard errors of the mean of 
triplicate measurements. 
3.3 Cellular localisation of NKCC1 in breast cancer cells 
The cellular localisation of NKCC1 in breast cancer cells was analysed by 
immunofluorescence.   
3.3.1 Optimisation of conditions and the antibody concentration 
Figure 3.2 shows the optimisation of different combinations of cell fixation and 
permeabilisation conditions prior to immunofluorescence to determine the ideal 
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condition for the NKCC1 antibody. MCF-7 cells were seeded onto 6-well plates 
containing coverslips and grown in maintenance medium. Cells were washed 
with PBS and fixed in methanol or 4% paraformaldehyde as detailed in the 
Materials and Methods section. Fixation was followed by blocking in 1x PBS, 5% 
goat serum and 0.3% triton X-100 or 0.2% saponin (blocking buffer) for 1 hour 
at room temperature. The cells were then incubated with the primary NKCC1 
antibody at a dilution of 1:100 and incubated overnight at 4 oC.   
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Figure 3.2 Optimisation of fixation and permeabilisation conditions for detection of 
NKCC1. MCF-7 cells were seeded at a density of 1x105 cells onto 6-well plates and cultured in 
routine culture medium for 24 hours. The next day, cells were washed with PBS and fixed in 
either methanol at -20 oC or in 4 % paraformaldehyde at room temperature. After fixation, the 
cells were washed with PBS thrice with each wash lasting 20 minutes. Cells were then blocked 
in blocking buffer containing either triton or saponin for 1 hour at room temperature. The 
blocking buffer was aspirated and the primary antibody NKCC1 was added at 1:100 dilution and 
incubated overnight at 4 oC. The following day the primary antibody was aspirated and the cells 
were washed 3 times with PBS, 15 minutes each. The secondary antibody Alexa fluor 488 
conjugated goat anti-rabbit were added at a dilution of 1:1000 and the coverslips were covered 
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in foil and the cells were incubated for 1 - 2 hours at room temperature. Cells were washed 3 
times with PBS. DAPI mounting media was added to the glass slides prior to placing the 
coverslip on the slide and the cells were examined under the fluorescent microscope (Leica 
DMR) using a 40x objective. Results are shown for different treatment conditions of fixation and 
permeabilisation. Images on the column indicated with “DAPI” show nuclear staining, whereas 
the images indicated with “NKCC1” show the immunoreaction for NKCC1. The “Merged” images 
show both nuclear (blue) and NKCC1 (green) staining together. Scale bar = 45 µm. 
 
Cells with either no NKCC1 antibody or probed with AF488 anti-rabbit (1:1000 
dilution) secondary antibody only was used to determine whether there would 
be an indication of any non-specific signal. This showed that there was no 
autofluorescence from the cells itself and there was no background signal. 
Results showed that fixing cells with methanol was better than with 
paraformaldehyde. Permeabilisation with either Saponin or Triton produced 
similar intensities of fluorescence and NKCC1 was localised to the cellular 
membranes. Therefore in future experiments, cells were fixed with methanol 
and permeabilised with saponin.      
3.3.2 Localisation of NKCC1 in MCF-7, EFM-19 and EFF-3 cells 
The cellular localisation of NKCC1 in MCF-7, EFM-19 and EFF-3 cells was 
investigated by immunofluorescence. As stated previously, we plated cells onto 
coverslips in 6-well plates and incubated for 24 hours. The primary antibody 
NKCC1 diluted in PBS was added at a dilution of 1:100 and the secondary 
antibody Alexa fluor 488 conjugated goat anti-rabbit IgG was added at a dilution 
of 1:1000. The coverslips were mounted with DAPI mounting media and 
examined under the fluorescent microscope.  
As illustrated in Figure 3.3, the immunofluorescence images A3, B3 and C3 
show localisation of NKCC1 at the plasma membrane in all three cell lines. 
However, a few EFM-19 cells (B2) and EFF-3 cells (C2) show a stronger 
immunoreaction at some sites in the membrane. Also we can observe some 
NKCC1 expression of vesicular nature especially in EFF-3 cells.  
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Figure 3.3 Localisation of NKCC1 in cell lines. MCF-7, EFM19 and EFF-3 cells were seeded 
onto 6-well plates and cultured in routine culture medium for 24 hours. Cells were washed with 
PBS and fixed in methanol at -20 oC. After fixation, cells were washed with PBS three times for 
15 minutes each. Cells were then blocked in blocking buffer containing saponin for 1 hour at 
room temperature. The blocking medium was aspirated and the primary antibody NKCC1 was 
added at 1:100 dilution and incubated overnight at 4 oC. Cells were washed 3 times with PBS, 
15 minutes each. The secondary antibody Alexa fluor 488 conjugated goat anti-rabbit were 
added at a dilution of 1:1000 and were covered in foil and the cells were incubated for 1 hour at 
room temperature. Cells were washed 3 times with PBS. DAPI mounting media was added to 
the glass slides prior to placing the coverslip on the slide and the cells were examined under the 
fluorescent microscope (Leica DMR) using a 40x objective. Images A1, B1 and C1 show the 
nuclear staining, whereas the images A2, B2 and C2 show the immunoreaction for NKCC1 in 
MCF-7, EFM-19 and EFF-3 cells, respectively. The merged images A3, B3 and C3 show DAPI 
(blue) and NKCC1 (green) staining combined together. Scale bar = 45 µm. The white arrow ( ) 
indicate examples of clear vesicular expression. 
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3.4 Regulation of NKCC1 by oestrogen 
3.4.1 Investigation of the regulation of NKCC1 expression by oestradiol 
in MCF-7 cells 
MCF-7 cells were cultured in maintenance medium, and withdrawn from growth 
factors, by growing in phenol-red-free DMEM containing 10 % dextran-coated 
charcoal treated newborn calf serum and 1 µg/ml insulin for 5 days. Following 
the withdrawal, cells were cultured in the absence or presence of 10-9 M 
oestradiol for different lengths of time from 0 hours to 8 days.  
The Figure 3.4 illustrates the effect of exposure to oestrogen on the morphology 
of MCF-7 cells. As indicated on the diagram “Day 1 - withdrawal”, which is the 
first day of media change from routine culture media to withdrawal media, the 
cells appear rounded and large in size. The cells are densely packed and lack 
any space between cells. When the cells have been cultured in withdrawal 
media for 5 days, their morphology was observed to change. The cells are less 
spherical and look elongated. An increase in intercellular space is noticeable. 
Cells start to form blister-like structures. These fluid-filled blisters contains small 
vesicles within them. When MCF-7 cells have been treated with 10-9 M 
oestradiol, the intercellular space disappears and the cells return to being more 
spherical.  
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Figure 3.4 Morphological changes of MCF-7 cells in the absence and presence of 
oestrogen. MCF-7 cells were plated at density of 50,000 cells per well in a 24-well plate and 
cultured in withdrawal media for 5 days. Then cells were cultured in the absence and presence 
of 10-9 M oestradiol from 0 hours to 8 days. The photographs were taken at 20x magnification. 
The yellow arrow ( ) indicate examples of a blister, the white arrow ( ) indicates 
intercellular space and the green arrow ( ) indicates piled cells. 
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This experiment was designed to determine the regulation of NKCC1 by 
oestrogen. MCF-7 cells were seeded onto 24-well plates at a density of 50,000 
cells per well. They were grown in routine culture medium for 24 hours, and 
then withdrawn from growth factors, by culturing in withdrawal media for 5 days. 
Following withdrawal, cells were cultured in the absence or presence of 10-9 M 
oestradiol for varying time periods from 0 hours to 12 days.  
As shown in Figure 3.5, the effect of 10-9 M oestradiol was noticeable from 4 
days. The presence of oestradiol, in comparison with the absence of oestradiol, 
showed a marked decrease in the expression of NKCC1 protein. This significant 
decrease in protein expression was more noticeable at 8 days. There seems to 
be a reduction of NKCC1 expression with time in the untreated cells, therefore 
future experiments in MCF-7 cells were devised for treatments lasting for 8 days 
and not any further than that.  
 
Figure 3.5 Effect of oestrogen on expression of NKCC1 in MCF-7 cells. Cells were steroid 
deprived by growing in phenol-red-free media containing 10% dextran-coated charcoal treated 
serum and 1 µg/ml insulin, for 5 days and then treated with 10-9 M of 17β-oestradiol for different 
lengths of time upto 12 days. Both the oestradiol-treated and untreated cells were lysed and 
protein extracts prepared. Protein aliquots of 20 µg were separated by 12% polyacrylamide gel 
62 
 
electrophoresis and then transferred to nitrocellulose membranes. The membranes were 
incubated with anti-NKCC1 antibody (dilution 1:10000) overnight at 4 oC, followed by 
horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 37 oC. 
Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A. The protein expression of NKCC1 in MCF-7 cells after 
oestrogen stimulation for a timecourse of 0 hours to 12 days, comparing serum withdrawn (-E2 
) samples with oestrogen-stimulated (+E2 ) samples. B. Quantification of NKCC1 normalised 
against the corresponding GAPDH signal, *p < 0.05 and **p < 0.001 by ANOVA. Error bars 
indicate SEM of triplicate measurements. 
 
3.4.2 Investigation of the regulation of NKCC1 expression by oestradiol 
in EFM-19 cells 
A similar experiment investigated changes in NKCC1 protein expression with 
the duration of exposure to 10-9 M oestradiol in EFM-19 cells.  
The changes in cellular morphology are shown in Figure 3.6. On the first day of 
media change from routine culture media, to withdrawal media, the cells are 
confluent and the intercellular space is smaller. After 5 days of culturing cells in 
withdrawal media, the increase is intercellular space is clearly visible. Cells 
cultured in withdrawal media tend to give rise to fluid-filled blisters as indicated 
in the diagram. When comparing the images of untreated and cells grown in the 
presence of oestrogen at 8 days after treatment, there is a noticeable increase 
in the number of cells.     
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Figure 3.6 Morphological changes of EFM-19 cells in the absence and presence of 
oestrogen. EFM-19 cells were plated at density of 50,000 cells per well in a 24-well plate and 
cultured in withdrawal media for 5 days. Then cells were cultured in the absence and presence 
of 10-9 M oestradiol from 0 hours to 8 days. The photographs were taken at 20x magnification. 
The yellow arrow ( ) indicate examples of a blister and the white arrow ( ) indicates 
intercellular space. 
 
Representative data from western transfer is shown in Figure 3.7. NKCC1 
protein expression decreases with oestradiol treatment at 2 days. When 
comparing the expression of the treated cells with the untreated cells at 4 and 6 
days, there is not much of a difference. The maximum effect of oestrogen on 
the reduction of NKCC1 was observed at 8 days treatment. After longer 
incubation, untreated cells expressed lower levels of NKCC1.     
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Figure 3.7 Effect of oestrogen on expression of NKCC1 in EFM-19 cells. Cells were steroid 
deprived by growing in phenol-red-free media containing 10% dextran-coated charcoal treated 
serum and 1 µg/ml insulin, for 5 days and then treated with 10-9 M of 17β-oestradiol for different 
lengths of time ranging from 0 hours to a maximum of 10 days. Both the oestradiol-treated and 
untreated cells were lysed and protein extracts prepared. Protein aliquots of 20 µg were 
separated by 12% polyacrylamide gel electrophoresis and then transferred to nitrocellulose 
membranes. The membranes were incubated with anti-NKCC1 antibody (dilution 1:10000) 
overnight at 4 oC, followed by horseradish peroxidase conjugated goat-anti-rabbit secondary 
antibody for 1 hour at 37 oC. Proteins were visualised by enhanced chemiluminescence with 
SuperSignal West Dura Extended Duration Substrate. A. The protein expression of NKCC1 in 
EFM-19 cells after oestrogen stimulation for a timecourse of 0 hours to 10 days, comparing 
serum withdrawn (-E2 ) samples with oestrogen-stimulated (+E2 ) samples. B. Quantification 
of NKCC1 normalised against the corresponding GAPDH signal, *p < 0.05 and **p < 0.001 by 
ANOVA. Error bars indicate SEM of triplicate measurements. 
 
3.4.3 Investigation of the regulation of NKCC1 expression by oestradiol 
in EFF-3 cells 
The effect of oestrogen on the expression of NKCC1 in EFF-3 cells was tested. 
The results are shown in Figure 3.8. A decrease in expression is observed from 
2 days onwards, but a significant decrease in the expression of NKCC1 in the 
presence of oestradiol is observed at longer exposures from 8 days to 10 days. 
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From 6 days onwards the strong diffused protein band somewhat disappears, 
and leaves a double band. The higher molecular weight band does not change 
much with exposure to oestradiol nor with time. However the lower molecular 
weight band decreases in the presence of oestradiol from 6th day onwards and 
disappears completely at 10 days.     
 
Figure 3.8 Effect of oestrogen on expression of NKCC1 in EFF-3 cells. EFF-3 cells were 
plated at a density of 100,000 cells per well onto a 24-well plate. Cells were steroid deprived by 
growing in phenol-red-free media containing 10% dextran-coated charcoal treated serum and 1 
µg/ml insulin, for 5 days and then treated with 10-9 M of 17β-oestradiol for different lengths of 
time ranging from 0 hours to a maximum of 10 days. Both the oestradiol-treated and untreated 
cells were lysed and protein extracts prepared. Protein aliquots of 20 µg were separated by 12% 
polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. The 
membranes were incubated with anti-NKCC1 antibody (dilution 1:10000) overnight at 4 oC, 
followed by horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 
37 oC. Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A. The protein expression of NKCC1 in EFF-3 cells after 
oestrogen stimulation for a timecourse of 0 hours to 10 days, comparing serum withdrawn (-E2 
) samples with oestrogen-stimulated (+E2 ) samples. B. Quantification of NKCC1 
normalised against the corresponding GAPDH signal, *p < 0.05 by ANOVA. Error bars indicate 
SEM of triplicate measurements. 
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3.4.4 Effect of oestradiol on the expression of NKCC1 in MCF-7 cells by 
immunofluorescence 
The aim of this experiment was to visualise the expression of NKCC1 in the 
absence and presence of 10-9 M oestradiol. MCF-7 cells were seeded onto 
coverslips in 12-well plates and cultured in withdrawal media for 5 days and 
then grown in the absence or presence of 10-9 M oestradiol for a further 8 days. 
Cells were isolated at 0 hours, 4 days and 8 days and fixed with methanol at -20 
oC for 20 minutes, as this is the optimum fixation condition detailed in section 
3.3.1. Immunofluorescence procedure was followed as stated in Materials and 
Methods. MCF-7 cells were blocked in blocking buffer containing saponin. 
Following primary and secondary antibody incubations, DAPI mounting media 
was added and cells were observed under the laser scanning spectral confocal 
microscope (Leica TCS SP2). The fluorochrome settings were kept the same 
throughout the timecourse to minimise variations in intensities, thus allowing 
slight changes in expression to be visualised.   
The results obtained are shown in Figure 3.9. NKCC1 is localised to the cell 
membrane. There is evidence of vesicular expression, which is more clearly 
evident in some cells. Similar to data from timecourse experiments, there is a 
marked reduction in the expression of NKCC1 in the presence of oestradiol.          
Figure 3.10 illustrates the x-z cross-sections from the same experiment. The 
images were taken with a 63x oil immersion objective. NKCC1 protein is 
lateralised and MCF-7 cells cultured in the absence of oestrogen appear to be 
flattened in comparison to the oestrogen-treated cells. Upon oestrogen 
stimulation, there is a reduction in the NKCC1 expression in the lateral aspects 
of the cell. Also the increase in cell proliferation in the presence of oestradiol, is 
more visible at 8 days, as the cells are more dense and no longer in a 
monolayer. The depth of cells has increased.    
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Figure 3.9 Effect of oestradiol on the expression and localisation of NKCC1 in MCF-7 
cells. MCF-7 cells were seeded onto 12-well plates and cultured in routine culture medium for 
24 hours. Cells were cultured in withdrawal media for 5 days and grown in the absence or 
presence of 10-9 M oestradiol for different time periods ranging from 0 hours to 8 days. Cells 
were washed with PBS and fixed in methanol at -20 oC. After fixation, cells were washed with 
PBS three times for 15 minutes each. Cells were then blocked in blocking buffer containing 
saponin for 1 hour at room temperature. The blocking medium was aspirated and the primary 
antibody NKCC1 was added at 1:100 dilution and incubated overnight at 4 oC. Cells were 
washed 3 times with PBS, 15 minutes each. The secondary antibody Alexa fluor 488 
conjugated goat anti-rabbit were added at a dilution of 1:1000 and were covered in foil and the 
cells were incubated for 1 hour at room temperature. Cells were washed 3 times with PBS. 
DAPI mounting media was added to the glass slides prior to placing the coverslip on the slide 
and the cells were examined under the confocal microscope using a 63x objective (Oil, 1.63). X-
Y images show DAPI (blue) and NKCC1 (green) staining at the times indicated on the left of the 
diagram. The images on the right show cells treated with 10-9 M of 17β-oestradiol. Scale bars = 
47 µm. The white arrow ( ) indicate examples of vesicular expression.  
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Figure 3.10 Cross-sectional images of the effect of oestradiol on the expression and 
localisation of NKCC1 in MCF-7 cells. MCF-7 cells were seeded onto 12-well plates and 
cultured in routine culture medium for 24 hours. Cells were cultured in withdrawal media for 5 
days and grown in the absence or presence of 10-9 M oestradiol for different time periods 
ranging from 0 hours to 8 days. Cells were washed with PBS and fixed in methanol at -20 oC. 
After fixation, cells were washed with PBS three times for 15 minutes each. Cells were then 
blocked in blocking buffer containing saponin for 1 hour at room temperature. The blocking 
medium was aspirated and the primary antibody NKCC1 was added at 1:100 dilution and 
incubated overnight at 4 oC. Cells were washed 3 times with PBS, 15 minutes each. The 
secondary antibody Alexa fluor 488 conjugated goat anti-rabbit were added at a dilution of 
1:1000 and were covered in foil and the cells were incubated for 1 hour at room temperature. 
Cells were washed 3 times with PBS. DAPI mounting media was added to the glass slides prior 
to placing the coverslip on the slide and the cells were examined under the confocal microscope 
using a 63x objective (Oil, 1.63). X-Z images show DAPI (blue) and NKCC1 (green) staining at 
the times indicated on the left of the diagram. The images on the right show cells treated with 
10-9 M of 17β-oestradiol. Scale bars = 25 µm. The white arrow head ( ) point towards the top of 
cell. 
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3.4.5 Effect of oestradiol on the expression of NKCC1 in EFM-19 cells by 
immunofluorescence 
To study the effect on oestradiol, EFM-19 cells were seeded onto permeable 
Transwell filter supports at a high density of 1 million each. The filter supports 
were held in place in a 12-well plate. Cell culture media was changed from 
routine culture media to withdrawal media. The upper compartment containing 
cells and the lower compartments were carefully washed with PBS and 
replenished with withdrawal media. Further to withdrawal for 5 days, cells were 
cultured with or without 10-9 M oestradiol for 8 days. The cells were fixed with 
methanol and the filters were removed from the Transwell insert by carefully 
cutting around the membrane edges with a scalpel. The filters were then 
blocked in blocking buffer and permeabilised with saponin and processed 
accordingly.       
The results are presented in Figure 3.11 below. As illustrated previously, 
NKCC1 has been localised to the cell membrane of EFM-19 cells. This 
experiment demonstrated the effect of oestradiol on the expression of NKCC1 
by immunofluorescence. It clarified the reduction of NKCC1 protein in response 
to oestradiol treatment, as observed with western transfer too.      
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Figure 3.11 Effect of oestradiol on the expression and localisation of NKCC1 in EFM-19 
cells. EFM-19 cells were seeded onto Transwell filter supports at a density of 1,000,000 cells 
per filter and cultured in routine culture medium for 24 hours. Cells were cultured in withdrawal 
media for 5 days and grown in the absence or presence of 10-9 M oestradiol for 8 days. Cells 
were washed with PBS and fixed in methanol at -20 oC. After fixation, cells were washed with 
PBS three times for 15 minutes each. Cells were then blocked in blocking buffer containing 
saponin for 1 hour at room temperature. The blocking medium was aspirated and the primary 
antibody NKCC1 was added at 1:100 dilution and incubated overnight at 4 oC. Cells were 
washed 3 times with PBS, 15 minutes each. The secondary antibody Alexa fluor 488 
conjugated goat anti-rabbit were added at a dilution of 1:1000 and were covered in foil and the 
cells were incubated for 1 hour at room temperature. Cells were washed 3 times with PBS. 
DAPI mounting media was added to the glass slides prior to placing the coverslip on the slide 
and the cells were examined under the confocal microscope using a 63x objective (Oil, 1.63). X-
Y images show DAPI (blue) and NKCC1 (green) staining at 8 days in the absence or presence 
of 10-9 M of 17β-oestradiol. The treatments conditions are indicated to the left of the diagram. 
Scale bars = 47 µm. 
 
The X-Z sections shown in Figure 3.12, are indicative of basolateral staining of 
NKCC1. There is an increase in the number of cell layers in the presence of 
oestradiol, whereas in its absence, cells are in a monolayer. The reduction in 
the NKCC1 expression at the basolateral surface when treated with oestradiol is 
clearly evident.  
 
Figure 3.12 Effect of oestradiol on the expression and localisation of NKCC1 in EFM-19 
cells. EFM-19 cells were seeded onto Transwell filter supports at a density of 1,000,000 cells 
per filter in routine culture medium for 24 hours. Cells were cultured in withdrawal media for 5 
days and grown in the absence or presence of 10-9 M oestradiol for 8 days. Cells were washed 
with PBS and fixed in methanol at -20 oC. After fixation, cells were washed with PBS three times 
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for 15 minutes each. Cells were then blocked in blocking buffer containing saponin for 1 hour at 
room temperature. The blocking medium was aspirated and the primary antibody NKCC1 was 
added at 1:100 dilution and incubated overnight at 4 oC. Cells were washed 3 times with PBS, 
15 minutes each. The secondary antibody Alexa fluor 488 conjugated goat anti-rabbit were 
added at a dilution of 1:1000 and were covered in foil and the cells were incubated for 1 hour at 
room temperature. Cells were washed 3 times with PBS. DAPI mounting media was added to 
the glass slides prior to placing the coverslip on the slide and the cells were examined under the 
confocal microscope using a 63x objective (Oil, 1.63). X-Z images show DAPI (blue) and 
NKCC1 (green) staining at 8 days in the absence or presence of 10-9 M of 17β-oestradiol. The 
treatments conditions are indicated to the left of the diagram. Scale bars = 23 µm. The white 
arrow head ( ) point towards the top of cell. 
 
3.5 The concentration dependence of the regulation of NKCC1 by 
oestrogen 
3.5.1 Evaluation of concentration dependent effects of oestradiol on the 
regulation of NKCC1 protein expression in MCF-7, EFM-19 and EFF-
3 cells 
The aim of these experiments was to determine the effect of different 
concentrations of oestradiol ranging from 10-13 M to 10-7 M. A stock 
concentration of 10-4 M was prepared and serially diluted to obtain a range of 
concentrations 10-5 M, 10-6 M, 10-7 M, 10-8 M, 10-9 M and 10-10 M. Cells were 
withdrawn for 5 days, and then cultured in the presence of the different 
oestradiol concentrations given above. These stock concentrations were diluted 
1:1000 times with withdrawal media to the required final concentrations.     
Concentration dependent effect of oestradiol on the expression of NKCC1 in 
MCF-7 cells is shown in Figure 3.13. NKCC1 expression was maximal when 
cells were cultured in the absence of oestradiol. With increasing concentrations 
of oestradiol, the expression of NKCC1 decreases. The expression was minimal 
following the addition of 10-10 M oestradiol to the culture medium.  
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Figure 3.13 Effect of oestradiol on NKCC1 protein expression in MCF-7 cells. MCF-7 cells 
were seeded onto 24-well plates and withdrawn for 5 days and treated with different 
concentrations of oestradiol for a period of 8 days. Cells were lysed and protein extracts 
prepared. Protein aliquots of 10 µg were separated by 12% polyacrylamide gel electrophoresis 
and then transferred to nitrocellulose membranes. The membranes were incubated with anti-
NKCC1 antibody (dilution 1:20000) overnight at 4 oC, followed by horseradish peroxidase 
conjugated goat-anti-rabbit secondary antibody for 1 hour at 37 oC. Proteins were visualised by 
enhanced chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A. 
The protein expression of NKCC1 in MCF-7 cells treated with different concentrations of 
oestradiol for 8 days. Image shown are from a representative experiment which has been 
repeated three times. B. Densitometric quantification of NKCC1 with Labworks 4.0 software, 
normalised against the corresponding GAPDH signal. Error bars indicate SEM of duplicate 
measurements. 
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The concentration dependent effect of oestradiol on NKCC1 protein expression 
in EFM-19 cells is shown in Figure 3.14. Similar to the results for MCF-7 cells, 
the expression level decrease dramatically at 10-10 M oestradiol, and continues 
to stay low with further increasing concentrations of oestradiol.   
 
Figure 3.14 Effect of oestradiol on NKCC1 protein expression in EFM-19 cells. EFM-19 
cells were seeded onto 24-well plates and withdrawn for 5 days and treated with different 
concentrations of oestradiol for a period of 8 days. Cells were lysed and protein extracts 
prepared. Protein aliquots of 10 µg were separated by 12% polyacrylamide gel electrophoresis 
and then transferred to nitrocellulose membranes. The membranes were incubated with anti-
NKCC1 antibody (dilution 1:20000) overnight at 4 oC, followed by horseradish peroxidase 
conjugated goat-anti-rabbit secondary antibody for 1 hour at 37 oC. Proteins were visualised by 
enhanced chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A. 
The protein expression of NKCC1 in EFM-19 cells treated with different concentrations of 
oestradiol for 8 days. Image shown are from a representative experiment which has been 
repeated three times. B. Densitometric quantification of NKCC1 with Labworks 4.0 software, 
normalised against the corresponding GAPDH signal. Error bars indicate SEM of duplicate 
measurements.   
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EFF-3 cells were plated onto 24-well tissue culture plates, and were withdrawn 
from steroids for 5 days followed by treatments with a range of oestradiol 
concentrations for a further 8 days. Untreated EFF-3 cells expressed higher 
amounts of NKCC1 protein, whereas cells treated with oestradiol showed a 
concentration dependent effect. A decline in protein content was observed with 
increasing concentrations of oestradiol from 2x10-10 M onwards. These results 
are indicated in Figure 3.15 given below. 
 
Figure 3.15 Effect of oestradiol on NKCC1 protein expression in EFF-3 cells. EFF-3 cells 
were seeded onto 24-well plates and withdrawn for 5 days and treated with different 
concentrations of oestradiol for a period of 8 days. Cells were lysed and protein extracts 
prepared. Protein aliquots of 10 µg were separated by 12% polyacrylamide gel electrophoresis 
and then transferred to nitrocellulose membranes. The membranes were incubated with anti-
NKCC1 antibody (dilution 1:20000) overnight at 4 oC, followed by horseradish peroxidase 
conjugated goat-anti-rabbit secondary antibody for 1 hour at 37 oC. Proteins were visualised by 
enhanced chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A. 
The protein expression of NKCC1 in EFF-3 cells treated with different concentrations of 
oestradiol for 8 days. Image shown are from a representative experiment which has been 
repeated three times. B. Densitometric quantification of NKCC1 with Labworks 4.0 software, 
normalised against the corresponding GAPDH signal. Error bars indicate SEM of duplicate 
measurements.  
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3.6 Functional activity of NKCC1 in breast cancer cells 
This section investigates the activity of NKCC1 in oestrogen-responsive breast 
cancer cells MCF-7 and EFM-19. Radioactive Rubidium, 86Rb+ provides an 
isotopic tracer for K+ ion movement. 86Rb+ has a half-life of approximately 19 
days.  
3.6.1 86Rb+ (K+) influx measurement and the effect of inhibitors furosemide 
and ouabain on MCF-7 and EFM-19 cells cultured in full medium 
The initial experiment was designed to evaluate the time dependence of 86Rb+ 
(K+) influx in MCF-7 cells. Cells were incubated in the absence or presence of 
the inhibitors 10-4 M furosemide and 10-5 M ouabain. Furosemide is an NKCC1 
inhibitor and ouabain is a Na+K+ATPase inhibitor. These inhibitor concentrations 
were well known to cause maximal inhibition of the transporters (Lamb et al., 
1981; Aiton and Simmons, 1984). The linearity of the uptake curve indicates 
that the optimal time is between 10-15 minutes as shown in Figure 3.16. During 
this period, the 86Rb+ (K+) influx into MCF-7 cells approximates 1st order kinetics. 
Hence, in subsequent experiments, cells were incubated for 15 minutes in 
Krebs’s solutions containing 86Rb+ (K+) isotope along with the inhibitors. 
 
Figure 3.16 Time dependence of 86Rb+ (K+) uptake into MCF-7 cells. MCF-7 cells were 
cultured in routine culture medium in 6-well plates. Cells were washed with Krebs’ solution and 
86Rb+ was added. Cells were washed 4 times and lysed in distilled water. Cell lysates were 
collected and 86Rb+ activity was measured. The 86Rb+ (K+) influx of total MCF-7 cell samples in 
the absence of any inhibitors (total ) and cell samples with furosemide at 10-4 M in the 
presence of ouabain at 10-5 M (F + O ). Data is normalised against the cell number. Error bars 
indicate standard error of the mean of three replicates per condition from one experiment.  
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The following experiment analysed 86Rb+ (K+) influx in MCF-7 cells grown in 
routine culture medium. MCF-7 cells were plated onto 6-well plates at a density 
of 50000 cells per well. They were cultured for 3 days in phenol-red DMEM, 
containing 10 % foetal calf serum and 1 µg/ml (0.17 µM) insulin. 86Rb+ (K+) influx 
in MCF-7 cells was measured. 
The 86Rb+ (K+) influx measurements made in the absence and presence of 
furosemide and ouabain is shown in Figure 3.17A. “Total” indicates the 
complete 86Rb+ (K+) influx in MCF-7 cells in the absence of any inhibitors. The 
total influx comprises of three components. “Furosemide-sensitive” component 
is either, total minus furosemide or ouabain minus (furosemide + ouabain). 
“Ouabain-sensitive” component is either total minus ouabain or furosemide 
minus (furosemide + ouabain). The “residual” component is both furosemide-
insensitive and ouabain-insensitive influx. The total influx was 13.28±0.71 
nmol/106 cells/15mins. In the presence of the NKCC1 inhibitor furosemide, there 
was no change in influx, which indicates that there is no significant furosemide-
sensitive influx (p = 0.9976, ANOVA). However, in the presence of the 
Na+K+ATPase inhibitor ouabain, the influx decreased to 6.71±0.38 nmol/106 
cells/15mins which is about half the total value (p = 0.0001, ANOVA). In the 
presence of both NKCC1 and Na+K+ATPase inhibitors the influx was reduced 
further to 5.54±0.51 nmol/106 cells/15mins (p = 0.0001, ANOVA) when 
comparing total influx with the influx in the presence of both inhibitors. This 
residual influx is due to the presence of other channels which may take up K+ 
ions in MCF-7 cells. 
Figure 3.17B shows the calculated furosemide-sensitive influx and ouabain-
sensitive influx in MCF-7 cells. The ouabain-sensitive influx of 7.93 nmol/106 
cells/15mins is considerably higher than the furosemide-sensitive influx of 1.17 
nmol/106 cells/15mins. Therefore, this suggests that K+ ion influx at the cell 
membrane occurs mostly through the Na+K+ATPase. The apparent lack of a 
significant furosemide-sensitive influx could be due to the activity of oestrogen 
present in foetal calf serum (FCS) in phenol-red DMEM (routine culture 
medium).  
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Figure 3.17 86Rb+ (K+) influx in MCF-7 cells. MCF-7 cells were cultured in routine culture 
medium in 6-well plates for 3 days. Cells were washed with Krebs’ solution and incubated in 
experimental solutions containing 86Rb+ (K+) isotope with the inhibitors alone and in combination 
for 15 minutes. Cells were washed 4 times with ice-cold Krebs’ solution and lysed in distilled 
water. Cell extracts were collected and 86Rb+ activity was measured. A. The 86Rb+ (K+) influx in 
the absence (Total) and presence of 10-4 M furosemide (Furo), 10-5 M ouabain (Ouab) and both 
furosemide and ouabain (F + O). Data is normalised against the cell number. **p < 0.0001 by 
ANOVA. Error bars indicate standard error of the mean of six replicates per condition from one 
experiment. B. An illustration of the furosemide-sensitive influx (NKCC1) and ouabain-sensitive 
influx (Na+K+ATPase) in MCF-7 cells. Furosemide-sensitive influx = (ouabain) - (furosemide + 
ouabain), Ouabain-sensitive influx = (furosemide) - (furosemide + ouabain). 
 
The functional activity of NKCC1 was evaluated in EFM-19 cells (Figure 3.18A). 
The total 86Rb+ (K+) influx was 15.55±0.59 nmol/106 cells/15mins and the influx 
decreased to 14.45±0.55 nmol/106 cells/15mins in the presence of furosemide. 
This slight inhibition by furosemide was not significant (p = 0.3117, ANOVA). 
However in the presence of ouabain, the influx dropped even further to 
3.80±0.26 nmol/106 cells/15mins and was statistically significant (p = 0.0001 
ANOVA).  
Figure 3.18B shows a representative graph of the furosemide-sensitive influx 
and ouabain-sensitive influx from the same experiment. Similar to the MCF-7 
cells there is a considerably higher ouabain-sensitive influx of 12.86 nmol/106 
cells/15mins and was significantly different (p = 0.0001 ANOVA). In contrast to 
MCF-7 cells, the lower furosemide-sensitive influx of 2.22 nmol/106 cells/15mins 
was of statistical significance (p = 0.0091 ANOVA). 
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Figure 3.18 86Rb+ (K+) influx in EFM-19 cells. EFM-19 cells were cultured in routine culture 
medium in 6-well plates for 3 days. Cells were washed with Krebs’ solution and incubated in 
experimental solutions containing 86Rb+ (K+) isotope with the inhibitors alone and in combination 
for 15 minutes. Cells were washed 4 times with ice-cold Krebs’ solution and lysed in distilled 
water. Cell lysates were collected and 86Rb+ activity was measured. A. The 86Rb+ (K+) influx in 
the absence (Total) and presence of 10-4 M furosemide (Furo), 10-5 M ouabain (Ouab) and both 
furosemide and ouabain (F + O). Data is normalised against the cell number. *p < 0.05 and **p 
< 0.0001 by ANOVA. Error bars indicate standard error of the mean of six replicates per 
condition from one experiment. B. An illustration of the furosemide-sensitive influx (NKCC1) and 
ouabain-sensitive influx (Na+K+ATPase) in EFM-19 cells. Furosemide-sensitive influx = (ouabain) 
- (furosemide + ouabain), Ouabain-sensitive influx = (furosemide) - (furosemide + ouabain). 
 
These data obtained from both cell lines MCF-7 and EFM-19 suggest that 
oestrogen present in foetal calf serum in the routine culture medium is 
responsible for mediating the lower furosemide-sensitive influx through the 
NKCC1 cotransporter at the cell membrane. The ouabain-sensitive 
Na+K+ATPase is shown to be the main driver facilitating K+ ion influx in MCF-7 
and EFM-19 cells. 
 
3.6.2 86Rb+ (K+) influx measurement under isosmotic and hypertonic 
conditions of MCF-7 cells grown in full media 
The effect of hypertonicity on the 86Rb+ (K+) influx in MCF-7 cells cultured in full 
medium was evaluated. One of the main roles of NKCC1 is cell volume 
regulation. Cell shrinkage causes activation of NKCC1 (Russell, 2000). The 
intracellular accumulation of Cl- ions leads to loss of water causing cells to 
shrink. The activation of NKCC1 is mediated through a cascade of protein 
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phosphorylation (Lytle and Forbush, 1992; Selvaraj et al., 2000). Data 
presented previously showed that cells grown in full media had very low levels 
of furosemide-sensitive (NKCC1) influx. Therefore we postulated that NKCC1 
present in the cell membrane or in recycling endosomes in close proximity to 
the plasma membrane, may be in a quiescent state. In order to reveal this 
inactive NKCC1, half the cells were treated with a hypertonic Krebs’s solution 
containing 200 mM mannitol along with the inhibitors ouabain (10-5 M) and 
furosemide (10-4 M). In the presence of mannitol, cells are subject to hypertonic 
stress and the external osmolarity is raised. This increase in osmolarity causes 
cell shrinkage leading to the activation of NKCC1.     
86Rb+ (K+) influx measurements under isosmotic and hypertonic conditions are 
shown below in Figure 3.19A. Hypertonicity leads to an increase in the 
furosemide-sensitive influx as indicated in Figure 3.19B. Under isosmotic 
conditions the furosemide-sensitive influx was 32.49 nmol/106 cells/15mins, 
whereas in the presence of mannitol the furosemide-sensitive influx increased 
to 68.74 nmol/106 cells/15mins (p = 0.9825, ANOVA). The ouabain-sensitive 
influx remained approximately at 231.07 nmol/106 cells/15mins in both isosmotic 
and hypertonic conditions. However, in comparison with the axis in Figure 
3.17B to that of Figure 3.19B, the effect of hypertonicity on the increased 86Rb+ 
(K+) influx is evident. These results suggests that hypertonic stimulation reveals 
the previously inactive NKCC1 present in the cell membrane. 
 
Figure 3.19 86Rb+ (K+) influx in MCF-7 cells under isosmotic and hypertonic conditions. 
MCF-7 cells were cultured in routine culture medium in 6-well plates for 3 days. Cells were 
washed with Krebs’ solution and incubated in experimental solutions containing 86Rb+ (K+) 
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isotope with the inhibitors alone and in combination for 15 minutes. Cells were washed 4 times 
with ice-cold Krebs’ solution and lysed in distilled water. Cell extracts were collected and 86Rb+ 
activity was measured. A. The 86Rb+ influx data of MCF-7 cells, comparing isosmotic ( ) to 
hypertonic ( ) conditions in the absence (Total) and presence of 10-4 M furosemide, 10-5 M 
ouabain and both furosemide and ouabain (F + O). Data is normalised against the cell number. 
*p < 0.05 and **p < 0.0001 by ANOVA. Error bars indicate standard error of the mean of four 
replicates per condition from one experiment. B. An illustration of the furosemide-sensitive 
(NKCC1) influx samples and ouabain-sensitive (Na+K+ATPase) influx in MCF-7 cells. 
Furosemide-sensitive influx = (ouabain) - (furosemide + ouabain), Ouabain-sensitive influx = 
(furosemide) - (furosemide + ouabain). 
 
3.6.3 86Rb+ (K+) influx measurement under isosmotic and hypertonic 
conditions of EFM-19 cells grown in full media 
The results of assessing the effect of hypertonicity in EFM-19 cells is shown in 
Figure 3.20A. In the presence of furosemide under hypertonic conditions, the 
total 86Rb+ (K+) influx decreased significantly from 101.40±11.73 nmol/106 
cells/15mins to 70.47±3.52 nmol/106 cells/15mins (p = 0.0233, ANOVA). 
Similarly when furosemide was added in the presence and absence of ouabain 
in hypertonic conditions, the 86Rb+ (K+) influx decreased further from 54.23±4.39 
nmol/106 cells/15mins to 5.89±0.31 nmol/106 cells/15mins (p = 0.0001, ANOVA) 
and was statistically significant. The calculated furosemide-sensitive and 
ouabain-sensitive influx is shown in Figure 3.20B. When comparing the 
furosemide-sensitive influx between isosmotic and hypertonic conditions, the 
furosemide-sensitive influx increased from 10.44 nmol/106 cells/15mins to 51.68 
nmol/106 cells/15mins and was statistically different (p = 0.0108, ANOVA). This 
activation of NKCC1 in response to decreased cell volume under hypertonic 
conditions further supports the well-known role of NKCC1 in the regulation of 
cell volume. There was no change in the ouabain-sensitive influx under both 
isosmotic and hypertonic conditions. 
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Figure 3.20 86Rb+ (K+) influx in EFM-19 cells under isosmotic and hypertonic conditions. 
EFM-19 cells were cultured in routine culture medium in 6-well plates for 3 days. Cells were 
washed with Krebs’ solution and incubated in experimental solutions containing 86Rb+ (K+) 
isotope with the inhibitors alone and in combination for 15 minutes. Cells were washed 4 times 
with ice-cold Krebs’ solution and lysed in distilled water. Cell lysates were collected and 86Rb+ 
activity was measured. A. The 86Rb+ influx data of EFM-19 cells, comparing isosmotic ( ) to 
hypertonic ( ) conditions in the absence (Total) and presence of 10-4 M furosemide, 10-5 M 
ouabain and both furosemide and ouabain (F + O). Data is normalised against the cell number. 
*p < 0.05 and **p < 0.0001 by ANOVA. Error bars indicate standard error of the mean of four 
replicates per condition from one experiment. B. An illustration of the furosemide-sensitive 
(NKCC1) influx samples and ouabain-sensitive (Na+K+ATPase) influx in EFM-19 cells. 
Furosemide-sensitive influx = (ouabain) - (furosemide + ouabain), Ouabain-sensitive influx = 
(furosemide) - (furosemide + ouabain). 
 
3.6.4 Action of oestradiol on 86Rb+ (K+) influx in MCF-7 cells 
The effect of oestrogen on 86Rb+ (K+) influx in MCF-7 cells was assessed. It 
was noted that in the presence of oestrogen, MCF-7 cells were prone to 
detachment during the washes required to perform the 86Rb+ (K+) influx 
measurements. As a result of this cell detachment the results obtained were not 
consistent. Therefore to overcome this problem of detachment and to increase 
adherence, MCF-7 cells were seeded onto collagen-coated plates. The cells 
grown on collagen-coated plates were able to withstand the rapid washes with 
Krebs’ solution subsequent to incubation. 
The 86Rb+ (K+) influx of MCF-7 cells grown on collagen-coated plates is shown 
in Figure 3.21A. The influx of cells cultured in the absence of oestrogen were 
always higher than the influx of oestrogen-treated cells. In the presence of 
furosemide, there was a decrease in total influx from 59.04±8.27 nmol/106 
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cells/15mins to 51.54±2.25 nmol/106 cells/15mins in the absence of oestrogen 
(p = 0.9926, ANOVA), and from 50.96±2.36 nmol/106 cells/15mins to 
38.66±4.87 nmol/106 cells/15mins in the presence of oestrogen (p = 0.5228, 
ANOVA). However, this comparison between the total influx in the absence and 
presence of oestrogen was not statistically significant (p = 0.9811, ANOVA).  
As shown in Figure 3.21B the furosemide-sensitive influx reduced from 6.97 
nmol/106 cells/15mins in the oestrogen withdrawn cells to 2.46 nmol/106 
cells/15mins, in the oestrogen treated cells and this difference was not 
statistically significant (p = 0.9593, ANOVA). Similarly the ouabain-sensitive 
influx was 36.37 nmol/106 cells/15mins in oestrogen withdrawn cells and 
decreased to 26.93 nmol/106 cells/15mins in oestrogen treated cells. However 
this decrease was not statistically significant (p = 0.4743, ANOVA).      
 
Figure 3.21 86Rb+ (K+) influx in MCF-7 cells grown on collagen-coated plates in the 
absence and presence of oestrogen. MCF-7 cells were seeded at a density of 10,000 cells 
per well in a 6-well plate and cultured in phenol-red-free media alone or in the presence of 10-9 
M of 17β-oestradiol for 8 days. The cells were cultured in steroid depleted media for 2 days prior 
to oestradiol treatment. Cells were washed with Krebs’ solution and incubated in experimental 
solutions containing 86Rb+ (K+) isotope with the inhibitors alone and in combination for 15 
minutes. Cells were washed 4 times with ice-cold Krebs’ solution and lysed in distilled water. 
Cell lysates were collected and 86Rb+ activity was measured. A. The 86Rb+ influx data of MCF-7 
cells after oestrogen stimulation for 8 days, comparing untreated (-E2 ) cells to oestrogen 
stimulated (+E2 ) cells in the absence (Total) and presence of 10-4 M furosemide, 10-5 M 
ouabain and both furosemide and ouabain (F + O). Data is normalised against the cell number. 
**p < 0.0001 by ANOVA. Error bars indicate standard error of the mean of four replicates per 
condition from one experiment. B. An illustration of the furosemide-sensitive (NKCC1) influx 
samples and ouabain-sensitive (Na+K+ATPase) influx in MCF-7 cells. Furosemide-sensitive 
influx = (ouabain) - (furosemide + ouabain), Ouabain-sensitive influx = (furosemide) - 
(furosemide + ouabain). 
 
83 
 
3.6.5 Action of oestradiol on 86Rb+ (K+) influx in EFM-19 cells 
Figure 3.22A displays the results from a similar experiment in EFM-19 cells. 
With the addition of furosemide, the influx in serum depleted cells dropped from 
57.54±6.96 nmol/106 cells/15mins to 39.66±4.18 nmol/106 cells/15mins. This 
decrease was not statistically significant (p = 0.1067, ANOVA). But in response 
to the addition of furosemide in the oestrogen treated cells the total influx 
decreased significantly from 54.14±2.54 nmol/106 cells/15mins to 29.56±6.22 
nmol/106 cells/15mins (p = 0.0056, ANOVA).  
However as shown in Figure 3.22B, the furosemide-sensitive influx was not 
significant (p = 0.8884, ANOVA) when comparing the oestrogen withdrawn and 
oestrogen treated EFM-19 cells. Also a comparison between the ouabain-
sensitive influx between oestrogen withdrawn and oestrogen treated cells was 
not statistically significant (p = 0.6783, ANOVA). 
 
Figure 3.22 86Rb+ (K+) influx in EFM-19 cells in the absence and presence of oestrogen. 
EFM-19 cells were cultured in phenol-red-free media alone or in the presence of 10-9 M of 17β-
oestradiol for 8 days. The cells were cultured in steroid depleted media for 2 days prior to 
oestradiol treatment. Cells were washed with Krebs’ solution and incubated in experimental 
solutions containing 86Rb+ (K+) isotope with the inhibitors alone and in combination for 15 
minutes. Cells were washed 4 times with ice-cold Krebs’ solution and lysed in distilled water. 
Cell extracts were collected and 86Rb+ activity was measured. A. The 86Rb+ influx data of EFM-
19 cells after oestrogen stimulation for 6 days, comparing untreated (-E2 ) cells to oestrogen 
stimulated (+E2 ) cells in the absence (Total) and presence of 10-4 M furosemide, 10-5 M 
ouabain and both furosemide and ouabain (F + O). Data is normalised against the cell number. 
*p < 0.05 and **p < 0.0001 by ANOVA. Error bars indicate standard error of the mean of four 
replicates per condition from one experiment. B. An illustration of the furosemide-sensitive 
(NKCC1) influx samples and ouabain-sensitive (Na+K+ATPase) influx in EFM-19 cells. 
Furosemide-sensitive influx = (ouabain) - (furosemide + ouabain), Ouabain-sensitive influx = 
(furosemide) - (furosemide + ouabain). 
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3.6.6 Effect of hypertonicity on 86Rb+ (K+) influx measurement of MCF-7 cells 
in the absence and presence of oestrogen 
In section 3.6.2, it was shown that hypertonic stimulation by 200 mM mannitol 
activated the previously quiescent NKCC1 in cells grown in full media. 
Therefore it is now possible to investigate whether there is an alteration in the 
activity of NKCC1 between untreated and oestrogen-treated cells. 
MCF-7 cells cultured on collagen-coated plates were withdrawn for 5 days and 
half the cells were treated with 10-9 M oestrogen for a period of 10 days before 
the 86Rb+ (K+) influx was measured. 
Figure 3.23A shows the variation of 86Rb+ (K+) influx in the absence and 
presence of oestrogen when subject to hypertonic stress. In the presence of the 
Na+K+ATPase inhibitor ouabain there was a significant difference in influx 
between the serum withdrawn and oestrogen-treated cells (p = 0.0001, 
ANOVA). Similarly, under hypertonic conditions the influx in the presence of 
ouabain decreased from 102.13±8.74 nmol/106 cells/15mins to 59.39±6.72 
nmol/106 cells/15mins which was of statistical significance (p = 0.0360, ANOVA). 
Nevertheless, there was almost no change in the bumetanide-sensitive influx 
between serum withdrawn and oestrogen treated cells and was not statistically 
significant under both isosmotic and hypertonic conditions (p = 0.9999, ANOVA) 
as shown in Figure 3.23B.     
The effect of hypertonicity on NKCC1 sensitive influx is also shown in Figure 
3.23B. NKCC1 is seen to be activated by the increase in the bumetanide-
sensitive influx from 7.46 nmol/106 cells/15mins to 45.17 nmol/106 cells/15mins 
in the absence of oestrogen and from 9.50 nmol/106 cells/15mins to 37.54 
nmol/106 cells/15mins in the presence of oestrogen. However both these 
increases did not reach statistical significance (p = 0.2740, ANOVA). 
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Figure 3.23 86Rb+ (K+) influx in MCF-7 cells grown on collagen-coated plates in the 
absence and presence of oestrogen under isosmotic and hypertonic conditions. MCF-7 
cells were cultured in phenol-red-free media alone or in the presence of 10-9 M of 17β-oestradiol 
for 10 days. The cells were cultured in steroid depleted media for 5 days prior to oestradiol 
treatment. Cells were washed with Krebs’ solution and incubated in experimental solutions 
containing 86Rb+ (K+) isotope with the inhibitors alone and in combination for 15 minutes. Cells 
were washed 4 times with ice-cold Krebs’ solution and lysed in distilled water. Cell extracts were 
collected and 86Rb+ activity was measured. A. The 86Rb+ influx data of MCF-7 cells after 
oestrogen stimulation for 10 days, comparing untreated (-E2 ) cells to oestrogen stimulated 
(+E2 ) cells in the presence of 10-5 M ouabain alone and both 10-4 M bumetanide and ouabain 
(B + O) under isosmotic and hypertonic conditions. Data is normalised against the cell number. 
*p < 0.05 and **p < 0.0001 by ANOVA. Error bars indicate standard error of the mean of four 
replicates per condition from one experiment. B. An illustration of the bumetanide-sensitive 
(NKCC1) influx samples and ouabain-sensitive (Na+K+ATPase) influx in MCF-7 cells. 
Bumetanide-sensitive influx = (ouabain) - (bumetanide + ouabain). 
 
3.6.7 Effect of hypertonicity on 86Rb+ (K+) influx measurement of EFM-19 cells 
in the absence and presence of oestrogen 
Similarly the effect of hypertonicity on the activation of NKCC1 in oestrogen 
withdrawn and oestrogen stimulated EFM-19 cells was evaluated. The 86Rb+ (K+) 
influx data from this experiment is shown below. 
From Figure 3.24A it is evident that the addition of ouabain under both 
isosmotic and hypertonic conditions caused a significant decrease (p = 0.0001, 
ANOVA) in influx when comparing between oestrogen withdrawn and oestrogen 
treated cells. 
As indicated in Figure 3.24B, hypertonicity causes a dramatic increase in the 
bumetanide-sensitive influx in both serum withdrawn and oestrogen treated 
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cells. In cells grown in the absence of oestrogen, the bumetanide-sensitive 
influx increased significantly from 15.57 nmol/106 cells/15mins to 119.32 
nmol/106 cells/15mins (p = 0.0001, ANOVA). Likewise, the bumetanide-
sensitive influx in cells in the presence of oestrogen increased significantly from 
4.37 nmol/106 cells/15mins to 52.02 nmol/106 cells/15mins (p = 0.0001, ANOVA). 
When comparing the bumetanide-sensitive influx between cells in the absence 
and presence of oestrogen, a slight non-significant decrease (p = 0.5559, 
ANOVA) was observed in isosmotic conditions. But under hypertonic conditions 
the bumetanide-sensitive influx decreased from 119.32 nmol/106 cells/15mins to 
52.02 nmol/106 cells/15mins in the presence of oestrogen. This difference was 
of statistical significance (p = 0.0001, ANOVA). 
 
Figure 3.24 86Rb+ (K+) influx in EFM-19 cells in the absence and presence of oestrogen 
under isosmotic and hypertonic conditions. EFM-19 cells were cultured in phenol-red-free 
media alone or in the presence of 10-9 M of 17β-oestradiol for 10 days. The cells were cultured 
in steroid depleted media for 5 days prior to oestradiol treatment. Cells were washed with Krebs’ 
solution and incubated in experimental solutions containing 86Rb+ (K+) isotope with the inhibitors 
alone and in combination for 15 minutes. Cells were washed 4 times with ice-cold Krebs’ 
solution and lysed in distilled water. Cell lysates were collected and 86Rb+ activity was measured. 
A. The 86Rb+ influx data of EFM-19 cells after oestrogen stimulation for 10 days, comparing 
untreated (-E2 ) cells to oestrogen stimulated (+E2 ) cells in the presence of 10-5 M ouabain 
alone and both 10-4 M bumetanide and ouabain (B + O) under isosmotic and hypertonic 
conditions. Data is normalised against the cell number. *p < 0.05 and **p < 0.0001 by ANOVA. 
Error bars indicate standard error of the mean of four replicates per condition from one 
experiment. B. An illustration of the bumetanide-sensitive (NKCC1) influx samples and ouabain-
sensitive (Na+K+ATPase) influx in EFM-19 cells. Bumetanide-sensitive influx = (ouabain) - 
(bumetanide + ouabain). 
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Collectively these results suggest that there is a possibility of inducing a loop-
diuretic-sensitive influx by activating the previously quiescent NKCC1 under 
hypertonic conditions. The effect of oestrogen on hypertonically activated 
NKCC1 in EFM-19 cells seems promising as it significantly reduced the 
bumetanide-sensitive influx. In MCF-7 cells, there was almost no difference in 
the bumetanide-sensitive influx between oestrogen withdrawn and oestrogen 
treated cells under hypertonic conditions. However this requires further 
evaluation due to discrepancy in the data obtained. 
 
3.7 Discussion 
3.7.1 Expression and localization 
Ion transporters have been implicated in many aspects of cancer pathogenesis 
and their stimulation may promote tumour cell migration and invasion. 
Microarrays using Affymetrix GeneChips identified a novel oestrogen-regulated 
gene SLC12A2 which was downregulated in response to oestrogen in three 
oestrogen receptor α-positive cell lines: MCF-7, EFM-19 and EFF-3 (Wright et 
al., 2009). The data presented in this chapter evaluated the expression and 
function of the NKCC1 protein which is encoded by the SLC12A2 gene.   
This is the first study that investigated the protein expression of NKCC1 in 
breast cancer cells. Western transfer analysis revealed the variability of 
glycosylated NKCC1 protein expression between different oestrogen-
responsive and oestrogen-unresponsive cell lines. The highest level of 
expression was observed in the ZR-75 and Hs578T cells, whereas the lowest 
levels were in the cell lines SKBR3 and BT-20. BT-474, EFF-3 and EFM-19 
cells had a higher NKCC1 expression in comparison to the cell lines MCF-7, 
MDA-MB-231 and HBL-100. Also there was no detectable NKCC1 expression 
in T47-D cells. 
Experiments using immunofluorescence discovered the cellular localisation of 
NKCC1 in the three oestrogen-responsive breast cancer cell lines MCF-7, EFM-
19 and EFF-3. Results showed that NKCC1 is localised to the plasma 
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membrane in all three cells lines. In EFF-3 cells, vesicle-like immunoreactions 
were observed in addition to the stronger immunoreaction at the plasma 
membrane. In virgin mouse mammary ductal epithelial cells, NKCC1 was 
localised to the basolateral membrane (Shillingford et al., 2002).          
3.7.2 Oestrogen regulation 
The previously unrecognised regulation of SLC12A2 gene and its protein 
NKCC1 by oestrogen was confirmed. In this study, the NKCC1 protein 
expression was clearly decreased in response to oestrogen treatment. After 
eight days of oestrogen treatment there was almost complete reduction of 
NKCC1 expression in all three cell lines. This result was consistent with the 
previous findings demonstrating the downregulation of the gene SLC12A2 and 
the reduction in mRNA expression of NKCC1 by oestrogen (Wright et al., 2009). 
In the current study, immunofluorescence images of MCF-7 and EFM-19 cells 
showed a honeycomb appearance, suggesting that NKCC1 is localised to the 
lateral aspects of the cell. The x-z images revealed that the oestrogen-
stimulated cells do not show marked lateralisation of NKCC1 at the membrane, 
in comparison to the unstimulated cells. Also the oestrogen-treated cells form a 
multilayer, suggesting that oestrogen promotes cell proliferation. The reduction 
in NKCC1 protein expression was oestrogen concentration dependent. 
Together, these data support that NKCC1 is under direct regulation of 
oestrogen.  
3.7.3 Functional activity 
Radioactive Rubidium 86Rb+ is an isotopic tracer that allows measurement of 
the movement of K+ ions. This 86Rb+ (K+) influx assay provides a measure of the 
activity of NKCC1 in breast cancer cells. Influx measurements were made in the 
presence of two types of inhibitors: a Na+K+ATPase inhibitor, ouabain, and the 
NKCC1 inhibitors, furosemide and bumetanide. The loop diuretic bumetanide is 
a more potent inhibitor of NKCC1 than furosemide. 
Results indicated that MCF-7 and EFM-19 cells cultured in routine medium had 
higher ouabain-sensitive influx and a lower furosemide-sensitive influx, 
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suggesting that the functional activity of NKCC1 is low in these cells. The 
reason for this low activity of NKCC1 could perhaps be due to oestrogens in the 
foetal calf serum which suppresses the expression of SLC12A2. Any residual 
NKCC1 at the cell membrane exists presumably in a quiescent state under such 
conditions, giving rise to very low 86Rb+ (K+) influx measurements. Therefore the 
main mode of K+ ion influx is through Na+K+ATPase in MCF-7 and EFM-19 cells. 
Although these results formed a positive basis for determining the effects of 
oestrogen in the regulation of functional NKCC1, further experimentation was 
required to come to a firm conclusion.          
The addition of 200 mM osmolyte mannitol to the experimental solutions 
introduced hypertonicity leading to a significant increase in the furosemide-
sensitive influx which is representative of the activation of NKCC1. Similar 
hypertonicity-induced NKCC1 activation have been demonstrated in other 
studies (Glanville et al., 2001; Delpire and Gagnon, 2011). The addition of 
mannitol increases the osmolarity, leading to loss of water from the cells, which 
in turn cause cell shrinkage. Data from the present study supports the known 
ability of NKCC1 to regulate cell volume and the activation of NKCC1 in 
response to cell shrinkage (Russell, 2000; Hebert et al., 2004). These data 
demonstrated also that NKCC1 present at the cell membrane was previously 
inactive under isosmotic conditions. The activation of NKCC1 in response to 
hypertonic stress is mediated via phosphorylation and activation of the WNK 
signalling pathway. The phosphorylation of WNK leads to the phosphorylation of 
SPAK/OSR1, which then phosphorylates and activates NKCC1 (Smith et al., 
2008; Thastrup et al., 2012). A decrease in intracellular concentration of Cl- ions 
plays a major role in the regulatory volume increase by allowing the transport of 
Na+, K+ and Cl- ions through activation of NKCC1 (Lytle and McManus, 2002; 
Monette and Forbush, 2012).      
There was a possibility that the high-confluency of cells cultured in 6-well plates 
limited the access of 86Rb+ to the basal surface of cells, on which NKCC1 is 
located, therefore lower seeding densities were tested. This too proved 
impossible as cells especially MCF-7 cells detached from the plate during the 
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rapid washes. Therefore alternate methods of strengthening cell attachment to 
the 6-well plates, such as the use of collagen-coated plates were considered.  
The effect of oestrogen on the functional regulation of NKCC1 was evaluated. 
The influx data indicated that there is a slight but statistically insignificant 
decrease in the loop-diuretic-sensitive influx in both MCF-7 and EFM-19 cells 
cultured in the presence of oestrogen, despite a significant decrease in NKCC1 
protein expression in response to oestrogen. Further investigation of untreated 
and oestrogen treated EFM-19 cells showed a statistically significant decrease 
in the bumetanide-sensitive influx under hypertonic conditions in the presence 
of mannitol. However, this notable decrease in bumetanide-sensitive influx is 
not observed under isosmotic conditions. It is observed only under hypertonic 
conditions.          
3.8 Conclusion 
In summary, it was shown that NKCC1 is expressed in a variety of breast 
cancer cell lines, both ER-positive and ER-negative. Also data from western 
transfer and immunofluorescence showed positive results, as NKCC1 protein 
expression was decreased in oestrogen-stimulated cells in comparison to the 
unstimulated cells. These results confirmed the previously obtained microarray 
data in MCF-7, EFM-19 and EFF-3 cells. The functional studies showed that the 
NKCC1 present at the cell membrane is inactive under isotonic conditions. 
NKCC1 could be activated via induction of hypertonic stress. Results from this 
functional assay demonstrate the role of NKCC1 in the regulation of cell volume 
in oestrogen-responsive breast cancer cell lines MCF-7 and EFM-19. Although 
it is difficult to conclude firmly that oestrogen reduces the bumetanide-sensitive 
influx in MCF-7 and EFM-19 cells, there is a hint of such a reduction. 
Collectively, these results demonstrate that the total NKCC1 protein expression 
in these cells might have decreased in response to oestrogen, but the functional 
NKCC1 present in the cell membrane has not. Further investigation is required 
to elucidate the possible revelation of functional activity of NKCC1 at the cell 
membrane. 
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Chapter 4.    PDZK1 (NHERF3) 
4.1 Introduction 
The oestrogen-responsive gene PDZK1, located in chromosome 1, encodes the 
NHERF3 protein. The 519 amino acid protein NHERF3 is a Na+ H+ exchange 
regulatory co-factor. NHERF3 is a member of the NHERF family that has four 
members, NHERF1, NHERF2, NHERF3 and NHERF4. These proteins contain 
PDZ domains that have roles in many cellular functions such as cell proliferation, 
differentiation and ion transport. The expression of NHERF3 is limited to 
epithelial cells of breast, pancreas, gastrointestinal tract and proximal tubule of 
the kidney (Kocher et al., 1998). NHERF1 and NHERF2 have two PDZ domains, 
while NHERF3 and NHERF4 have four PDZ domains. These PDZ family 
proteins are also known as adapter proteins, because they facilitate the 
organisation of proteins at the cell membrane. The PDZ domains can interact 
simultaneously with several membrane-associated proteins at the cell 
membrane.  
NHERF3 has been reported to be overexpressed in cancers originating from 
epithelial cells (Kocher et al., 1999). NHERF3 overexpression is more common 
in oestrogen receptor-positive breast cancers, than in oestrogen receptor-
negative breast cancers. Several gene expression studies have identified 
PDZK1 as an oestrogen-regulated gene that is increased in response to 
oestrogen (Ghosh et al., 2000; Wright et al., 2009).         
4.1.1 Aim 
The experiments described in this chapter, firstly aim to evaluate the expression 
and localisation of NHERF3 protein in MCF-7, EFM-19 and EFF-3 cells. 
Secondly, the effects of oestrogen and anti-oestrogens on the expression of 
NHERF3 were studied. The final section measures the internal pH of these 
oestrogen-responsive breast cancer cells, as a model designed to assess the 
functional role of NHERF3.  
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4.2 Expression of NHERF3 in breast cancer cells 
4.2.1 Expression of NHERF3 in breast cancer cell lines 
The expression of NHERF3 protein in several oestrogen-responsive and 
oestrogen-unresponsive cell lines was evaluated by western transfer analysis. 
Protein lysates were extracted from T75 flasks of breast cancer cells and equal 
amounts of 20 µg of protein were separated by gel electrophoresis. The results 
are shown below in Figure 4.1. 
Strong immunoreactive protein bands were detected at 66 kDa, corresponding 
to the theoretical mass of the NHERF3 protein. The oestrogen responsive cell 
line ZR-75 had the highest level of protein expression, followed by MCF-7, T47-
D and EFM-19. The high molecular mass band present in ZR-75 cells was a 
strong diffuse protein band. The rabbit polyclonal antibody detected also an 
additional protein band at around 46 kDa. This 46 kDa band was slightly more 
abundant than the 66 kDa band in MCF-7 and EFM-19 cells, whereas it was 
less abundant in T47-D and ZR-75 cell lines. However, EFF-3 and BT-474 cells 
had no detectable expression of the NHERF3 protein. None of the oestrogen 
unresponsive cell lines MDA-MB-231, SKBR3, BT-20, Hs578T and HBL-100 
had detectable expression of the NHERF3 protein.     
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Figure 4.1 Expression of NHERF3 in breast cancer cells. Different breast cancer cell lines 
were cultured in routine culture medium in T75 flasks. Cells were lysed and protein extracts 
were prepared. Equal amounts of 20 µg of protein were separated by 12% polyacrylamide gel 
electrophoresis and then transferred to nitrocellulose membranes. The membranes were 
incubated with anti-NHERF3 antibody (1:10000 dilution) overnight at 4 oC, followed by 
horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 37 oC. 
Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A. The protein expression of NHERF3 was determined by 
Western transfer analysis in MCF-7, EFM-19, EFF-3, BT-474, T47-D, ZR-75, MDA-MB-231 
(MDA-231), SKBR3, BT-20, Hs578T and HBL-100 cells. B. Densitometric quantification of the 
66 kDa band for NHERF3. The black bars ( ) represent oestrogen-responsive cell lines, 
whereas the grey bars ( ) indicate the oestrogen-unresponsive cell lines. Error bars indicate 
standard errors of the mean of triplicate measurements. 
 
4.3 Cellular localisation of NHERF3 in breast cancer cells 
This section aims to identify the cellular localisation of NHERF3 in three 
oestrogen responsive breast cancer cells MCF-7, EFM-19 and EFF-3 by 
immunofluorescence.   
4.3.1 Optimisation of conditions  
One of the most important steps in immunofluorescence is the fixation and 
permeabilisation treatment. Typically several different combinations of 
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treatments have to be tested. The cell fixation and permeabilisation conditions 
were optimised to determine the best conditions for the NHERF3 antibody.  
Cells were fixed in either methanol or 4% paraformaldehyde and permeabilised 
in either 0.3% triton X-100 or 0.2% saponin. Immunofluorescence procedure is 
as described in Materials and Methods. 
The evaluation of the effects of different fixation and permeabilisation conditions 
are shown in Figure 4.2. When cells were fixed in methanol and permeabilised 
with blocking buffer containing triton, and then incubated with no primary 
NHERF3 antibody or only with the AF488 anti-rabbit (1:1000 dilution) secondary 
antibody, there was no signal. These results indicate that under these 
conditions there was no non-specific immunofluorescence. The results indicated 
that the optimum condition for detection of NHERF3 by immunofluorescence 
are cell fixation with 4% paraformaldehyde and permeabilisation with saponin. 
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Figure 4.2 Optimisation of fixation and permeabilisation conditions for detection of 
NHERF3. MCF-7 cells were seeded at a density of 1x105 cells onto 6-well plates and cultured in 
routine culture medium for 24 hours. The next day, cells were washed with PBS and fixed in 
either methanol at -20 oC or in 4 % paraformaldehyde at room temperature. After fixation, the 
cells were washed with PBS thrice with each wash lasting 20 minutes. Cells were then blocked 
in blocking buffer containing either triton or saponin for 1 hour at room temperature. The 
blocking buffer was aspirated and the primary antibody NHERF3 was added at 1:100 dilution 
and incubated overnight at 4 oC. The following day the primary antibody was aspirated and the 
cells were washed 3 times with PBS, 15 minutes each. The secondary antibody Alexa fluor 488 
conjugated goat anti-rabbit were added at a dilution of 1:1000 and the coverslips were covered 
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in foil and the cells were incubated for 1 - 2 hours at room temperature. Cells were washed 3 
times with PBS. DAPI mounting media was added to the glass slides prior to placing the 
coverslip on the slide and the cells were examined under the fluorescent microscope (Leica 
DMR) using a 40x objective. Results are shown for different treatment conditions of fixation and 
permeabilisation. Images on the column indicated with “DAPI” show nuclear staining, whereas 
the images indicated with “NHERF3” show the immunoreaction for NHERF3. The “Merged” 
images show both nuclear (blue) and NHERF3 (green) staining together. Scale bar = 45 µm. 
 
4.3.2 Localisation of NHERF3 in oestrogen-responsive cell lines 
After the fixation and permeabilisation conditions had been optimised, the next 
step was to analyse the cellular localisation of NHERF3 protein in the MCF-7, 
EFM-19 and EFF-3 cells. 
The images A3, B3 and C3 of Figure 4.3 illustrate the localisation of NHERF3 in 
MCF-7, EFM-19 and EFF-3 cells, respectively. NHERF3 protein is observed to 
be localised to the cytoplasm. There is a variation in the expression between 
cells within each image. As observed in images A2 (MCF-7) and B2 (EFM-19) 
cells show a degree of heterogeneous immunoreaction between cells. In some 
cells, clear vesicular expression is noticeable as indicated by the white arrows. 
This vesicular nature is more frequently observed in EFF-3 cells. 
Images presented in Figure 4.4 were collected with a 63x oil immersion 
objective of a confocal microscope and then the cross-sectional view was 
computed. Figure 4.4B clearly represents the vesicular expression of NHERF3 
in MCF-7 cells. The red fluorescence is the AF555 conjugated phalloidin, which 
binds to the actin filaments of the cell and identifies the cytoskeleton. The white 
arrow in Figure 4.4C indicates phalloidin immunoreaction on the perijunctional 
ring. Also notice the stronger expression of actin at the surface where the cells 
attach to the coverslip. Pointed out by the yellow arrows in Figure 4.4D, are 
sites where NHERF3 is co-localised with actin. 
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Figure 4.3 Localisation of NHERF3 in cell lines. MCF-7, EFM19 and EFF-3 cells were 
seeded onto coverslips in 6-well plates and cultured in routine culture medium for 24 hours. 
Cells were washed with PBS and fixed in 4% paraformaldehyde at room temperature. After 
fixation, cells were washed with PBS three times for 15 minutes each. Cells were then blocked 
in blocking buffer containing saponin for 1 hour at room temperature. The blocking medium was 
aspirated and the primary antibody NHERF3 was added at 1:100 dilution and incubated 
overnight at 4 oC. Cells were washed 3 times with PBS, 15 minutes each. The secondary 
antibody Alexa fluor 488 conjugated goat anti-rabbit were added at a dilution of 1:1000 and 
were covered in foil and the cells were incubated for 1 hour at room temperature. Cells were 
washed 3 times with PBS. DAPI mounting media was added to the glass slides prior to placing 
the coverslip on the slide and the cells were examined under the fluorescent microscope (Leica 
DMR) using a 40x objective. Images A1, B1 and C1 show the nuclear staining, whereas the 
images A2, B2 and C2 show the immunoreaction for NHERF3 in MCF-7, EFM-19 and EFF-3 
cells, respectively. The merged images A3, B3 and C3 show both nuclear (blue) and NHERF3 
(green) staining combined together. Scale bar = 45 µm. The white arrow ( ) indicate 
examples of clear vesicular expression. 
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Figure 4.4 Cross-sectional images of the localisation of NHERF3 in MCF-7 cells. MCF-7 
cells were seeded onto coverslips in 6-well plates and cultured in routine culture medium for 24 
hours. Cells were washed with PBS and fixed in 4% paraformaldehyde at room temperature. 
After fixation, cells were washed with PBS three times for 15 minutes each. Cells were then 
blocked in blocking buffer containing saponin for 1 hour at room temperature. The blocking 
medium was aspirated and the primary antibody NHERF3 was added at 1:100 dilution and 
incubated overnight at 4 oC. Cells were washed 3 times with PBS, 15 minutes each. The 
secondary antibody Alexa fluor 488 conjugated goat anti-rabbit were added at a dilution of 
1:1000 and were covered in foil and the cells were incubated for 1 hour at room temperature. 
Cells were washed 3 times with PBS. Alexa fluor 555 conjugated phalloidin was added at a 
dilution of 1:100 and incubated for 15 minutes at room temperature. DAPI mounting media was 
added to the glass slides prior to placing the coverslip on the slide and the cells were examined 
under the confocal microscope using a 63x objective (Oil, 1.63). X-Z images A, B and C show 
nuclear (blue), NHERF3 (green) and phalloidin (red) staining, respectively. X-Z image D is an 
overlay of A, B and C. Scale bars = 25 µm. The white arrow ( ) indicate a perijunctional ring 
and the yellow arrow ( ) indicate examples of co-localisation of NHERF3 with actin.  
 
4.4 Evaluation of the regulation of NHERF3 by oestrogen 
4.4.1 Effect of oestradiol on NHERF3 protein expression in MCF-7 cells 
The regulation of protein expression of NHERF3 by oestrogen was tested. The 
temporal response to oestrogen stimulation was studied by culturing MCF-7 
cells in steroid depleted media for 5 days followed by addition of 10-9 M 
oestradiol for different lengths of time from 0 hours upto 10 days. A similar set 
of untreated cells for each timepoint were used for comparison. Cells were 
lysed and protein extracts were separated by gel electrophoresis. The results 
are shown in Figure 4.5.         
In comparison to the expression measured in cells grown in routine culture 
medium (Figure 4.1A), after the cells have been withdrawn from growth factors 
for 5 days, the NHERF3 expression diminishes completely as observed at the 0 
hours timepoint. This observation suggests that oestrogen present in the FCS of 
full DMEM medium is responsible for the induction of NHERF3 expression. 
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When MCF-7 cells are cultured in the presence of oestrogen, there is a 
significant stimulation of NHERF3 protein expression starting from 2 days 
onwards. This stimulation is maximal at 6 days and persists with time. 
 
Figure 4.5 Effect of oestrogen on expression of NHERF3 in MCF-7 cells. Cells were steroid 
deprived by growing in phenol-red-free media containing 10% dextran-coated charcoal treated 
serum and 1 µg/ml insulin, for 5 days and then treated with 10-9 M of 17β-oestradiol for different 
lengths of time upto 10 days. Both the oestradiol-treated and untreated cells were lysed and 
protein extracts prepared. Protein aliquots of 20 µg were separated by 12% polyacrylamide gel 
electrophoresis and then transferred to nitrocellulose membranes. The membranes were 
incubated with anti-NHERF3 antibody (dilution 1:5000) overnight at 4 oC, followed by 
horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 37 oC. 
Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A. The protein expression of NHERF3 in MCF-7 cells after 
oestrogen stimulation for a timecourse of 0 hours to 10 days, comparing serum withdrawn (-E2 
) samples with oestrogen-stimulated (+E2 ) samples. Images shown are representative of 
results from experiments which have been replicated thrice. B. Quantification of NHERF3 
normalised against the corresponding GAPDH signal, **p < 0.001 by ANOVA. Error bars 
indicate SEM of triplicate measurements. 
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4.4.2 Effect of oestradiol on NHERF3 protein expression in EFM-19 cells 
The regulation of expression of NHERF3 protein by oestrogen in EFM-19 cells 
was investigated. The addition of oestrogen to cells resulted in an increase in 
NHERF3 protein expression. After 2 days of treatment, there was a slight 
induction, which increased gradually with longer incubation times. The 
stimulation of NHERF3 expression was highest at day 8, but detected a lower 
level of induction at 10 days. (Figure 4.6)      
 
Figure 4.6 Effect of oestrogen on expression of NHERF3 in EFM-19 cells. Cells were 
steroid deprived by growing in phenol-red-free media containing 10% dextran-coated charcoal 
treated serum and 1 µg/ml insulin, for 5 days and then treated with 10-9 M of 17β-oestradiol for 
different lengths of time upto 10 days. Both the oestradiol-treated and untreated cells were 
lysed and protein extracts prepared. Protein aliquots of 20 µg were separated by 12% 
polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. The 
membranes were incubated with anti-NHERF3 antibody (dilution 1:5000) overnight at 4 oC, 
followed by horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 
37 oC. Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A. The protein expression of NHERF3 in EFM-19 cells after 
oestrogen stimulation for a timecourse of 0 hours to 10 days, comparing serum withdrawn (-E2 
) samples with oestrogen-stimulated (+E2 ) samples. Images shown are representative of 
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results from experiments which have been replicated thrice. B. Quantification of NHERF3 
normalised against the corresponding GAPDH signal, *p<0.05 and **p < 0.001 by ANOVA. 
Error bars indicate SEM of triplicate measurements. 
 
4.4.3 Effect of oestradiol on NHERF3 protein expression in EFF-3 cells 
Although there was no expression of NHERF3 protein detected in EFF-3 cells 
cultured in full medium, we evaluated the effects of oestrogen on NHERF3 
expression after different times of treatment. Results from this experiment are 
illustrated in Figure 4.7. There was no induction of NHERF3 during the first 4 
days. However, very little expression was detected after 6 days of oestradiol 
treatment. Interestingly, there was a more prominent induction at 8 and 10 days. 
 
Figure 4.7 Effect of oestrogen on expression of NHERF3 in EFF-3 cells. EFF-3 cells were 
plated at a density of 150,000 cells per well onto a 24-well plate. Cells were steroid deprived by 
growing in phenol-red-free media containing 10% dextran-coated charcoal treated serum and 1 
µg/ml insulin, for 5 days and then treated with 10-9 M of 17β-oestradiol for different lengths of 
time upto 10 days. Both the oestradiol-treated and untreated cells were lysed and protein 
extracts prepared. Protein aliquots of 20 µg were separated by 12% polyacrylamide gel 
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electrophoresis and then transferred to nitrocellulose membranes. The membranes were 
incubated with anti-NHERF3 antibody (dilution 1:5000) overnight at 4 oC, followed by 
horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 37 oC. 
Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A. The protein expression of NHERF3 in EFF-3 cells after 
oestrogen stimulation for a timecourse of 0 hours to 10 days, comparing serum withdrawn (-E2 
) samples with oestrogen-stimulated (+E2 ) samples. Images shown are representative of 
results from experiments which have been replicated twice. B. Quantification of NHERF3 
normalised against the corresponding GAPDH signal, *p<0.05 and **p < 0.001 by ANOVA. 
Error bars indicate SEM of triplicate measurements. 
  
4.4.4 Regulatory effect of oestradiol on the expression of NHERF3 in 
MCF-7 cells by immunofluorescence 
The regulation of NHERF3 protein expression with time in the absence or 
presence of oestrogen was tested by immunofluorescence. This method 
enables clear observation of the localisation of NHERF3. 
MCF-7 cells were plated onto 13 mm coverslips in 12-well plates and withdrawn 
from growth factors for 5 days. Cells were then treated with 10-9 M oestradiol for 
various times. Cells were isolated at 0, 2, 4, 6 and 8 days and fixed in 4 % 
paraformaldehyde as described in Materials and Methods section. The confocal 
microscope settings for the different fluorochromes were unchanged throughout 
the duration of the timecourse experiment, to facilitate objective visualisation of 
changes in protein expression.        
The cytoplasmic and vesicular expression of NHERF3 (green) is clearly visible 
in the MCF-7 cells treated with oestrogen (Figure 4.8). There is agreement 
between data obtained from the western transfer (Figure 4.5), in which, 
oestrogen causes an increase in the expression of NHERF3 protein.      
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Figure 4.8 Effect of oestradiol on the expression and localisation of NHERF3 in MCF-7 
cells. MCF-7 cells were seeded onto coverslips in 12-well plates and cultured in routine culture 
medium for 24 hours. Cells were cultured in withdrawal media for 5 days and grown in the 
absence or presence of 10-9 M oestradiol for different time periods ranging from 0 hours to 8 
days. Cells were washed with PBS and fixed in 4% paraformaldehyde at room temperature. 
After fixation, cells were washed with PBS three times for 15 minutes each. Cells were then 
blocked in blocking buffer containing saponin for 1 hour at room temperature. The blocking 
medium was aspirated and the primary antibody NHERF3 was added at 1:100 dilution and 
incubated overnight at 4 oC. Cells were washed 3 times with PBS, 15 minutes each. The 
secondary antibody Alexa fluor 488 conjugated goat anti-rabbit were added at a dilution of 
1:1000 and were covered in foil and the cells were incubated for 1 hour at room temperature. 
Cells were washed 3 times with PBS. Alexa fluor 555 conjugated phalloidin was added at a 
dilution of 1:200 and incubated for 15 minutes at room temperature. DAPI mounting media was 
added to the glass slides prior to placing the coverslip on the slide and the cells were examined 
under the confocal microscope using a 63x objective (Oil, 1.63). Images show DAPI (blue), 
NHERF3 (green) and phalloidin (red) staining at the times indicated to the left of the diagram. 
The panels on the left are untreated cells and the panel on the right are cells treated with 10-9 M 
oestradiol for the indicated duration. Scale bars = 47 µm.  
 
 
 
Illustrated in Figure 4.9 below, are the x-z cross sectional images from the same 
experiment. The effect of oestrogen on cell proliferation is visible, as there is an 
increase in the depth of the cell layer. NHERF3 (green) is mostly confined 
intracellularly, but the distribution is variable between cells. Phalloidin (red) 
stains the actin cytoskeleton. The stimulation of NHERF3 protein expression 
increases with time in the presence of oestrogen.   
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Figure 4.9 Cross-sectional images of the effect of oestradiol on the expression and 
localisation of NHERF3 in MCF-7 cells. MCF-7 cells were seeded onto coverslips in 12-well 
plates and cultured in routine culture medium for 24 hours. Cells were cultured in withdrawal 
media for 5 days and grown in the absence or presence of 10-9 M oestradiol for different time 
periods ranging from 0 hours to 8 days. Cells were washed with PBS and fixed in 4% 
paraformaldehyde at room temperature. After fixation, cells were washed with PBS three times 
for 15 minutes each. Cells were then blocked in blocking buffer containing saponin for 1 hour at 
room temperature. The blocking medium was aspirated and the primary antibody NHERF3 was 
added at 1:100 dilution and incubated overnight at 4 oC. Cells were washed 3 times with PBS, 
15 minutes each. The secondary antibody Alexa fluor 488 conjugated goat anti-rabbit were 
added at a dilution of 1:1000 and were covered in foil and the cells were incubated for 1 hour at 
room temperature. Cells were washed 3 times with PBS. Alexa fluor 555 conjugated phalloidin 
was added at a dilution of 1:200 and incubated for 15 minutes at room temperature. DAPI 
106 
 
mounting media was added to the glass slides prior to placing the coverslip on the slide and the 
cells were examined under the confocal microscope using a 63x objective (Oil, 1.63). Images 
show DAPI (blue), NHERF3 (green) and phalloidin (red) staining at the times indicated to the 
left of the diagram. The panels on the left are untreated cells and the panel on the right are cells 
treated with 10-9 M oestradiol for the indicated duration. Scale bars = 23 µm. 
 
4.5 The regulation of NHERF3 by oestrogen in a concentration dependent 
manner 
4.5.1 Concentration dependent effects of oestradiol on NHERF3 in 
oestrogen responsive cells 
The following experiments were designed to test the concentration dependent 
effects of oestradiol on the regulation of expression of NHERF3 protein. Cells 
were cultured in the absence or presence of a range of concentrations of 
oestradiol varying from 10-13 M to 10-7 M for a period of 8 days. 
The results obtained for the three oestrogen responsive cell lines; MCF-7, EFM-
19 and EFF-3 are depicted in Figure 4.10. All cell lines exhibit a concentration 
dependent effect. In MCF-7 cells (A), NHERF3 is expressed at concentrations 
of oestradiol between 2x10-10 M and 10-8 M, with the maximal induction at 10-9 
M. However, in EFM-19 cells (B), NHERF3 protein is detected at oestradiol 
concentrations above 10-9 M. The expression of NHERF3 in EFF-3 cells (C) 
was similar to that of MCF-7 cells, as protein was detected at oestradiol 
concentrations from 2x10-10 M to 10-8 M, with the highest expression measured 
at 10-9 M. 
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Figure 4.10 Concentration dependent effects of oestradiol on NHERF3 protein expression in MCF-7, EFM-19 and EFF-3 cells. Cells were seeded onto 24-well plates 
and withdrawn for 5 days and treated with different concentrations of oestradiol for 8 days. Protein aliquots of 10 µg were separated by 12% polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membranes. Membranes were incubated with anti-NHERF3 antibody (dilution 1:10000) overnight at 4 oC, followed by 
horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 37 oC. Proteins were visualised by enhanced chemiluminescence with SuperSignal West 
Dura Extended Duration Substrate. A, B, C. The protein expression of NHERF3 in MCF-7, EFM-19 and EFF-3 cells treated with different concentrations of oestradiol for 8 
days. Images shown are from representative experiments which have been repeated three times. D, E, F. Densitometric quantification of NHERF3 with Labworks 4.0 
software, normalised against the corresponding GAPDH signal in MCF-7, EFM-19 and EFF-3 cells, respectively. Error bars indicate SEM of duplicate measurements.
108 
 
4.6 Measurement of pHi in breast cancer cells 
The expression of NHERF3 protein has been shown to be regulated by 
oestrogen as depicted in the previous sections within this chapter. This section 
aims to assess the functional activity of NHERF3. It is well known that NHERF3 
acts as a scaffolding protein for Na+/H+ exchangers (NHE) allowing the 
attachment and organisation of such proteins at or in close proximity to the 
plasma membrane of epithelial cells (Thomson et al., 2005; Zachos et al., 2009).  
Na+/H+ exchangers are responsible for balancing and regulating intracellular pH. 
These NHE are called antiporters because they transport Na+ ions into and H+ 
ions out of the cell. We hypothesised that an increase in the expression of 
NHERF3 in response to oestrogen would enhance the capacity of Na+/H+ 
exchange at the cell membrane. Therefore we measured the intracellular pH 
(pHi) of cells grown in full media, oestrogen-withdrawn media and in cells 
stimulated with oestrogen. 
A pH indicator dye, BCECF-AM allows measurement of the intracellular pH of 
breast cancer cells. BCECF-AM has single emission fluorescence at ~535 nm 
and dual-excitation at ~490 nm and ~440 nm. The pHi was determined on the 
basis of the pH-dependent ratio of excitation intensity using the high 
K+/Nigericin calibration technique as described in Materials and Methods 
section 2.6.3.    
4.6.1 Optimisation of conditions  
The optimum BCECF-AM concentrations and incubation times were evaluated. 
Cells were plated at a density of 10,000 cells per well onto 96-well plates. Cells 
were incubated for 2 days in routine culture medium. The culture media was 
removed by aspiration and cells were washed with Krebs’s Henseleit HEPES-
buffered (KHH) solution. Subsequently 1 µM, 5 µM and 10 µM of BCECF-AM in 
KHH were added to cells. Cells that do not contain any BCECF-AM were 
included in parallel. Cells were incubated for 15 min, 30 min and 60 min in a 
37oC incubator. It is important to cover the 96-well plates in foil, as the BCECF-
AM dye is sensitive to light. Cells were then washed with KHH solution. The 
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fluorescence intensity was measured with a FLUOstar Omega plate reader at 
485 nm and 420 nm. 
Results obtained are shown in Figure 4.11. The calibration curve was linear 
over the pH range from 6.0 to 7.8 (Figure 4.11A). Cells were incubated with 
different concentrations of BCECF-AM at 1 µM, 5 µM and 10 µM to determine 
the optimum concentration to be loaded into cells. Cells that do not contain any 
BCECF-AM are indicated as 0 µM. The fluorescent intensity ratio increased with 
increasing concentrations of BCECF-AM, with 10 µM producing the highest ratio. 
Figure 4.11B shows that the ideal incubation time would be 15 minutes. 
Therefore in subsequent experiments cells were incubated with 10 µM BCECF-
AM for 15 mins. 
 
Figure 4.11 Optimisation of BCECF-AM concentrations and incubation times. EFM-19 
cells were seeded at a density of 10,000 cells per well in 96-well plates in routine culture 
medium. Cells were washed with KHH solution once and incubated with 0 µM, 1 µM, 5 µM and 
10 µM BCECF-AM. Cells were incubated for 15 mins, 30 mins and 60 mins at 37oC. Cells were 
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then washed once with KHH solution. A. The calibration curve was constructed from cells 
resuspended in high K+ buffers of known pH ranging from 6.0 to 7.8. These buffers contained 10 
µM nigericin to equilibrate the internal and external pH of cells. Fluorescence intensities at 485 
nm and 420 nm were determined using the FLUOstar Omega plate reader. The ratio of 
absorbance at 485 nm and 420 nm was calculated and calibration curves of the fluorescence 
ratios against pH were produced. B. Calculated fluorescence ratio 485/420nm measurements in 
EFM-19 cells incubated with BCECF-AM at 0 µM ( ), 1 µM ( ), 5 µM ( ) and 10 µM ( ) for 15, 
30 and 60 mins in at 37oC. The pHi of the cells was estimated from the reference curves. Error 
bars indicate standard errors of the mean of four replicates per condition from one experiment.  
 
4.6.2 pHi measurement in MCF-7 and EFM-19 cells cultured in full 
medium 
The aim of this experiment was to determine the resting pHi of MCF-7 and 
EFM-19 cells. Cells were seeded onto 96-well plates at a density of 5000 cells 
per well and were grown in routine culture medium for 3 days. Cells were then 
incubated with KHH solution containing 10 µM BCECF-AM for 15 minutes. KHH 
solutions were prepared at two different pH. One was at pH 6.0, whereas the 
other was at pH 7.4. KHH solution at pH 6.0, would allow determination of the 
ability of cells to regulate pHi.  
Following incubation, cells were washed with KHH and half of the cells were 
incubated with a KHH solution at pH 6.0, whereas the other half of cells was 
incubated with pH 7.4 KHH solution. The fluorescent intensity readings were 
obtained and the steady-state (resting) pHi of MCF-7 and EFM-19 cells was 
determined (Figure 4.12). 
In a KHH solution at the physiological pH of 7.4, the steady-state pHi was 7.43 
and 7.35 in MCF-7 and EFM-19 cells, respectively. In an acidic pH 6.0, the 
resting pHi of MCF-7 cells was 6.73 and was 6.63 in EFM-19 cells. This 
suggests that in the presence of a more acidic extracellular pH, cells attempt to 
adjust and regulate its internal pH to the baseline resting pH. Intracellular 
buffering and pHi regulatory mechanisms prevent the pHi from equilibrating with 
the external acidic pH. The Na+/H+ exchangers function at a stoichiometry of 1:1, 
and allows the extrusion of H+ ions only when the gradient is less than the 
inverse Na+ ion gradient. Therefore at an external pH 6.0, the Na+/H+ 
exchangers are not completely effective at maintaining the pHi at physiological 
values.     
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Figure 4.12 Measurement of pHi in MCF-7 and EFM-19 cells. MCF-7 and EFM-19 cells were 
seeded at a density of 5,000 cells per well in 96-well plates in routine culture medium. Cells 
were washed with KHH solution once and incubated with 10 µM BCECF-AM for 15 mins. Cells 
were then washed once with KHH solution and a KHH solution of pH 6.0 ( ) was added to half 
the cells, whereas a KHH solution of pH 7.4 ( ) was added to the other half. Fluorescence 
intensities at 485 nm and 420 nm were determined using the FLUOstar Omega plate reader. 
The ratio of absorbance at 485 nm and 420 nm was calculated and the pHi was estimated from 
the calibration curve. Error bars indicate standard errors of the mean, where n=20 for MCF-7 
cells and n=25 for EFM-19 cells.  
 
4.6.3 Effect of oestrogen on pHi measurements of MCF-7 and EFM-19 cells  
To study the effect of oestrogen on the regulation of pHi, MCF-7 and EFM-19 
cells were withdrawn from growth factors for 5 days. Cells were then cultured in 
the absence or presence of 10-9 M oestradiol for 5 days. 
In MCF-7 cells (Figure 4.13A), oestrogen causes a significant decrease in pHi in 
KHH solution at pH 6.0, where the pHi decreases from 6.78±0.06 to 6.38±0.05 
(p=0.0047, ANOVA). In the KHH solution at pH 7.4, the pHi changes slightly 
from 7.48±0.16 to 7.40±0.12 (p=0.5268, ANOVA). This result was not expected, 
as we anticipated that in the presence of oestrogen, cells would have the 
capacity to increase their pHi, since we have previously confirmed that there is 
an induction of NHERF3 protein expression. However, the results obtained for 
MCF-7 cells at an external pH 6.0 show a decreased capacity whilst at pH 7.4 
the cells do not indicate a change in set-point. The set-point is the pH at which 
there is minimal transporter activity.        
In contrast to MCF-7 cells, the EFM-19 cells show a significant increase in pHi 
in both KHH solutions at pH 6.0 and pH 7.4 in response to the oestrogen 
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stimulus. At pH 6.0, the pHi increased from 6.73±0.05 to 6.99±0.09 (p=0.0049, 
ANOVA), whereas at pH 7.4 the pHi increased significantly from 7.28±0.09 to 
7.60±0.10 (p=0.0042, ANOVA). These results suggest that there is a shift in the 
set-point and that oestrogen-treated EFM-19 cells have an increased capacity 
to regulate pHi.    
 
 
Figure 4.13 Effect of oestrogen on pHi of MCF-7 and EFM-19 cells. MCF-7 and EFM-19 
cells were seeded at a density of 5,000 cells per well in collagen-coated 96-well plates. Cells 
were cultured in steroid depleted media for 5 days. For a further 5 days, cells were grown in 
phenol-red-free media alone or in the presence of 10-9 M of 17β-oestradiol. Cells were washed 
with KHH solution once and incubated with 10 µM BCECF-AM for 15 mins. Cells were then 
washed once incubated with either a KHH solution at pH 6.0 or at pH 7.4. Fluorescence 
intensities at 485 nm and 420 nm were determined using the FLUOstar Omega plate reader. 
The ratio of absorbance at 485 nm and 420 nm was calculated and the pHi was estimated from 
the calibration curve. A. the intracellular pH of MCF-7 cells and B. EFM-19 cells, comparing 
untreated (-E2 ) and oestrogen stimulated (+E2 ) cells. *p < 0.05 by ANOVA. Error bars 
indicate standard errors of the mean of four replicates per condition from 4 separate 
experiments.  
 
4.6.4 Effect of hypertonicity on pHi of MCF-7 and EFM-19 cells cultured in 
full media   
Cells subject to hyperosmotic conditions by incubation with mannitol undergo 
cell shrinkage. This cell shrinkage should result in activation of Na+/H+ 
exchangers, which allows to increase the entry of Na+ ions into the cell. This 
increased intracellular Na+ subsequently leads to cell swelling due to the 
113 
 
osmotic uptake of water. The process of swelling of cells following hyperosmotic 
stress is referred to as regulatory volume increase (RVI).    
Mannitol was added to KHH solutions at concentrations of 80, 100, 150 and 200 
mM to study its effects in activation of Na+/H+ exchangers in MCF-7 and EFM-
19 cells cultured in full medium. 
The steady-state intracellular pH of MCF-7 cells was 6.50 when exposed to an 
external pH 6.0 KHH solution. As shown in Figure 4.14A, the pHi increased 
dramatically to 7.40, 7.33, 7.30, 7.19, in the presence of 80 mM, 100 mM, 150 
mM and 200 mM mannitol, respectively. The shows that stimulation of Na+/H+ 
exchangers is greatly enhanced when subject to hypertonicity. The baseline pHi 
when exposed to a KHH solution of pH 7.4 was 7.61. A reduction in pHi to 7.45, 
7.31, 7.32, and 7.24 is observed in the presence of increasing concentrations of 
mannitol. 
In EFM-19 cells, the steady-state pH in the absence of mannitol was 6.25 at 
external pH 6.0. With the addition of 80 mM, 100 mM, 150 mM and 200 mM 
mannitol, there was alkalisation of pH to 6.54, 6.47, 6.44 and 6.49. Similar to 
the effect of mannitol in MCF-7 cells, a decrease in pHi was observed with the 
addition of mannitol to KHH solution at pH 7.4. The baseline pH decreased from 
7.35 to 7.00, 6.97, 6.94, and 6.91 with increasing concentrations of mannitol. 
These results are shown in Figure 4.14B.    
These results indicate that when cells are exposed to an external pH of 6.0 in 
the presence of mannitol, alkalisation occurs. In contrast, the pHi acidifies when 
the external pH is 7.4 in the presence of mannitol. Therefore these observations 
suggest that at an acidic external pH, the cells alkalinise by extruding H+ ions 
through Na+/H+ exchangers. The hypertonic effect of mannitol causes activation 
of NHE, allowing for movement of H+ ions out of the cell. Conversely, at an 
external pH of 7.4, the pHi acidifies even in the presence of mannitol, signifying 
a reversal effect of NHE by the accumulation of H+ ions within the cell. The 
decrease in pH may well be mediated by other transporters such as sodium-
driven Cl-/HCO3- exchanger. In both cells lines at pH 7.4, the set-point shifts 
towards a more acidic pH. As shown in the previous chapter, the Na+/K+/Cl- co-
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transporter, NKCC1 is also activated under hypertonic conditions resulting in an 
influx of Cl- ions. Therefore in the presence of mannitol the sodium-driven Cl-
/HCO3- exchanger might be activated in order to regulate pH as well as to 
extrude the increased Cl- ion concentration.            
 
Figure 4.14 Effect of mannitol on pHi of MCF-7 and EFM-19 cells. MCF-7 and EFM-19 cells 
were seeded at a density of 5,000 cells per well in 96-well plates in routine culture medium. 
Cells were washed with KHH solution once and incubated with 10 µM BCECF-AM for 15 mins. 
Cells were then washed once with KHH solution and incubated with either a KHH solution of pH 
6.0 or a KHH solution of pH 7.4. Fluorescence intensities at 485 nm and 420 nm were 
determined using the FLUOstar Omega plate reader. After the initial fluorescent readings were 
taken, cells were incubated with one of the following; 80, 100, 150 or 200 µM mannitol. The ratio 
of absorbance at 485 nm and 420 nm was calculated and the pHi was estimated from the 
calibration curve. A. The effect of mannitol on intracellular pH of MCF-7 cells and B. EFM-19 
cells, comparing baseline pHi ( ) to the effect of 80, 100, 150 and 200 µM mannitol (from left to 
right) at an external pH of 6.0 (left panel) or pH 7.4 (right panel). *p < 0.05 by ANOVA. Error 
bars indicate standard errors of the mean of four replicates per condition from 3 separate 
experiments.  
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4.6.5 Effect of hypertonicity on pHi of MCF-7 cells in the absence and 
presence of oestrogen 
The effect of hypertonicity on pHi of withdrawn and oestrogen stimulated MCF-7 
cells was tested. Cells were grown on collagen-coated 96-well plates and 
withdrawn for 5 days and then cultured in the presence or absence of 10-9 M 
oestradiol for 5 days before measuring the pHi. Once the initial steady-state pHi 
was measured, cells were subject to hypertonic stress by the addition of 
mannitol to KHH solutions of pH 6.0 or 7.4. Mannitol was added at either 80 mM 
or 200 mM.  
Results are shown in Figure 4.15. When cells were incubated with KHH at pH 
6.0, the pHi was 6.66±0.03 in withdrawn cells and 6.29±0.04 in the oestrogen 
treated cells. This difference was statistically significant (p=0.0001, ANOVA). In 
the presence of 80 and 200 mM mannitol, a significant decrease in pHi was 
observed when comparing the untreated and oestrogen-treated cells. In the 
presence of 80 and 200 mM mannitol, the pHi decreased from 6.69±0.06 to 
6.30±0.02 (p=0.0001, ANOVA) and from 6.41±0.03 to 6.03±0.04 (p=0.0001, 
ANOVA), respectively. However this was not the case for cells in a KHH 
solution of pH 7.4, as there was no significant difference observed between 
withdrawn and oestrogen-treated cells. The effect of oestrogen was only 
noticeable in cells incubated with 80 mM mannitol, as there was a statistically 
significant decrease from 6.98±0.03 to 6.82±0.02 (p=0.0137, ANOVA).  
From our previous observations of the effect of mannitol in full media (Figure 
4.14A), we expected the cells treated with oestrogen to alkalise when incubated 
with KHH at pH 6.0 and acidify when exposed to an external pH of 7.4 in the 
presence of 80 or 200 mM mannitol. However, this effect of mannitol was 
noticeable when cells were exposed to KHH solution at pH 7.4 in the presence 
of 80 mM mannitol. Acidification was observed in both withdrawn and 
oestrogen-treated cells. But exposure to 200 mM mannitol in KHH of pH 7.4 had 
no effect on the pHi. At an external pH 6.0, our previous findings showed an 
increase in pHi in response to addition of mannitol. However in comparison to 
cells in full media, oestrogen-treated cells show a significant difference, but in 
the opposite direction, as it should alkalise instead of acidify. These results 
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suggest that untreated MCF-7 cells do not have an increase in Na+/H+ 
exchange capacity to maintain pHi when exposed to an external pH 6.0. This 
effect could possibly due to that lack / reduction in organisation of NHE at the 
plasma membrane, since untreated cells do not express NHERF3 protein.    
 
Figure 4.15 Effect of mannitol on pHi of MCF-7 cells in the absence and presence of 
oestrogen. MCF-7 cells were seeded at a density of 5,000 cells per well in collagen-coated 96-
well plates in routine culture medium. Cells were cultured in steroid depleted media for 5 days. 
For a further 5 days, cells were grown in phenol-red-free media alone or in the presence of 10-9 
M of 17β-oestradiol. Cells were washed with KHH solution once and incubated with 10 µM 
BCECF-AM for 15 mins. Cells were then washed once with KHH solution and incubated with 
either a KHH solution of pH 6.0 or a KHH solution of pH 7.4. Fluorescence intensities at 485 nm 
and 420 nm were determined using the FLUOstar Omega plate reader. After the initial 
fluorescent readings were taken, cells were incubated with either 80 or 200 µM mannitol. The 
ratio of absorbance at 485 nm and 420 nm was calculated and the pHi was estimated from the 
calibration curve. The intracellular pH of MCF-7 cells, comparing untreated (-E2 ) and 
oestrogen stimulated (+E2 ) cells incubated with 80 or 200 µM mannitol as indicated. *p < 0.05 
and **p < 0.0001 by ANOVA, ns- not significant. Error bars indicate standard errors of the mean 
of 4 replicates per condition from 3 separate experiments.  
 
4.6.6 Effect of hypertonicity on pHi of EFM-19 cells in the absence and 
presence of oestrogen 
Figure 4.16 displays the results obtained from a similar experiment investigating 
the effect of hypertonicity in unstimulated and oestrogen-stimulated EFM-19 
cells. Consistent with our previous findings shown in Figure 4.14B in EFM-19 
cells, there was a significant difference observed between untreated and 
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oestrogen-treated cells in all conditions, except in the presence of 80 mM 
mannitol at an external pH 6.0. In contrast to MCF-7 cells, the pHi of oestrogen-
treated cells was more alkaline with respect to that of the withdrawn untreated 
cells. At an external pH of 6.0, the pHi of withdrawn cells was 6.81±0.05, 
whereas that of oestrogen-treated cells was 6.97±0.04 (p=0.0368, ANOVA). 
The pHi increased from 7.13±0.05 to 7.35±0.06, when comparing the withdrawn 
cells to the oestrogen-treated cells at an external pH of 7.4 (p=0.0098, ANOVA).  
Similar to MCF-7 cells, the oestrogen-treated cells did not alkalise when 
exposed to hypertonic mannitol at an external pH 6.0. However, oestrogen-
treated cells incubated with KHH solution of pH 7.4 in the presence of mannitol 
acidified, as anticipated. The initial pHi was 7.35±0.06. The pHi then reduced to 
7.03±0.05 and 7.13±0.04 in the presence of 80 and 200 mM mannitol, 
respectively. The oestrogen-treated cells behave in a similar manner to the cells 
cultured in routine culture media, as the foetal calf serum contains oestrogen. 
The cells stimulated with oestrogen show increased pHi regulatory capacity in 
comparison to the withdrawn cells. However, it is unclear as to why the addition 
of mannitol causes an acidification when oestrogen-treated cells are incubated 
with KHH solution at pH 6.0. 
 
Figure 4.16 Effect of mannitol on pHi of EFM-19 cells in the absence and presence of 
oestrogen. EFM-19 cells were seeded at a density of 5,000 cells per well in 96-well plates in 
routine culture medium. Cells were cultured in steroid depleted media for 5 days. For a further 5 
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days, cells were grown in phenol-red-free media alone or in the presence of 10-9 M of 17β-
oestradiol. Cells were washed with KHH solution once and incubated with 10 µM BCECF-AM 
for 15 mins. Cells were then washed once with KHH solution and incubated with either a KHH 
solution of pH 6.0 or a KHH solution of pH 7.4. Fluorescence intensities at 485 nm and 420 nm 
were determined using the FLUOstar Omega plate reader. After the initial fluorescent readings 
were taken, cells were incubated with either 80 or 200 µM mannitol. The ratio of absorbance at 
485 nm and 420 nm was calculated and the pHi was estimated from the calibration curve. The 
intracellular pH of EFM-19 cells, comparing untreated (-E2 ) and oestrogen stimulated (+E2 ) 
cells incubated with 80 or 200 µM mannitol as indicated. *p < 0.05 and **p < 0.0001 by ANOVA. 
Error bars indicate standard errors of the mean of 4 replicates per condition from 3 separate 
experiments.  
 
4.6.7 Effect of NH4Cl on pHi of MCF-7 and EFM-19 cells cultured in full 
media 
The addition of NH4Cl leads to alkalisation of the intracellular pH of cells. This 
alkalisation occurs due to the passive entry of NH3 into the cell. NH3 binds to H+ 
ions present within the cell. Alkalisation tends to cease once the intracellular 
NH3 concentration equilibrates with the extracellular concentration of NH3. The 
slow influx of NH4+ ions into the cell causes a decrease in pHi. This slow 
acidification is a result of the dissociation of NH4+ into NH3 and H+ ions. The 
removal of NH4Cl causes the pHi to decrease further than the initial baseline 
levels as intracellular NH3 diffuses out from the cell resulting in an acid load. 
The NH4+ ions within the cell then dissociate into NH3 and H+ ions in order to 
maintain equilibrium. The additional H+ ions are then extruded by active 
transport, thus allowing cells to maintain their baseline pH.            
Cells were cultured in full media for 3 days and incubated with BCECF-AM. The 
initial fluorescence reading was obtained and cells were then subjected to an 
acid load by the addition of KHH solution containing 40 mM NH4Cl. The addition 
of NH4Cl allows to test the acid extrusion capability. Cells were exposed to 
NH4Cl for 10 minutes, and then incubated with KHH solution immediately. 
Fluorescent intensity readings were measured every 10 minutes for a period of 
1 hour. The results show the pHi recovery from an acid load in both MCF-7 
(Figure 4.17A) and EFM-19 cells (Figure 4.17B).    
In MCF-7 cells incubated with KHH of pH 7.4, the pHi raised rapidly from 
7.58±0.02 to 8.14±0.09 with the addition of 40 mM NH4Cl. The removal of 
NH4Cl leads to a rapid decline in pHi, even below the initial steady-state pH. 
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Further addition of KHH did not change the pHi. This indicates that the pHi 
recovery due to Na+/H+ exchange is substantially slower. Also the final pHi of 
7.14±0.04 was lower than the initial steady-state pHi. Conversely, the addition 
and removal of NH4Cl did not have much of an effect on pHi in cells exposed to 
an external pH 6.0.  
Shown in Figure 4.17B are the results from EFM-19 cells. The baseline pHi for 
cells incubated with KHH solution of pH 7.4 was 7.52±0.07, which then 
increased to 7.86±0.13 with the addition of 40 mM NH4Cl. Then there was a 
dramatic decrease to 6.49±0.10 with the rapid removal of NH4Cl. With the re-
addition of KHH solution there was a slight increase in pHi to a final value of 
upto 6.65±0.07, although it still did not reach the initial values of steady-state 
pHi. The recovery of pHi in EFM-19 cells was quicker than that of MCF-7 cells. 
In contrast to MCF-7 cells, the EFM-19 cells exposed to KHH of pH 6.0 showed 
a gradual overall decline in pHi. The initial pHi was 6.78±0.03, whereas the final 
pHi was 5.99±0.03. The cells are unable to recover their pHi as the ability of the 
Na+/H+ exchangers are limited at pH 6.0 since the chemical gradient for H+ ions 
out to in is higher than the Na+ ion gradient.             
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Figure 4.17 Effect of 40 mM NH4Cl on pHi of MCF-7 and EFM-19 cells. MCF-7 and EFM-19 
cells were seeded at a density of 5,000 cells per well in 96-well plates in routine culture medium. 
Cells were washed with KHH solution once and incubated with 10 µM BCECF-AM for 15 mins. 
Cells were then washed once with KHH solution and incubated with either a KHH solution of pH 
6.0 or a KHH solution of pH 7.4. Fluorescence intensities at 485 nm and 420 nm were 
determined using the FLUOstar Omega plate reader. After the initial fluorescent readings were 
taken, cells were incubated with 40 mM NH4Cl for 10 mins. Then NH4Cl was aspirated and KHH 
solutions of pH 6.0 and pH 7.4 were added to the appropriate cells. Fluorescence intensity 
readings were measured at 10 min intervals for a period of 60 mins in total. The ratio of 
absorbance at 485 nm and 420 nm was calculated and the pHi was estimated from the 
calibration curve. A. The effect of 40 mM NH4Cl on intracellular pH of MCF-7 cells and B. EFM-
19 cells, at an external pH of 6.0 ( ) or pH 7.4 ( ). The images shown are representative of 
experiments which have been replicated three times. Error bars indicate standard errors of the 
mean of four replicates per condition. 
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4.6.8 Effect of NH4Cl on pHi of MCF-7 cells in the absence and presence 
of oestrogen   
Since we have investigated the effect of NH4Cl in cells grown in routine media, 
it was important to study the effect of an acid load in withdrawn and cells that 
have been oestrogen-stimulated. MCF-7 cells were withdrawn for 5 days and 
cultured in the absence or presence of oestrogen for 5 days. The following 
result shown in Figure 4.18 is from such an experiment in MCF-7 cells.    
When both withdrawn and oestrogen-treated cells were incubated with a KHH 
solution of pH 7.4, there was hardly any difference in pHi throughout the 
experiment (Figure 4.18B). The addition of NH4Cl caused an alkalisation, while 
the removal of NH4Cl caused acidification in both untreated and oestrogen-
treated cells. With the re-addition of KHH solution, the pHi recovery was faster 
in the withdrawn cells than that of oestrogen stimulated cells, although neither 
reached the initial baseline pHi. In the case of cells incubated with a pH 6.0 
KHH solution, the oestrogen-treated cells had a more acidic initial steady-state 
pHi in comparison to withdrawn cells (Figure 4.18A). These results are 
contradictory to what we expected, as this suggests that withdrawn cells have 
more Na+/H+ exchange than oestrogen-treated cells. Yet, results from protein 
expression indicate a clear upregulation of the scaffolding protein NHERF3 in 
response to oestrogen.   
 
Figure 4.18 Effect of 40 mM NH4Cl on pHi of MCF-7 cells in the absence and presence of 
oestrogen. MCF-7 were seeded at a density of 5,000 cells per well in collagen-coated 96-well 
plates in routine culture medium. Cells were cultured in steroid depleted media for 5 days. For a 
further 5 days, cells were grown in phenol-red-free media alone or in the presence of 10-9 M of 
17β-oestradiol. Cells were washed with KHH solution once and incubated with 10 µM BCECF-
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AM for 15 mins. Cells were then washed once with KHH solution and incubated with either a 
KHH solution of pH 6.0 or a KHH solution of pH 7.4. Fluorescence intensities at 485 nm and 
420 nm were determined using the FLUOstar Omega plate reader. After the initial fluorescent 
readings were taken, cells were incubated with 40 mM NH4Cl for 10 mins. Then NH4Cl was 
aspirated and KHH solutions of pH 6.0 and pH 7.4 were added to the appropriate cells. 
Fluorescence intensity readings were measured at 10 min intervals for a period of 60 mins in 
total. The ratio of absorbance at 485 nm and 420 nm was calculated and the pHi was estimated 
from the calibration curve. A. The effect of 40 mM NH4Cl on intracellular pH of MCF-7 cells, 
comparing untreated cells (-E2 ) with oestrogen stimulated cells (+E2 ) at an external pH of 
6.0. and B. comparing untreated cells (-E2 ) with oestrogen stimulated cells (+E2 ) at an 
external pH of 7.4. The image shown is representative of an experiment which has been 
replicated three times. *p < 0.05 by ANOVA. Error bars indicate standard errors of the mean of 
four replicates per condition. 
 
4.6.9 Effect of NH4Cl on pHi of EFM-19 cells in the absence and presence 
of oestrogen   
Results obtained from a similar experiment in EFM-19 cells are shown in Figure 
4.19. Consistent with our previous findings, the oestrogen stimulated cells had a 
more alkaline pHi with respect to that of untreated cells, under both external pH 
of 6.0 and 7.4. With the addition of 40 mM NH4Cl, both withdrawn and 
oestrogen-treated cells incubated in a KHH solution at the external pH 7.4, 
showed a rapid increase in pHi. There was a significant difference between the 
pHi values of untreated and oestrogen-treated cells initially as well as during the 
first 10-20 minutes. Also the removal of NH4Cl caused an even faster decline in 
pHi. Although the recovery from 30-60 minutes appeared to be slightly faster in 
oestrogen stimulated cells, than in withdrawn cells (Figure 4.19B), there was no 
statistically significant difference observed during the recovery phases. When 
both withdrawn and oestrogen-treated cells were incubated in a KHH solution of 
pH 6.0, the pHi continued to decrease when NH4Cl was added. Also the 
removal of NH4Cl lead to a further decrease in pHi (Figure 4.19A). A similar 
effect was observed in EFM-19 cells cultured in full DMEM media when 
incubated with pH 6.0 KHH (Figure 4.17B). These cells do not seem to be able 
to increase its pHi and reach its initial baseline pHi. The difference in pHi 
between untreated and oestrogen-treated cells was significant at 30 minutes 
(p=0.0493, ANOVA) and at 40 minutes (p=0.0243, ANOVA).      
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Figure 4.19 Effect of 40 mM NH4Cl on pHi of EFM-19 cells in the absence and presence of 
oestrogen. EFM-19 were seeded at a density of 5,000 cells per well in 96-well plates in routine 
culture medium. Cells were cultured in steroid depleted media for 5 days. For a further 5 days, 
cells were grown in phenol-red-free media alone or in the presence of 10-9 M of 17β-oestradiol. 
Cells were washed with KHH solution once and incubated with 10 µM BCECF-AM for 15 mins. 
Cells were then washed once with KHH solution and incubated with either a KHH solution of pH 
6.0 or a KHH solution of pH 7.4. Fluorescence intensities at 485 nm and 420 nm were 
determined using the FLUOstar Omega plate reader. After the initial fluorescent readings were 
taken, cells were incubated with 40 mM NH4Cl for 10 mins. Then NH4Cl was aspirated and KHH 
solutions of pH 6.0 and pH 7.4 were added to the appropriate cells. Fluorescence intensity 
readings were measured at 10 min intervals for a period of 60 mins in total. The ratio of 
absorbance at 485 nm and 420 nm was calculated and the pHi was estimated from the 
calibration curve. A. The effect of 40 mM NH4Cl on intracellular pH of EFM-19 cells, comparing 
untreated cells (-E2 ) with oestrogen stimulated cells (+E2 ) at an external pH of 6.0. and B. 
comparing untreated cells (-E2 ) with oestrogen stimulated cells (+E2 ) at an external pH of 
7.4. The image shown is representative of an experiment which has been replicated three times. 
*p < 0.05 by ANOVA. Error bars indicate standard errors of the mean of four replicates per 
condition. 
 
4.7 Discussion 
4.7.1 Expression and localisation 
Previous studies have shown that the PDZK1 gene is regulated by oestrogen in 
breast and ovarian cancer (Ghosh et al., 2000; Walker et al., 2007; Wright et al., 
2009). In this chapter, the expression of the NHERF3 protein encoded by 
PDZK1 and the oestrogen regulation of PDZK1 in three oestrogen-responsive 
cell lines was investigated. Western transfer analysis detected the expression of 
NHERF3 protein in four out of six oestrogen-responsive cell lines studied. The 
NHERF3 antibody detected two protein bands, one with an approximate 
molecular mass of 66 kDa and the other of 46 kDa in cells cultured in routine 
culture medium. The 66 kDa protein band is likely full length NHERF3, as it has 
a close approximation to the theoretical molecular mass of the NHERF3 protein. 
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None of the oestrogen-unresponsive cell lines expressed NHERF3. Amongst 
the oestrogen-responsive cell lines, ZR-75 expressed the highest levels of 
NHERF3, followed by MCF-7, T47-D and EFM-19. Amongst the oestrogen-
responsive cell lines, the NHERF3 protein expression in MCF-7 cells, and not 
T47-D cells was consistent with the findings of O’Leary PC et al. (2013). The 
authors showed that T47-D cells expressed the most amount of NHERF3 
protein. Similar to the observations in this chapter, these authors did not detect 
any NHERF3 expression in the oestrogen-unresponsive cell lines.  
The cytoplasmic localisation of NHERF3 was confirmed by immunofluorescence 
in all three cell lines MCF-7, EFM-19 and EFF-3. Similarly, previous studies 
have demonstrated localisation of NHERF3 to the cytoplasm and sub-apical 
regions in opossum kidney (OK) cells and in colorectal adenocarcinoma-brush 
border expressing Caco2-BBE cells (Pribanic et al., 2003; Zachos et al., 2009).      
4.7.2 Oestrogen regulation 
The effect of oestrogen on the expression of NHERF3 protein was 
demonstrated in this study. Cells cultured in steroid-depleted media in the 
absence of oestradiol showed no expression of NHERF3, whereas cells grown 
in the presence of 10-9 M oestradiol expressed significant levels of NHERF3 
protein. The 46 kDa protein band detected in cells grown in full media was not 
detected in cells cultured either in steroid withdrawn media or in oestrogen 
treated media. Although there was no detectable expression of NHERF3 in 
EFF-3 cells cultured in routine culture medium, very low levels of NHERF3 
protein were detected in oestrogen-treated EFF-3 cells. These results suggest 
that oestrogen induces NHERF3 protein expression fairly rapidly in MCF-7 and 
EFM-19 cells. However, in EFF-3 cells the induction of NHERF3 by oestrogen 
occurs late that is after 6 days of oestradiol treatment.     
During this study, Kim et al. (2013) published their work in which they claim that 
there was no correlation between the expression of ERα and PDZK1 despite no 
data actually being shown. These authors also reported that there was a 
significant correlation between PDZK1 and IGF1R expression, and that the 
activity of IGF1R directly mediates PDZK1 via the stimulation of ERα. However, 
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they came to this conclusion of an association between induction of PDZK1 and 
IGF1R, based on the immunohistochemical analysis of thirty two breast cancer 
cases. Previously, results from our group indicated that IGF1R was expressed 
in all ERα-positive and also in all ERα-negative cell lines (Davison et al., 2011). 
Results from this chapter indicate that all oestrogen-responsive cells with the 
exception of BT-474 and none of the oestrogen-unresponsive cells express 
NHERF3 further confirming its regulation via oestrogen. It is also important to 
note that the addition of 1 µg/ml insulin to the phenol-red free DMEM in the 
current study, could be accountable to the differences in the results observed 
between the present study and the results from Kim et al. (2013) as they have 
not added insulin to the media. Insulin can bind to IGF1R with low affinity. 
Similarly, the ligand IGF-1 can also bind to the insulin receptor (IR) with a lower 
affinity than to IGF1R. Additionally, data from this chapter clearly suggest that 
NHERF3 expression is regulated by oestradiol, as cells grown in withdrawal 
media in the absence of oestrogen do not express any NHERF3 protein at all, 
despite insulin being present in the media. Therefore it is difficult to come to a 
definite conclusion that NHERF3 is indirectly regulated by IGF1R ligands. Often, 
findings from Kim et al. (2013) study were consistent with data from the present 
study. In MCF-7 cells, the NHERF3 protein expression was increased after 36 
hours of oestrogen treatment, which agree with the demonstration in this study 
that the expression of NHERF3 increased from 2 days and lasted for up to 10 
days. In addition, the Kim et al. (2013) study reported that oestrogen induced 
mainly the expression of NHERF3 located in the cytoplasm with some partial 
nuclear localisation.  
4.7.3 Regulation of Na+/H+ exchange 
NHERF3 is responsible for organisation of multiprotein complexes in the 
proximity of the plasma membrane of epithelial cells. NHERF3 anchors and 
regulates proteins and transporters such as the Na+/H+ exchangers that are 
responsible for the maintenance of intracellular pH (Thomson et al., 2005). The 
current study demonstrated that the expression of NHERF3 is regulated by 
oestrogen. Hence the involvement of NHERF3 in the regulation of the cellular 
distribution of Na+/H+ exchangers in MCF-7 and EFM-19 cells was tested. An 
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established pH-sensitive fluorophore, BCECF-AM was used in the 
measurement of intracellular pH. 
Initially, the steady-state pHi of MCF-7 and EFM-19 cells cultured in routine 
culture medium was measured. Findings indicated that the pHi of both MCF-7 
and EFM-19 cells is closely similar to the external physiological pH of 7.4. The 
resting pHi of MCF-7 breast cancer cells from previous studies were similar to 
the values obtained in the present study (Turturro et al., 2004; Friday et al., 
2007). When the external pH is highly acidic at 6.0, the cells’ internal pHi 
becomes acidic. Although the pHi is acidic, it is prevented from reaching 
equilibrium with the external pH, by pH regulatory mechanisms. Na+/H+ 
exchangers are ATP-independent and can only function using the driving force 
of the electrochemical Na+ gradient which is directed inwards. The Na+/H+ 
exchangers exchange one Na+ ion in for one H+ ion out. Therefore in these 
breast cancers cells exposed to acidic external pH, the Na+/H+ exchangers are 
partially effective and the pHi is not maintained at physiological values. Results 
from the pHi measurements made in MCF-7 cells, either withdrawn or 
oestrogen-treated, indicated that at pH 7.4, there is no change in Na+/H+ 
exchange, whereas at pH 6.0, there is a decreased capacity of the Na+/H+ 
exchangers to regulate pH. Alternatively in comparison to withdrawn cells, 
oestrogen-treated EFM-19 cells demonstrated an increase in buffering capacity 
when exposed to KHH solutions at both pH 6.0 and pH 7.4.  
MCF-7 and EFM-19 cells grown in full media were subject to volume regulatory 
stress with the addition of mannitol. In acidic external pH, both cell lines 
responded by increasing pHi, thus representing hypertonic activation of the 
Na+/H+ exchangers. Results from the experiments testing the effect of mannitol 
in withdrawn and oestrogen-treated MCF-7 cells, depicted that at external pH 
6.0, the withdrawn cells do not have the capacity to regulate pHi. In contrast to 
the findings from MCF-7 cells grown in full media, the oestrogen-treated MCF- 7 
cells show a further decrease in the ability to maintain pHi. MCF-7 cells grown in 
the absence or presence of oestrogen did not respond well to hypertonicity. In 
EFM-19 cells that were withdrawn from growth factors and steroids, the addition 
of mannitol did not hypertonically activate Na+/H+ exchangers. However 
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oestrogen-treated EFM19 cells show an increase in activity in comparison to the 
withdrawn cells. The effect of mannitol in EFM-19 cells is not consistent with the 
results obtained from cells grown in full medium.      
The addition of NH4Cl causes an immediate cellular alkalisation followed by a 
slow pHi recovery in response to cellular acidosis. The passive entry of NH3 
causes pHi alkalisation initially, which then ceases as the intracellular and 
extracellular NH3 concentrations reach equilibrium. The removal of external 
NH4Cl, leads to acidification of the cytosol. Therefore cells recover their internal 
pH via Na+/H+ exchange or Cl-/HCO3- exchange. Results obtained from this 
study indicate that in both MCF-7 and EFM-19 cells at external pH 7.4, the 
addition of NH4Cl alkalinises pHi and the removal of NH4Cl leads to acidification 
of pHi. The slow recovery of pHi is due to regulation by Na+/H+ exchangers. 
Other studies have demonstrated that MCF-7 cells express Na+/H+ exchangers 
particularly NHE1 and NHE3 (Turturro et al., 2004; Mehdawi et al., 2012; Amith 
et al., 2015; Wang et al., 2015). When the cells are exposed to an external pH 
of 6.0, the pHi does not vary much after being exposed to NH4Cl. This is 
because the Na+/H+ exchangers are limited in their ability to extrude H+ ions 
against the electrochemical gradient. Furthermore, data from MCF-7 cells 
cultured in withdrawal media and in oestrogen-supplemented media do not 
show a difference in the expected direction in response to recovery of pHi after 
acidification. In oestrogen-stimulated EFM-19 cells at external pH 7.4, although 
there was a slight increase in recovery in comparison to oestrogen-depleted 
cells, it did not reach statistical significance.               
4.8 Conclusion 
Together, results from this chapter show that NHERF3 expression is limited to 
oestrogen-responsive cells and that its expression is regulated by oestradiol. 
The increase in NHERF3 protein expression is consistent with the results 
obtained from microarray analysis and confirms that oestrogen is an important 
regulator of PDZK1 gene expression. The pHi measurements provide evidence 
for the presence of Na+/H+ exchange in breast cancer cells MCF-7 and EFM-19. 
Despite the increase in NHERF3 protein expression in oestrogen-stimulated 
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cells there was no considerable difference in the ability of cells to recover pHi. 
Therefore, it is still questionable whether NHERF3 provides an enhancement in 
pHi regulatory capacity via activation of Na+/H+ exchangers at the plasma 
membrane.    
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Chapter 5.    SCNN1B (ENaC-β) 
5.1 Introduction 
The SCNN1B gene encodes the epithelial sodium channel β subunit (ENaC-β). 
The epithelial sodium channel consists of three subunits namely ENaC-α, 
ENaC-β and ENaC-γ. A fourth subunit ENaC-δ has also been identified more 
recently in human epithelial cells (Yamamura et al., 2008). The three subunits α, 
β and γ form heterotrimeric transmembrane segments and span the apical 
membrane of epithelial cells. Proteolytic cleavage and post-translational 
modifications are important for the regulation of activity and expression of ENaC.    
The epithelial sodium channel is located in the apical surface of many epithelial 
cells types, including the lung, kidney, breast, salivary ducts and colon (Garty 
and Palmer, 1997; Gambling et al., 2004; Quesnell et al., 2007a). Correct 
function of ENaC is crucial for the maintenance of sodium homeostasis of cells. 
ENaC plays a role in the regulation of blood pressure and blood volume 
(Rossier et al., 2002). ENaC is involved in cell migration. Cells that have 
migrated through narrow spaces activate ENaC in response to shrinkage to 
allow them to regain their cell volume (Cuddapah and Sontheimer, 2011). 
Studies have shown that knockdown of ENaC prevents cell migration (Kapoor 
et al., 2009). Gain of function or loss of function mutations that result in 
increased or decreased activity of ENaC cause several diseases such as 
Liddle’s syndrome, cystic fibrosis and type 1 pseudohypoaldosteronism (Knight 
et al., 2006; Donaldson and Boucher, 2007).   
The activity of ENaC is regulated by several hormones such as oestrogen, 
aldosterone, insulin and vasopressin (Nicco et al., 2001; Liang et al., 2010). 
These hormones activate ENaC, whereas bradykinin, epidermal growth factor 
(EGF) and endothelin inhibit ENaC activity (Gilmore et al., 2001; Mamenko et 
al., 2012). Drugs such as amiloride and benzamil are ENaC blockers that are 
used widely in studies to assess ENaC activity. 
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5.1.1 Aim 
Previous data from microarray studies have identified the SCNN1B gene to be 
upregulated by oestrogen. This chapter aims to investigate the expression of 
ENaC-β protein in oestrogen-responsive breast cancer cell lines. The effect of 
17β-oestradiol on the regulation of ENaC-β protein will be studied in MCF-7, 
EFM-19 and EFF-3 cells.   
 
5.2 Expression of ENaC-β in breast cancer cells 
5.2.1 Expression of ENaC-β in breast cancer cell lines 
The protein expression of ENaC-β in different oestrogen-responsive and 
oestrogen-unresponsive cell lines was evaluated by western transfer analysis. 
Cells were cultured in full medium, lysed and proteins extracted and analysed 
by western transfer. Results are shown in Figure 5.1. Immunoreactive bands 
corresponding to a molecular mass of 72 kDa were detected in four oestrogen 
responsive, and three oestrogen unresponsive cell lines. Since the theoretical 
molecular mass of ENaC-β is 72 kDa coinciding with the observed band, we 
concluded that it is ENaC-β. We quantified this 72 kDa band only to produce the 
histogram (Figure 5.1B). Bands were also detected at approximately 30 kDa 
and 25 kDa in some cell lines. The highest expression of ENaC-β was detected 
in EFF-3 cells, followed by BT-474 and SKBR-3 expressing similar amounts. 
EFM-19, MDA-MB-231, Hs578T and MCF-7 expressed lower amounts of 
ENaC-β protein. 
 
A band at 30 kDa was detected in the BT-20 cell line only. For the BT-20 cell 
line, there was no expression detected apart from the protein band of 30 kDa. 
The protein band at an apparent molecular mass of 25 kDa is more abundant 
than the 75 kDa band in SKBR-3 cells, whereas in EFF-3 and BT-474 cells, the 
30 kDa band is much less abundant in comparison to the ENaC-β protein band 
at 72 kDa. There was no expression of ENaC-β in the oestrogen-responsive cell 
lines T47-D, ZR-75 and the oestrogen-unresponsive HBL-100 cells.       
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Figure 5.1 Expression of ENaC-β in breast cancer cells. Different breast cancer cell lines 
were cultured in routine culture medium in T75 flasks. Cells were lysed and protein extracts 
were prepared. Equal amounts of 20 µg of protein were separated by 12% polyacrylamide gel 
electrophoresis and then transferred to nitrocellulose membranes. The membranes were 
incubated with anti-ENaC-β antibody (1:100 dilution) overnight at 4 oC, followed by horseradish 
peroxidase conjugated horse-anti-mouse secondary antibody for 1 hour at 37 oC. Proteins were 
visualised by enhanced chemiluminescence with SuperSignal West Dura Extended Duration 
Substrate. A. The protein expression of ENaC-β was determined by Western transfer analysis 
in MCF-7, EFM-19, EFF-3, BT-474, T47-D, ZR-75, MDA-MB-231 (MDA-231), SKBR3, BT-20, 
Hs578T and HBL-100 cells. B. Densitometric quantification of ENaC-β. The black bars ( ) 
represent oestrogen-responsive cell lines, whereas the grey bars ( ) indicate the oestrogen-
unresponsive cell lines. Error bars indicate standard errors of the mean of triplicate 
measurements. 
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5.3 Cellular localisation of ENaC-β in breast cancer cells 
5.3.1 Localisation of ENaC-β in MCF-7, EFM-19 and EFF-3 cells 
The localisation of ENaC-β in the three cell lines was evaluated. Cells were 
cultured in full media on coverslips in 6-well plates. Cells were fixed in 4% 
paraformaldehyde and permeabilised with saponin.  
As illustrated in Figure 5.2, MCF-7 (A2) and EFM-19 (B2) cells showed 
immunoreaction within the nucleus and cytoplasm. For the EFF-3 (C2) cell line, 
we detected immunoreactions in the cytoplasm. There was also some 
expression of vesicular nature. There was no clear indication of any localisation 
to the cell membrane. 
We found that different fixation and permeabilisation combinations gave rise to 
immunoreactions at different locations within the cell (data not shown). Mostly 
fixation with either methanol or 4% paraformaldehyde and permeabilisation with 
either triton or saponin showed immunofluorescence reactions within the 
nucleus. However, in one instance only, fixation with 4% paraformaldehyde and 
permeabilisation with saponin showed some localisation at the cell membrane. 
Also there were variations in localisation amongst the three different cell lines. 
These data were not consistent. It may well be that the fixation and 
permeabilisation conditions allowed the antibody to access through the cell 
membrane and bind to non-specific sites within the cell. Since this antibody 
gave rise to several immunoreactive bands for western analysis too, it might 
suggest there is some binding of non-specific nature. Alternatively, the antibody 
might be recognising cleaved forms of ENaC, hence explaining the vesicular 
and cytoplasmic localisation. The reason for these mixed results is unclear, 
therefore this antibody was not investigated any further for immunofluorescence. 
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Figure 5.2 Localisation of ENaC-β in cell lines. MCF-7, EFM19 and EFF-3 cells were seeded 
onto coverslips in 6-well plates and cultured in routine culture medium for 24 hours. Cells were 
washed with PBS and fixed in 4% paraformaldehyde at room temperature. After fixation, cells 
were washed with PBS three times for 15 minutes each. Cells were then blocked in blocking 
buffer containing saponin for 1 hour at room temperature. The blocking medium was aspirated 
and the primary antibody ENaC-β was added at 1:50 dilution and incubated overnight at 4 oC. 
Cells were washed 3 times with PBS, 15 minutes each. The secondary antibody Alexa fluor 488 
conjugated goat anti-mouse were added at a dilution of 1:1000 and were covered in foil and the 
cells were incubated for 1 hour at room temperature. Cells were washed 3 times with PBS. 
DAPI mounting media was added to the glass slides prior to placing the coverslip on the slide 
and the cells were examined under the fluorescent microscope (Leica DMR) using a 40x 
objective. Images A1, B1 and C1 show the nuclear staining, whereas the images A2, B2 and C2 
show the immunoreaction for ENaC-β in MCF-7, EFM-19 and EFF-3 cells, respectively. The 
merged images A3, B3 and C3 show both nuclear (blue) and ENaC-β (green) staining 
combined together. Scale bar = 45 µm. 
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5.4 Clarification of the role of oestrogen in the regulation of ENaC-β 
5.4.1 Regulation of ENaC-β protein expression by oestradiol in MCF-7 
cells 
The aim of these experiments was to determine the effects of oestrogen on the 
expression on ENaC-β. Cells were seeded onto 12-well plates and cultured in 
full media for 24 hours. Cells were then grown in withdrawal media for 5 days. 
Oestradiol was added to half the cells for a period ranging from 0 to 10 days.   
The results shown in Figure 5.3 indicate a strong immunoreaction at 72 kDa 
that correspond to ENaC-β. Faint bands are observed at 50 kDa. ENaC-β is 
regulated by oestradiol after treatment for 6 days or longer. In comparison to 
untreated cells, there is a significant increase in protein expression when cells 
were grown in the presence of oestrogen.   
 
Figure 5.3 Regulation of ENaC-β protein expression in MCF-7 cells. Cells were steroid 
deprived by growing in phenol-red-free media containing 10% dextran-coated charcoal treated 
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serum and 1 µg/ml insulin, for 5 days and then treated with 10-9 M of 17β-oestradiol for different 
lengths of time upto 10 days. Both the oestradiol-treated and untreated cells were lysed and 
protein extracts prepared. Protein aliquots of 20 µg were separated by 12% polyacrylamide gel 
electrophoresis and then transferred to nitrocellulose membranes. The membranes were 
incubated with anti-ENaC-β antibody (dilution 1:100) overnight at 4 oC, followed by horseradish 
peroxidase conjugated horse-anti-mouse secondary antibody for 1 hour at 37 oC. Proteins were 
visualised by enhanced chemiluminescence with SuperSignal West Dura Extended Duration 
Substrate. A. The protein expression of ENaC-β in MCF-7 cells after oestrogen stimulation for a 
timecourse of 0 hours to 10 days, comparing serum withdrawn (-E2 ) samples with oestrogen-
stimulated (+E2 ) samples. Images shown are representative of results from experiments 
which have been replicated twice. B. Quantification of ENaC-β normalised against the 
corresponding GAPDH signal, *p < 0.001 by ANOVA. Error bars indicate SEM of triplicate 
measurements. 
 
5.4.2 Regulation of ENaC-β protein expression by oestradiol in EFM-19 
cells 
Results from a similar experiment in EFM-19 cells are shown in Figure 5.4. In 
contrast to MCF-7 cells, only 72 kDa bands were observed. There was no 
additional band at detected around 50 kDa. The protein expression of untreated 
cells gradually declined with time. There was a marked increase in ENaC-β 
expression in the cells treated with oestrogen for 6 days or more. The 
stimulation of expression by oestrogen was greatest at 8 days, but decreased 
slightly at 10 days. Therefore we continued to treat cells for 8 days in future 
experiments.   
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Figure 5.4 Regulation of ENaC-β protein expression in EFM-19 cells. Cells were steroid 
deprived by growing in phenol-red-free media containing 10% dextran-coated charcoal treated 
serum and 1 µg/ml insulin, for 5 days and then treated with 10-9 M of 17β-oestradiol for different 
lengths of time upto 10 days. Both the oestradiol-treated and untreated cells were lysed and 
protein extracts prepared. Protein aliquots of 20 µg were separated by 12% polyacrylamide gel 
electrophoresis and then transferred to nitrocellulose membranes. The membranes were 
incubated with anti-ENaC-β antibody (dilution 1:100) overnight at 4 oC, followed by horseradish 
peroxidase conjugated horse-anti-mouse secondary antibody for 1 hour at 37 oC. Proteins were 
visualised by enhanced chemiluminescence with SuperSignal West Dura Extended Duration 
Substrate. A. The protein expression of ENaC-β in EFM-19 cells after oestrogen stimulation for 
a timecourse of 0 hours to 10 days, comparing serum withdrawn (-E2 ) samples with 
oestrogen-stimulated (+E2 ) samples. Images shown are representative of results from 
experiments which have been replicated twice. B. Quantification of ENaC-β normalised against 
the corresponding GAPDH signal, *p < 0.001 by ANOVA. Error bars indicate SEM of triplicate 
measurements. 
5.4.3 Regulation of ENaC-β protein expression by oestradiol in EFF-3 
cells  
The effect of oestrogen treatment over time is shown in Figure 5.5. There is 
some background signal, but stronger immunoreactions are observed at 72 kDa 
and 50 kDa. In cells cultured in full media the 72 kDa band corresponding to 
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ENaC-β has a much greater expression than the withdrawn or oestrogen-
treated cells. However, the diffused 50 kDa band expression is lower in cells in 
full media, in comparison to the withdrawn or oestrogen treated cells. ENaC-β 
expression was observed to increase in response to oestradiol. The differences 
were very small from 2 to 6 days, but there was a significant increase in ENaC-
β expression at 8 and 10 days.      
 
Figure 5.5 Regulation of ENaC-β protein expression in EFF-3 cells. Cells were steroid 
deprived by growing in phenol-red-free media containing 10% dextran-coated charcoal treated 
serum and 1 µg/ml insulin, for 5 days and then treated with 10-9 M of 17β-oestradiol for different 
lengths of time upto 10 days. Both the oestradiol-treated and untreated cells were lysed and 
protein extracts prepared. Protein aliquots of 20 µg were separated by 12% polyacrylamide gel 
electrophoresis and then transferred to nitrocellulose membranes. The membranes were 
incubated with anti-ENaC-β antibody (dilution 1:100) overnight at 4 oC, followed by horseradish 
peroxidase conjugated horse-anti-mouse secondary antibody for 1 hour at 37 oC. Proteins were 
visualised by enhanced chemiluminescence with SuperSignal West Dura Extended Duration 
Substrate. A. The protein expression of ENaC-β in EFF-3 cells after oestrogen stimulation for a 
timecourse of 0 hours to 10 days, comparing serum withdrawn (-E2 ) samples with oestrogen-
stimulated (+E2 ) samples. Images shown are representative of results from experiments 
which have been replicated twice. B. Quantification of ENaC-β normalised against the 
corresponding GAPDH signal, *p < 0.001 by ANOVA. Error bars indicate SEM of triplicate 
measurements. 
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5.5 Concentration dependent effects of oestradiol on the regulation of 
ENaC-β by oestrogen 
5.5.1 Concentration dependent effects of oestradiol in MCF-7 cells 
We investigated the concentration dependent effects of oestrogen on the 
expression of ENaC-β in MCF-7 cells. Cells were withdrawn from growth factors 
for 5 days and oestrogen treated with different concentrations of 17-β oestradiol 
ranging from 10-8 M to 10-13 M. As expected from our previous data, we 
observed immunoreactive bands at 72 and 50 kDa. Both bands were expressed 
in a concentration dependent manner. There was a dramatic increase from 10-12 
M to 10-11 M, with the highest expression of the 72 kDa band (ENaC-β) at 10-10 
M (Figure 5.6).    
 
Figure 5.6 Effect of oestradiol on ENaC-β protein expression in MCF-7 cells. MCF-7 cells 
were seeded onto 24-well plates and withdrawn for 5 days and treated with different 
concentrations of oestradiol for a period of 8 days. Cells were lysed and protein extracts 
prepared. Protein aliquots of 10 µg were separated by 12% polyacrylamide gel electrophoresis 
and then transferred to nitrocellulose membranes. The membranes were incubated with anti-
ENaC-β antibody (dilution 1:100) overnight at 4 oC, followed by horseradish peroxidase 
conjugated horse-anti-mouse secondary antibody for 1 hour at 37 oC. Proteins were visualised 
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by enhanced chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A. 
The protein expression of ENaC-β in MCF-7 cells treated with different concentrations of 
oestradiol for 8 days. Image shown are from a representative experiment which has been 
repeated three times. B. Densitometric quantification of ENaC-β with Labworks 4.0 software, 
normalised against the corresponding GAPDH signal. Error bars indicate SEM of duplicate 
measurements. 
 
5.5.2 Concentration dependent effects of oestradiol in EFM-19 cells 
Results from a similar concentration dependent experiment in EFM-19 cells are 
shown in Figure 5.7. The untreated cells have very low expression of ENaC-β. 
In comparison to MCF-7 cells, there was a marked increase in ENaC-β 
expression when EFM-19 cells were treated with an oestradiol concentration of 
10-11 M. Also the maximal effect was observed to be at 2x10-10 M. In contrast to 
MCF-7 cells, there was no band detected at 50 kDa. The absence of the 50 kDa 
band was consistent with our previous findings.   
 
Figure 5.7 Effect of oestradiol on ENaC-β protein expression in EFM-19 cells. EFM-19 
cells were seeded onto 24-well plates and withdrawn for 5 days and treated with different 
concentrations of oestradiol for a period of 8 days. Cells were lysed and protein extracts 
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prepared. Protein aliquots of 10 µg were separated by 12% polyacrylamide gel electrophoresis 
and then transferred to nitrocellulose membranes. The membranes were incubated with anti-
ENaC-β antibody (dilution 1:100) overnight at 4 oC, followed by horseradish peroxidase 
conjugated horse-anti-mouse secondary antibody for 1 hour at 37 oC. Proteins were visualised 
by enhanced chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A. 
The protein expression of ENaC-β in EFM-19 cells treated with different concentrations of 
oestradiol for 8 days. Image shown are from a representative experiment which has been 
repeated three times. B. Densitometric quantification of ENaC-β with Labworks 4.0 software, 
normalised against the corresponding GAPDH signal. Error bars indicate SEM of duplicate 
measurements. 
 
5.5.3 Concentration dependent effects of oestradiol in EFF-3 cells 
The effect of different concentrations of oestradiol on the expression of ENaC-β 
protein in EFF-3 cells was assessed. As shown in Figure 5.8, bands were 
detected at 72 kDa and a lower expression of the 50 kDa band too. The 
expression of ENaC-β remained unchanged in the untreated and oestrogen 
treated cells upto 10-11 M. A significant increase in expression was observed 
thereafter from increasing concentrations of 2x10-10 M upto 10-8 M.    
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Figure 5.8 Effect of oestradiol on ENaC-β protein expression in EFF-3 cells. EFF-3 cells 
were seeded onto 24-well plates and withdrawn for 5 days and treated with different 
concentrations of oestradiol for a period of 8 days. Cells were lysed and protein extracts 
prepared. Protein aliquots of 10 µg were separated by 12% polyacrylamide gel electrophoresis 
and then transferred to nitrocellulose membranes. The membranes were incubated with anti-
ENaC-β antibody (dilution 1:100) overnight at 4 oC, followed by horseradish peroxidase 
conjugated horse-anti-mouse secondary antibody for 1 hour at 37 oC. Proteins were visualised 
by enhanced chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A. 
The protein expression of ENaC-β in EFF-3 cells treated with different concentrations of 
oestradiol for 8 days. Image shown are from a representative experiment which has been 
repeated three times. B. Densitometric quantification of ENaC-β with Labworks 4.0 software, 
normalised against the corresponding GAPDH signal. Error bars indicate SEM of duplicate 
measurements. 
 
5.6 Discussion 
5.6.1 Expression and localisation 
The expression, localisation and the effect of oestrogen on the regulation of 
ENaC-β protein was studied in detail in this chapter. ENaC-β protein was 
detected in the oestrogen-responsive cell lines MCF-7, EFM-19, EFF-3 and BT-
474 with the highest expression being in EFF-3 cells. Out of the five oestrogen-
unresponsive cell lines, only three cell lines MDA-MB-231, SKBR-3 and Hs578T 
expressed ENaC-β protein. The cell lines T47-D, ZR-75, BT-20 and HBL-100 
did not express any ENaC-β. Two other studies have also reported the 
expression of ENaC-β mRNA and protein in the normal breast epithelial cell line 
MCF-10A and cancerous breast cell lines MCF-7 and T47-D (Boyd and Naray-
Fejes-Toth, 2007; Wang and Schultz, 2014). Although Boyd and Naray-Fejes-
Toth (2007) showed that T47-D cells express ENaC-β mRNA, the current study 
did not detect any ENaC-β protein in T47-D cells. A possible explanation for this 
inconsistency may be that ENaC-β mRNA is not translated into protein. 
However, this study did not investigate the mRNA expression of ENaC-β in 
breast cancer cells lines; therefore it is difficult to come to a definite conclusion.          
The localisation of ENaC-β in oestrogen-responsive cell lines was determined 
by immunofluorescence. However the antibody did not detect ENaC-β at the 
cell membrane, instead immunoreactions were observed intracellularly, either in 
the nuclei or cytoplasm of these cells. There was also some evidence of 
vesicular expression. These results were in agreement with studies in a mouse 
collecting duct cell line (Dooley et al., 2013) and also in the renal collecting 
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system of rats (Hager et al., 2001; Sauter et al., 2006), in which ENaC-β was 
detected in the cytoplasm. It is difficult to interpret this result of the lack of 
ENaC-β expression in the plasma membrane, but it could be related to vesicular 
trafficking of ENaC to the cell membrane. Nevertheless, discrepancies in the 
data obtained, led to the conclusion that this antibody was unsuitable for 
immunofluorescence. Therefore this antibody was not investigated any further 
to study the localisation of ENaC-β.   
5.6.2 Oestrogen regulation 
One of the main objectives was to evaluate the effects of oestrogen on the 
regulation of ENaC-β expression. Other studies have investigated the regulation 
of ENaC by steroidal and non-steroidal hormones; aldosterone, dexamethasone, 
vasopressin, oestrogen and progesterone (Gambling et al., 2004; Boyd and 
Naray-Fejes-Toth, 2007; Liang et al., 2010; Frindt and Palmer, 2012; Qi et al., 
2014; Yusef et al., 2014). The effect of oestrogen on the expression of ENaC-β 
is controversial as some studies have shown that oestrogen increases the 
expression of ENaC-β (Gambling et al., 2004; Riazi et al., 2006; Chinigarzadeh 
et al., 2015), whereas other studies have reported conflicting results. Yusef et al. 
(2014) showed that the total protein expression of ENaC-β was unchanged in a 
mouse collecting duct cell line treated with oestrogen for 30 minutes. Laube et 
al. (2011) reported that oestrogen alone does not increase the ENaC-β mRNA 
expression, instead the presence of both oestrogen and progesterone is 
required to induce expression of ENaC-β. Results from this chapter showed that 
there is an increase in the expression of ENaC-β in response to oestrogen in 
the breast cancer cells MCF-7, EFM-19 and EFF-3. The induction of ENaC-β 
protein was clearly evident and a significant difference was observed after 6 
days of treatment with oestradiol in MCF-7 and EFM-19 cells and after 8 days in 
EFF-3 cells. This is the first study that investigates the role of oestrogen in 
regulation of ENaC-β expression in breast cancer cells. The present study 
showed that ENaC-β protein expression increased in an oestrogen 
concentration dependent manner in all three cell lines.    
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5.7 Conclusion 
In conclusion, the results described in this chapter has shown that ENaC-β is 
expressed in a wide range of oestrogen-responsive and oestrogen-
unresponsive breast cancer cell lines. The effect of oestrogen on ENaC-β 
protein expression was studied in detail. The expression of ENaC-β has been 
shown to increase in MCF-7, EFM-19 and EFF-3 cells stimulated with 
oestrogen. The EFF-3 cells were slower to respond in comparison to the other 
two cell lines. 
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Chapter 6.    Role of anti-oestrogens 
6.1 Introduction 
Oestrogen receptor positive breast cancers are commonly treated with 
endocrine receptor-based therapies. Inhibition of the action of oestrogen by 
endocrine therapy has resulted in a decrease in mortality rates (Early Breast 
Cancer Trialists' Collaborative et al., 2011b). Approximately two-thirds of breast 
cancers are hormone-responsive and respond to endocrine therapy. However, 
many patients either do not respond to endocrine therapy or acquire resistance 
with time.      
Anti-oestrogens such as tamoxifen are often administered to patients with 
oestrogen receptor positive disease and have prolonged the survival of these 
patients (Osborne, 1998; Pritchard, 2005). 4-hydroxytamoxifen is a more potent 
active metabolite of tamoxifen which was detected in plasma and tumour 
extracts (Robinson and Jordan, 1988). Fulvestrant is a pure ER antagonist and 
has been shown to have no oestrogen agonist activity (DeFriend et al., 1994b). 
Anti-oestrogens such as raloxifene, bazedoxifene and lasofoxifene used in the 
prevention and treatment of osteoporosis have also been beneficial in the 
treatment of breast cancer.  
The concentrations of anti-oestrogens were chosen according to their binding 
affinities for the oestrogen receptor (Blair et al., 2000; Li et al., 2012). Previous 
studies have shown that tamoxifen alone is effective at 10-7 M, while a 
concentration of 5x10-6 M provides a more effective inhibition of the actions of 
oestrogens when tamoxifen is competing with oestrogen (Johnson et al., 1989; 
Molloy et al., 2000). 4-hydroxytamoxifen has a stronger ER binding affinity than 
tamoxifen (Favoni and de Cupis, 1998). Raloxifene and bazedoxifene are 
similar in structure and their binding affinities for ER were similar to each other. 
All three anti-oestrogens tamoxifen, raloxifene and lasofoxifene have a similar 
mechanism of action. They bind to the ligand binding domain of the ER and 
induce a change in conformation in which helix 12 is repositioned to occupy the 
AF-2. The blockage of the AF-2 prevents the binding of coactivators to its 
surface (Brzozowski et al., 1997; Vajdos et al., 2007). Toremifene is a tamoxifen 
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analogue, with comparable binding affinities for the ER. Therefore toremifene 
was added to the culture medium at 10-7 M. Fulvestrant was previously shown 
to be effective at 10-8 M (Molloy et al., 2000), and the anti-oestrogen 
lasofoxifene had a similar ER binding affinity to that of fulvestrant, therefore 
lasofoxifene was added at a concentration of 10-8 M (Gennari et al., 2006).  
    
Anti-oestrogen Binding affinity for ER Concentration
Tamoxifen 5.55 x 10-8 M 10-7 M 
5x10-6 M 
4-Hydroxytamoxifen 5.13 x 10-10 M 10-8 M 
Fulvestrant 2.40 x 10-9 M 10-8 M 
Bazedoxifene 2.60 x 10-8 M 10-7 M 
Toremifene 6.50 x 10-8 M 10-7 M 
Raloxifene 7.58 x 10-8 M 10-7 M 
Lasofoxifene 1.50 x 10-9 M 10-8 M 
 
Table 6.1 Binding affinities of anti-oestrogens. Anti-oestrogens and their binding affinities for 
the oestrogen receptor.  
 
Previous chapters have confirmed the repression of NKCC1 and induction of 
NHERF3 and ENaC-β in response to oestrogen. The experiments described in 
this chapter were designed to determine the agonist and oestrogen antagonist 
effects of anti-oestrogens on the protein expression of NKCC1, NHERF3 and 
ENaC-β.  
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6.2 Role of anti-oestrogens on NKCC1 expression 
6.2.1 Characterisation of the agonist activity of anti-oestrogens on 
NKCC1 expression 
 
The agonist effects of tamoxifen were tested at concentrations 10-7 M and 5x10-
6 M, and the agonist effects of 4-hydroxytamoxifen and fulvestrant were tested 
at 10-8 M concentration. Cells were grown in steroid-withdrawn media for 5 days, 
followed by treatments with anti-oestrogens for 8 days.   
The results for MCF-7, EFM-19 and EFF-3 cells are shown in Figure 6.1A, B 
and C, respectively. The protein expression of NKCC1 in MCF-7 and EFM-19 
cells treated with the different anti-oestrogens were not significantly different 
from the NKCC1 expression in untreated cells. These results indicate that the 
anti-oestrogens tamoxifen, 4-hydroxytamoxifen and fulvestrant do not show 
agonist activity. At concentrations of 10-9 M oestradiol, expression of NKCC1 
was decreased completely in MCF-7 cells. In comparison to untreated EFM-19 
cells, a 9-fold reduction in NKCC1 expression was observed in the presence of 
10-9 M oestradiol.       
In EFF-3 cells, treatments with anti-oestrogens alone showed no oestrogen-like 
activity. The expression of NKCC1 was significantly higher in cells treated with 
4-hydroxytamoxifen and fulvestrant with respect to the NKCC1 expression of 
untreated EFF-3 cells. The expression of NKCC1 decreased significantly when 
EFF-3 cells were treated with 2x10-10 M oestradiol. 
Collectively, the anti-oestrogens tamoxifen, 4-hydroxytamoxifen and fulvestrant 
displayed no agonism in all three cell lines. 
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Figure 6.1 Agonist activity of anti-oestrogens on NKCC1 expression. MCF-7, EFM-19 
(50,000 per well) and EFF-3 (100,000 per well) cells were plated onto a 24-well plate. Cells 
were steroid deprived by growth in phenol-red-free media containing 10% dextran-coated 
charcoal treated serum and 1 µg/ml insulin, for 5 days and then cultured in withdrawal medium 
alone (utr) or treated with either 10-7 M or 5x10-6 M tamoxifen (TAM), 10-8 M 4-hydroxytamoxifen 
(4OHT), 10-8 M Fulvestrant (FUL) and 10-9 M 17β-oestradiol alone for 8 days. Cells were lysed 
and protein extracts were prepared. Protein aliquots of 10 µg were separated by 12% 
polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. The 
membranes were incubated with anti-NKCC1 antibody (dilution 1:10000) overnight at 4 oC, 
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followed by horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 
37 oC. Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A, B, C. The protein expression of NKCC1 in MCF-7, EFM-19 
and EFF-3 cells treated with anti-oestrogens, comparing serum withdrawn (-E2 ) samples with 
oestrogen-stimulated (+E2 ) samples. The images shown are representative of an experiment 
which has been replicated three times in MCF-7 and EFM-19 cells and twice in EFF-3 cells. D, 
E, F. Quantification of NKCC1 normalised against the corresponding GAPDH signal, *p < 0.05 
and **p < 0.001 by ANOVA, compared with the untreated (utr) cells. Error bars indicate SEM of 
duplicate measurements. 
 
The following experiments were designed to study the agonist effect of the anti-
oestrogens bazedoxifene, toremifene, raloxifene and lasofoxifene on expression 
of NKCC1. Bazedoxifene, toremifene, and raloxifene were added at a 
concentration of 10-7 M, whereas lasofoxifene was added at 10-8 M. The results 
are shown in Figure 6.2. 
The NKCC1 protein expression of MCF-7 cells treated with the different anti-
oestrogens were similar to the NKCC1 expression in untreated cells. In the 
presence of 10-9 M oestradiol, a statistically significant decrease was observed.  
In contrast to the results obtained from MCF-7 cells, bazedoxifene displays 
weak agonistic effects than toremifene, raloxifene and lasofoxifene in EFM-19 
cells (Figure 6.2B). A 2.2-fold decrease in expression was observed in cells 
treated with bazedoxifene in comparison to untreated cells. This decrease was 
statistically significant.  
In comparison to the untreated cells, the expression of NKCC1 did not vary 
much when EFF-3 cells were treated with bazedoxifene, toremifene, raloxifene 
and lasofoxifene alone. In the presence of oestradiol, the amount of NKCC1 
protein detected was approximately 5.6-fold lower than that of untreated cells. 
These results suggest that all four anti-oestrogens bazedoxifene, toremifene, 
raloxifene and lasofoxifene do not exert any agonist activity in MCF-7 and EFF-
3 cells. However, bazedoxifene was obeserved to be weakly agonistic in EFM-
19 cells. 
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Figure 6.2 Agonist effect of anti-oestrogens BZA, TOR, RAL, LAS on NKCC1 expression. 
MCF-7, EFM-19 (50,000 per well) and EFF-3 (100,000 per well) cells were plated onto a 24-well 
plate. Cells were steroid deprived by growth in phenol-red-free media containing 10% dextran-
coated charcoal treated serum and 1 µg/ml insulin, for 5 days and then cultured in withdrawal 
medium alone (utr) or treated with either 10-7 M Bazedoxifene (BZA), 10-7 M Toremifene (TOR), 
10-7 M Raloxifene (RAL), 10-8 M Lasofoxifene (LAS) and 10-9 M 17β-oestradiol alone for 8 days. 
Cells were lysed and protein extracts were prepared. Protein aliquots of 10 µg were separated 
by 12% polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. 
The membranes were incubated with anti-NKCC1 antibody (dilution 1:10000) overnight at 4 oC, 
followed by horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 
37 oC. Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A, B, C. The protein expression of NKCC1 in MCF-7, EFM-19 
and EFF-3 cells treated with anti-oestrogens, comparing serum withdrawn (-E2 ) samples with 
oestrogen-stimulated (+E2 ) samples. The images shown are representative of an experiment 
which has been replicated twice. D, E, F. Quantification of NKCC1 normalised against the 
corresponding GAPDH signal, *p < 0.05 and **p < 0.001 by ANOVA, compared with the 
untreated (utr) cells. Error bars indicate SEM of triplicate measurements. 
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6.2.2 Characterisation of the antagonist activity of anti-oestrogens on 
NKCC1 expression 
 
Cells were treated with 5x10-6 M tamoxifen, 10-8 M 4-hydroxytamoxifen and 10-8 
M fulvestrant in combination with 2x10-10 M oestradiol to assess the antagonistic 
effects of the anti-oestrogens. 
In MCF-7 cells (Figure 6.3A), tamoxifen 5x10-6 M in the presence of 2x10-10 M 
oestradiol had the most antagonist effect on NKCC1 expression. The effect of 
oestradiol was largely reversed and NKCC1 expression was increased 15-fold. 
However, 4-hydroxytamoxifen and fulvestrant in the presence of oestradiol 
exerted partial antagonist activity. 4-hydroxytamoxifen increased the expression 
of NKCC1 by approximately 2-fold in comparison to 2x10-10 M oestradiol treated 
cells.  
When EFM-19 cells were treated with 10-9 M and 2x10-10 M oestradiol, the 
expression of NKCC1 decreased dramatically. The anti-oestrogens in the 
presence of 2x10-10 M oestradiol, did not inhibit the effects of oestrogen.  
A decrease in NKCC1 expression was observed in EFF-3 cells treated with 
2x10-10 M oestradiol. 4-hydroxytamoxifen in the presence of 2x10-10 M 
oestradiol were partially antagonistic. Compared to the expression of NKCC1 in 
the presence of 2x10-10 M oestradiol alone, tamoxifen and fulvestrant 
demonstrated antagonistic properties.    
 
151 
 
 
Figure 6.3 Antagonist activity of anti-oestrogens on NKCC1 expression. MCF-7, EFM-19 
(50,000 per well) and EFF-3 (100,000 per well) cells were plated onto a 24-well plate. Cells 
were steroid deprived by growth in phenol-red-free media containing 10% dextran-coated 
charcoal treated serum and 1 µg/ml insulin, for 5 days and then cultured in withdrawal medium 
alone (utr) or treated with 10-9 M, 2x10-10 M 17β-oestradiol alone, or 5x10-6 M tamoxifen (TAM), 
10-8 M 4-hydroxytamoxifen (4OHT), 10-8 M Fulvestrant (FUL) in combination with 2x10-10 M 17β-
oestradiol for 8 days. Cells were lysed and protein extracts were prepared. Protein aliquots of 
10 µg were separated by 12% polyacrylamide gel electrophoresis and then transferred to 
nitrocellulose membranes. The membranes were incubated with anti-NKCC1 antibody (dilution 
1:10000) overnight at 4 oC, followed by horseradish peroxidase conjugated goat-anti-rabbit 
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secondary antibody for 1 hour at 37 oC. Proteins were visualised by enhanced 
chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A, B, C. The 
protein expression of NKCC1 in MCF-7, EFM-19 and EFF-3 cells treated with anti-oestrogens, 
comparing serum withdrawn (-E2 ) samples with oestrogen-stimulated (+E2 ) samples. The 
images shown are representative of an experiment which has been replicated three times in 
MCF-7 and EFM-19 cells and twice in EFF-3 cells. D, E, F. Quantification of NKCC1 normalised 
against the corresponding GAPDH signal, *p < 0.05 and **p < 0.001 by ANOVA, compared with 
2x10-10 M oestradiol treated cells. Error bars indicate SEM of duplicate measurements.  
 
 
The oestrogen antagonist activities of bazedoxifene, toremifene, raloxifene and 
lasofoxifene are shown in Figure 6.4.   
In MCF-7 cells treated with these anti-oestrogens in the presence of 2x10-10 M 
oestradiol, toremifene showed partial antagonism with decreased NKCC1 
expression levels similar to that of cells treated with 2x10-10 M oestradiol alone. 
Bazedoxifene, raloxifene and lasofoxifene displayed completely antagonistic 
properties.        
Bazedoxifene and raloxifene exerts the most anti-estrogenic effect on the 
expression of NKCC1 in EFM-19 cells, by largely antagonising the effects of 
oestradiol. However, the partial antagonist activity of toremifene on the 
expression of NKCC1 is similar to the results observed in MCF-7 cells.  
In EFF-3 cells, all four anti-oestrogens in the presence of 2x10-10 M oestradiol 
contributed to antagonising the effects of oestradiol, resulting in a dramatic 
increase in the expression of NKCC1. Out of these anti-oestrogens raloxifene 
was the most anti-oestrogenic, followed by toremifene, bazedoxifene and 
lasofoxifene respectively.    
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Figure 6.4 Antagonist activity of anti-oestrogens BZA, TOR, RAL, LAS on NKCC1 
expression. MCF-7, EFM-19 (50,000 per well) and EFF-3 (100,000 per well) cells were plated 
onto a 24-well plate. Cells were steroid deprived by growth in phenol-red-free media containing 
10% dextran-coated charcoal treated serum and 1 µg/ml insulin, for 5 days and then cultured in 
withdrawal medium alone (utr) or treated with 10-9 M, 2x10-10 M 17β-oestradiol alone, or 10-7 M 
Bazedoxifene (BZA), 10-7 M Toremifene (TOR), 10-7 M Raloxifene (RAL), 10-8 M Lasofoxifene 
(LAS) in combination with 2x10-10 M 17β-oestradiol for 8 days. Cells were lysed and protein 
extracts were prepared. Protein aliquots of 10 µg were separated by 12% polyacrylamide gel 
electrophoresis and then transferred to nitrocellulose membranes. The membranes were 
incubated with anti-NKCC1 antibody (dilution 1:10000) overnight at 4 oC, followed by 
horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 37 oC. 
Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A, B, C. The protein expression of NKCC1 in MCF-7, EFM-19 
and EFF-3 cells treated with anti-oestrogens, comparing serum withdrawn (-E2 ) samples with 
oestrogen-stimulated (+E2 ) samples. The images shown are representative of an experiment 
which has been replicated twice. D, E, F. Quantification of NKCC1 normalised against the 
corresponding GAPDH signal, *p < 0.05 and **p < 0.001 by ANOVA, compared with 2x10-10 M 
oestradiol treated cells. Error bars indicate SEM of triplicate measurements.   
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6.3 Action of anti-oestrogens on the protein expression of NHERF3 
6.3.1 Analysis of the agonist activity of anti-oestrogens on the regulation 
of NHERF3 protein 
 
This section investigated the agonist effects of different anti-oestrogens on the 
expression of the protein NHERF3. The anti-oestrogens tamoxifen, 4-
hydroxytamoxifen and fulvestrant were tested at concentrations described in the 
previous section 6.1.  
Figure 6.5 compares the agonist effects of anti-oestrogens in MCF-7, EFM-19 
and EFF-3 cells. In MCF-7 cells, there was no expression of NHERF3 protein in 
the untreated cells, whereas cells treated with 10-9 M oestradiol had the most 
induction of NHERF3 expression. Tamoxifen at 5x10-6 M alone exerted a low 
oestrogen-like activity, in contrast to the other two anti-oestrogens 4-
hydroxytamoxifen and fulvestrant.  
EFM-19 cells treated with the different anti-oestrogens alone did not detect any 
NHERF3 protein expression and was similar to untreated EFM-19 cells (Figure 
6.5B). These results indicate that none of the anti-oestrogens have agonist 
activity. Oestradiol treatment significantly increased NHERF3 protein 
expression.  
Results obtained from western analysis of EFF-3 cells treated with anti-
oestrogens in the absence of oestradiol is shown in Figure 6.5C. Tamoxifen and 
4-hydroxytamoxifen on their own showed partial agonistic effects on the 
expression of NHERF3. The expression of NHERF3 was 1.5-fold higher in EFF-
3 cells treated with 4-hydroxytamoxifen in comparison to the NHERF3 
expression in cells with tamoxifen alone. In contrast to tamoxifen and 4-
hydroxytamoxifen, fulvestrant did not have any detectable agonist activity. In the 
presence of 2x10-10 M oestradiol, the expression of NHERF3 was increased. 
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Figure 6.5 Agonist effects of anti-oestrogens on NHERF3 expression. MCF-7, EFM-19 
(50,000 per well) and EFF-3 (100,000 per well) cells were plated onto a 24-well plate. Cells 
were steroid deprived by culturing in phenol-red-free media containing 10% dextran-coated 
charcoal treated serum and 1 µg/ml insulin, for 5 days and then cultured in withdrawal medium 
alone (utr) or treated with either 10-7 M or 5x10-6 M tamoxifen (TAM), 10-8 M 4-hydroxytamoxifen 
(4OHT), 10-8 M fulvestrant (FUL) and 10-9 M 17β-oestradiol alone for 8 days. Cells were lysed 
and protein extracts were prepared. Protein aliquots of 10 µg were separated by 12% 
polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. The 
membranes were incubated with anti-NHERF3 antibody (dilution 1:10000) overnight at 4 oC, 
followed by horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 
37 oC. Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A, B, C. The protein expression of NHERF3 in MCF-7, EFM-19 
and EFF-3 cells treated with anti-oestrogens, comparing serum withdrawn (-E2 ) samples with 
oestrogen-stimulated (+E2 ) samples. The image shown is representative of an experiment 
which has been replicated three times in MCF-7 and EFM-19 cells and twice in EFF-3 cells. D, 
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E, F. Quantification of NHERF3 normalised against the corresponding GAPDH signal, *p < 0.05 
and **p < 0.001 by ANOVA, compared with the untreated (utr) cells. Error bars indicate SEM of 
duplicate measurements.  
 
 
The agonist effects of the anti-oestrogens bazedoxifene, toremifene, raloxifene 
and lasofoxifene were explored (Figure 6.6).  
A slight increase in NHERF3 expression was observed in MCF-7 cells treated 
with toremifene and lasofoxifene, which indicates weak partial agonist activity. 
There was no detectable induction of NHERF3 expression in cells grown in the 
presence of bazedoxifene and raloxifene alone. Treatment with 10-9 M 
oestradiol resulted in a marked increase in NHERF3 expression.  
Figure 6.6B shows the effects of anti-oestrogens bazedoxifene, toremifene, 
raloxifene and lasofoxifene on the expression of NHERF3 protein in EFM-19 
cells. There was no NHERF3 protein detected suggesting that all four of these 
anti-oestrogens alone exerted no oestrogen-like activity. 
The agonistic properties of the four anti-oestrogens in EFF-3 cells was tested. 
The results were similar to that observed in EFM-19 cell as all four anti-
oestrogens displayed no agonism. Treatment with oestradiol induced 
expression of NHERF3. 
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Figure 6.6 Agonist effects of anti-oestrogens BZA, TOR, RAL, LAS on NHERF3 
expression. MCF-7, EFM-19 (50,000 per well) and EFF-3 (100,000 per well) cells were plated 
onto a 24-well plate. Cells were steroid deprived by culturing in phenol-red-free media 
containing 10% dextran-coated charcoal treated serum and 1 µg/ml insulin, for 5 days and then 
cultured in withdrawal medium alone (utr) or treated with either 10-7 M Bazedoxifene (BZA), 10-7 
M Toremifene (TOR), 10-7 M Raloxifene (RAL), 10-8 M Lasofoxifene (LAS) and 10-9 M 17β-
oestradiol alone for 8 days. Cells were lysed and protein extracts were prepared. Protein 
aliquots of 10 µg were separated by 12% polyacrylamide gel electrophoresis and then 
transferred to nitrocellulose membranes. The membranes were incubated with anti-NHERF3 
antibody (dilution 1:10000) overnight at 4 oC, followed by horseradish peroxidase conjugated 
goat-anti-rabbit secondary antibody for 1 hour at 37 oC. Proteins were visualised by enhanced 
chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A, B, C. The 
protein expression of NHERF3 in MCF-7, EFM-19 and EFF-3 cells treated with anti-oestrogens, 
comparing serum withdrawn (-E2 ) samples with oestrogen-stimulated (+E2 ) samples. The 
image shown is representative of an experiment which has been replicated twice. D, E, F. 
Quantification of NHERF3 normalised against the corresponding GAPDH signal, *p < 0.05 and 
**p < 0.001 by ANOVA, compared with the untreated (utr) cells. Error bars indicate SEM of 
triplicate measurements.  
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6.3.2 Analysis of the antagonist activity of anti-oestrogens on the 
regulation of NHERF3 protein 
 
The antagonist effects of tamoxifen, 4-hydroxytamoxifen and fulvestrant was 
evaluated in the three cell lines (Figure 6.7).   
Treatment of MCF-7 cells with tamoxifen 5x10-6 M and 4-hydroxytamoxifen 10-8 
M in the presence of 2x10-10 M oestradiol, resulted in an increase in NHERF3 
expression. These results indicate that tamoxifen and 4-hydroxytamoxifen 
displayed partial antagonistic properties. However fulvestrant 10-8 M inhibited 
completely the effect of 2x10-10 M oestradiol. 
While tamoxifen 5x10-6 M and 4-hydroxytamoxifen 10-8 M in the presence of 
oestradiol caused partial antagonism in MCF-7 cells, a similar observation was 
not made in EFM-19 cells. The anti-oestrogens tamoxifen, 4-hydroxytamoxifen 
and fulvestrant completely blocked the actions of oestrogen on NHERF3 protein 
expression (Figure 6.7). 
Treatment of EFF-3 cells with 2x10-10 M oestradiol, stimulated expression of 
NHERF3. Tamoxifen and 4-hydroxtamoxifen did not inhibit the effect of 
oestrogen, whereas fulvestrant inhibited completely the effect of oestrogen on 
NHERF3 expression. 
 
159 
 
 
Figure 6.7 Antagonist effects of anti-oestrogens on NHERF3 expression. MCF-7, EFM-19 
(50,000 per well) and EFF-3 (100,000 per well) cells were plated onto a 24-well plate. Cells 
were steroid deprived by culturing in phenol-red-free media containing 10% dextran-coated 
charcoal treated serum and 1 µg/ml insulin, for 5 days and then cultured in withdrawal medium 
alone (utr) or treated with 10-9 M, 2x10-10 M 17β-oestradiol alone, or 5x10-6 M tamoxifen (TAM), 
10-8 M 4-hydroxytamoxifen (4OHT), 10-8 M Fulvestrant (FUL) in combination with 2x10-10 M 17β-
oestradiol for 8 days. Cells were lysed and protein extracts were prepared. Protein aliquots of 
10 µg were separated by 12% polyacrylamide gel electrophoresis and then transferred to 
nitrocellulose membranes. The membranes were incubated with anti-NHERF3 antibody (dilution 
1:10000) overnight at 4 oC, followed by horseradish peroxidase conjugated goat-anti-rabbit 
secondary antibody for 1 hour at 37 oC. Proteins were visualised by enhanced 
chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A, B, C. The 
protein expression of NHERF3 in MCF-7, EFM-19 and EFF-3 cells treated with anti-oestrogens, 
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comparing serum withdrawn (-E2 ) samples with oestrogen-stimulated (+E2 ) samples. The 
image shown is representative of an experiment which has been replicated three times in MCF-
7 and EFM-19 cells and twice in EFF-3 cells. D, E, F. Quantification of NHERF3 normalised 
against the corresponding GAPDH signal, *p < 0.05 and **p < 0.001 by ANOVA, compared with 
2x10-10 M oestradiol treated cells. Error bars indicate SEM of duplicate measurements. 
 
Figure 6.8 shows the oestrogen antagonist effects of bazedoxifene, toremifene, 
raloxifene and lasofoxifene. 
In MCF-7 cells, treatment with 10-9 M and 2x10-10 M oestradiol resulted in a 
marked increase in NHERF3 expression. Toremifene did not completely 
antagonise the stimulatory effects of oestrogen, instead showed partial 
antagonism. There was almost a two-fold reduction in NHERF3 expression in 
comparison to the effect of oestrogen alone. In contrast to the effects of 
toremifene, the other three anti-oestrogens bazedoxifene, raloxifene and 
lasofoxifene exerted opposing effects. No expression of NHERF3 was detected 
as these anti-oestrogens completely antagonised the effects of oestrogen.  
An induction in NHERF3 protein expression was observed in EFM-19 cells 
treated with toremifene 10-7 M in the presence of 2x1010 M oestradiol. This 
stimulation of NHERF3 expression was approximately 1.3-fold higher than that 
of 2x1010 M oestradiol alone. It is evident that toremifene is unable to inhibit the 
effects of oestrogen. The effects of bazedoxifene, raloxifene and lasofoxifene 
on the expression of NHERF3 differ from that of toremifene, as they completely 
opposed the effects of oestradiol and displayed complete antagonism.  
The antagonistic effect of toremifene on the expression of NHERF3 in EFF-3 
cells is comparable to that of EFM-19 cells. The expression of NHERF3 is about 
2-fold higher when cells were treated with toremifene in the presence of 
oestradiol than in oestradiol alone. This suggests that toremifene was unable to 
antagonise the effects of oestrogen. Bazedoxifene and raloxifene completely 
blocked the effects of oestrogen. Interestingly, lasofoxifene showed no 
antagonistic effects, as there was almost no difference in NHERF3 expression, 
between cells treated with 2x10-10 M oestradiol and cells treated with 
lasofoxifene plus oestradiol. 
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Figure 6.8 Antagonist effects of anti-oestrogens BZA, TOR, RAL, LAS on NHERF3 
expression. MCF-7, EFM-19 (50,000 per well) and EFF-3 (100,000 per well) cells were plated 
onto a 24-well plate. Cells were steroid deprived by culturing in phenol-red-free media 
containing 10% dextran-coated charcoal treated serum and 1 µg/ml insulin, for 5 days and then 
cultured in withdrawal medium alone (utr) or treated with 10-9 M, 2x10-10 M 17β-oestradiol alone, 
or 10-7 M Bazedoxifene (BZA), 10-7 M Toremifene (TOR), 10-7 M Raloxifene (RAL), 10-8 M 
Lasofoxifene (LAS) in combination with 2x10-10 M 17β-oestradiol for 8 days. Cells were lysed 
and protein extracts were prepared. Protein aliquots of 10 µg were separated by 12% 
polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. The 
membranes were incubated with anti-NHERF3 antibody (dilution 1:10000) overnight at 4 oC, 
followed by horseradish peroxidase conjugated goat-anti-rabbit secondary antibody for 1 hour at 
37 oC. Proteins were visualised by enhanced chemiluminescence with SuperSignal West Dura 
Extended Duration Substrate. A, B, C. The protein expression of NHERF3 in MCF-7, EFM-19 
and EFF-3 cells treated with anti-oestrogens, comparing serum withdrawn (-E2 ) samples with 
oestrogen-stimulated (+E2 ) samples. The image shown is representative of an experiment 
which has been replicated twice. D, E, F. Quantification of NHERF3 normalised against the 
corresponding GAPDH signal, *p < 0.05 and **p < 0.001 by ANOVA, compared with 2x10-10 M 
oestradiol treated cells. Error bars indicate SEM of triplicate measurements.  
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Furthermore, the concentration-dependent agonist and antagonist activity of 
toremifene was investigated. Previously we showed that in the presence of 
oestradiol, toremifene induced NHERF3 expression above the level induced by 
oestradiol. Therefore this experiment would further test the concentration-
dependent effects of toremifene on NHERF3 protein expression.  
EFF-3 cells were cultured in steroid depleted media for 5 days and treated with 
concentrations of toremifene ranging from 10-10 M to 10-6 M in the absence or 
presence of 2x10-10 M oestradiol for 8 days. Results shown in Figure 6.9 
indicate that there are two immunoreactive bands detected. The higher 
molecular weight band was quantified, as it matched more closely the molecular 
mass of NHERF3 protein. This protein band was not detected in cells treated 
with toremifene alone, which was consistent with our previous findings. There 
was a degree of variability in NHERF3 expression between different 
concentrations of toremifene in the presence of oestrogen. As for 10-7 M 
toremifene in the presence of oestrogen, the result was not similar to the 
previous experiment (Figure 6.8C), as NHERF3 expression was not induced to 
levels above that of oestradiol alone.   
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Figure 6.9 Effect of TOR on NHERF3 expression in EFF-3 cells. EFF-3 cells were plated at a 
density of 100,000 cells per well onto a collagen-coated 24-well plate. Cells were steroid 
deprived by culturing in phenol-red-free media containing 10% dextran-coated charcoal treated 
serum and 1 µg/ml insulin, for 5 days and then cultured in withdrawal medium alone (utr) or 
treated with toremifene (TOR) concentrations varying from 10-10 M to 10-6 M, alone or in 
combination with 2x10-10 M 17β-oestradiol for 8 days. Cells were lysed and protein extracts were 
prepared. Protein aliquots of 10 µg were separated by 12% polyacrylamide gel electrophoresis 
and then transferred to nitrocellulose membranes. The membranes were incubated with anti-
NHERF3 antibody (dilution 1:10000) overnight at 4 oC, followed by horseradish peroxidase 
conjugated goat-anti-rabbit secondary antibody for 1 hour at 37 oC. Proteins were visualised by 
enhanced chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A. 
The protein expression of NHERF3 in EFF-3 cells treated with anti-oestrogen toremifene, 
comparing serum withdrawn (-E2 ) samples with oestrogen-stimulated (+E2 ) samples. B. 
Quantification of NHERF3 normalised against the corresponding GAPDH signal. The dashed 
line indicates the level on NHERF3 protein expression in cells treated with 2x10-10 M 17β-
oestradiol alone. Error bars indicate SEM of triplicate measurements. 
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6.4 Regulation of ENaC-β by anti-oestrogens 
6.4.1 Investigation of the agonist activity of anti-oestrogens on the 
regulation of ENaC-β expression 
 
The purpose of these experiments was to study the agonist effects of a range of 
anti-oestrogens on the expression of ENaC-β protein in oestrogen-responsive 
cell lines. 
In the following experiments, cells were cultured in withdrawal media for 5 days. 
Treatments with different anti-oestrogens tamoxifen, 4-hydroxytamoxifen and 
fulvestrant lasted for 8 days.  
Results for MCF-7 cells are presented in Figure 6.10A. Immunoreactive bands 
were detected at 70 kDa and around 50 kDa. For the purpose of this experiment 
the corresponding ENaC-β band at 70 kDa was quantified. Tamoxifen did not 
show agonism whilst, 4-hydroxytamoxifen and fulvestrant demonstrated 
substantial oestrogen-like effects. There is a clear indication of a significant 
increase in ENaC-β protein expression in cells treated with 10-9 M oestradiol.  
Results from an experiment evaluating the effects of anti-oestrogens tamoxifen, 
4-hydroxytamoxifen and fulvestrant in EFM-19 cells are shown in Figure 6.10B. 
Tamoxifen 10-7 M had oestrogen-like activity and increased ENaC-β protein 
expression to levels similar to that of oestradiol alone. Tamoxifen at 5x10-6 M, 4-
hydroxytamoxifen and fulvestrant showed no agonist activity. 
The action of anti-oestrogens on the expression of ENaC-β was tested in EFF-3 
cells. As shown in Figure 6.10C, the anti-oestrogens had no significant effect on 
ENaC-β expression and did not show any agonist activity. Oestrogen induced 
the ENaC-β expression by approximately 2.5-fold. 
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Figure 6.10 Agonist activity of anti-oestrogens on ENaC-β expression. MCF-7, EFM-19 
(50,000 per well) and EFF-3 (100,000 per well) cells were plated onto a 24-well plate. Cells 
were steroid deprived by culturing in phenol-red-free media containing 10% dextran-coated 
charcoal treated serum and 1 µg/ml insulin, for 5 days and then cultured in withdrawal medium 
alone (utr) or treated with either 10-7 M or 5x10-6 M tamoxifen (TAM), 10-8 M 4-hydroxytamoxifen 
(4OHT), 10-8 M fulvestrant (FUL) and 10-9 M 17β-oestradiol alone for 8 days. Cells were lysed 
and protein extracts were prepared. Protein aliquots of 10 µg were separated by 12% 
polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. The 
membranes were incubated with anti-ENaC-β antibody (dilution 1:100) overnight at 4 oC, 
followed by horseradish peroxidase conjugated horse-anti-mouse secondary antibody for 1 hour 
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at 37 oC. Proteins were visualised by enhanced chemiluminescence with SuperSignal West 
Dura Extended Duration Substrate. A, B, C. The protein expression of ENaC-β in MCF-7, EFM-
19 and EFF-3 cells treated with anti-oestrogens, comparing serum withdrawn (-E2 ) samples 
with oestrogen-stimulated (+E2 ) samples. The image shown is representative of an 
experiment which has been replicated three times in MCF-7 and EFM-19 cells and twice in EFF-
3 cells. D, E, F. Quantification of ENaC-β normalised against the corresponding GAPDH signal, 
*p < 0.05 and **p < 0.001 by ANOVA, compared with the untreated (utr) cells. Error bars 
indicate SEM of duplicate measurements.  
 
 
The agonist activity of anti-oestrogens bazedoxifene, toremifene, raloxifene and 
lasofoxifene was tested. 
As shown in Figure 6.11A, there was no difference in ENaC-β expression 
observed between the untreated MCF-7 cells and the cells treated with the 
different anti-oestrogens. However, cells treated with oestradiol showed 
approximately 1.5-fold increase in the expression of ENaC-β protein.  
In EFM-19 cells, the ENaC-β expression was insensitive to bazedoxifene, 
toremifene, raloxifene and lasofoxifene. All four anti-oestrogens alone did not 
show any agonist activity. Oestradiol alone increased the expression of ENaC-β 
protein by about 2-fold. The results obtained in MCF-7 cells were comparable to 
the results in EFM-19 cells. 
The agonist effects of bazedoxifene, toremifene, raloxifene and lasofoxifene on 
ENaC-β protein expression in EFF-3 cells is shown in Figure 6.11C. 
Surprisingly, there was no induction of ENaC-β expression by oestrogen. All 
four anti-oestrogens alone reduced the levels of ENaC-β expression by about 
half of that detected in untreated cells. 
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Figure 6.11 Agonist activity of anti-oestrogens BZA, TOR, RAL, LAS on ENaC-β 
expression. MCF-7, EFM-19 (50,000 per well) and EFF-3 (100,000 per well) cells were plated 
onto a 24-well plate. Cells were steroid deprived by culturing in phenol-red-free media 
containing 10% dextran-coated charcoal treated serum and 1 µg/ml insulin, for 5 days and then 
cultured in withdrawal medium alone (utr) or treated with either 10-7 M Bazedoxifene (BZA), 10-7 
M Toremifene (TOR), 10-7 M Raloxifene (RAL), 10-8 M Lasofoxifene (LAS) and 10-9 M 17β-
oestradiol alone for 8 days. Cells were lysed and protein extracts were prepared. Protein 
aliquots of 10 µg were separated by 12% polyacrylamide gel electrophoresis and then 
transferred to nitrocellulose membranes. The membranes were incubated with anti-ENaC-β 
antibody (dilution 1:100) overnight at 4 oC, followed by horseradish peroxidase conjugated 
horse-anti-mouse secondary antibody for 1 hour at 37 oC. Proteins were visualised by enhanced 
chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A, B, C. The 
protein expression of ENaC-β in MCF-7, EFM-19 and EFF-3 cells treated with anti-oestrogens, 
comparing serum withdrawn (-E2 ) samples with oestrogen-stimulated (+E2 ) samples. The 
image shown is representative of an experiment which has been replicated twice. D, E, F. 
Quantification of ENaC-β normalised against the corresponding GAPDH signal, *p < 0.05 and 
**p < 0.001 by ANOVA, compared with the untreated (utr) cells. Error bars indicate SEM of 
triplicate measurements. 
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6.4.2 Investigation of the antagonist activity of anti-oestrogens on the 
regulation of ENaC-β expression 
 
The antagonist activity of tamoxifen, 4-hydroxytamoxifen and fulvestrant on the 
expression of ENaC-β was evaluated. 
As shown in Figure 6.12A, tamoxifen was a partial antagonist in MCF-7 cells, 
and caused a 3.2-fold reduction in the oestrogen-stimulated ENaC-β protein 
expression. In contrast, 4-hydroxytamoxifen and fulvestrant showed the 
opposite effect of tamoxifen, as they increased ENaC-β expression by 2-fold 
and 1.5-fold, respectively. 4-hydroxytamoxifen and fulvestrant did not inhibit the 
effects of oestrogen, instead they caused an additive effect to that of oestrogen 
alone.      
In EFM-19 cells, oestrogen induced ENaC-β expression. However, the three 
anti-oestrogens tamoxifen, 4-hydroxytamoxifen and fulvestrant in the presence 
of oestrogen, were weak antagonists. 
Results from an experiment investigating the antagonist activity of anti-
oestrogens in EFF-3 cells are shown in Figure 6.12C. All three anti-oestrogens 
were capable of significantly reducing the ENaC-β expression, largely reversing 
the induction by oestradiol.    
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Figure 6.12 Antagonist activity of anti-oestrogens on ENaC-β expression. MCF-7, EFM-19 
(50,000 per well) and EFF-3 (100,000 per well) cells were plated onto a 24-well plate. Cells 
were steroid deprived by culturing in phenol-red-free media containing 10% dextran-coated 
charcoal treated serum and 1 µg/ml insulin, for 5 days and then then cultured in withdrawal 
medium alone (utr) or treated with 10-9 M, 2x10-10 M 17β-oestradiol alone, or 5x10-6 M tamoxifen 
(TAM), 10-8 M 4-hydroxytamoxifen (4OHT), 10-8 M Fulvestrant (FUL) in combination with 2x10-10 
M 17β-oestradiol for 8 days. Cells were lysed and protein extracts were prepared. Protein 
aliquots of 10 µg were separated by 12% polyacrylamide gel electrophoresis and then 
transferred to nitrocellulose membranes. The membranes were incubated with anti-ENaC-β 
antibody (dilution 1:100) overnight at 4 oC, followed by horseradish peroxidase conjugated 
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horse-anti-mouse secondary antibody for 1 hour at 37 oC. Proteins were visualised by enhanced 
chemiluminescence with SuperSignal West Dura Extended Duration Substrate. A, B, C. The 
protein expression of ENaC-β in MCF-7, EFM-19 and EFF-3 cells treated with anti-oestrogens, 
comparing serum withdrawn (-E2 ) samples with oestrogen-stimulated (+E2 ) samples. The 
image shown is representative of an experiment which has been replicated three times in MCF-
7 and EFM-19 cells and twice in EFF-3 cells. D, E, F. Quantification of ENaC-β normalised 
against the corresponding GAPDH signal, *p < 0.05 and **p < 0.001 by ANOVA, compared with 
2x10-10 M oestradiol treated cells. Error bars indicate SEM of duplicate measurements. 
 
 
Figure 6.13 shows the antagonist activity of bazedoxifene, toremifene, 
raloxifene and lasofoxifene in MCF-7, EFM-19 and EFF-3 cells.   
In MCF-7 cells, bazedoxifene and lasofoxifene in the presence of oestradiol 
reduced the expression of ENaC-β to levels almost below that of untreated cells, 
suggesting that they were antagonistic to the effects of oestrogen. In the 
presence of oestrogen, toremifene and raloxifene increased the expression of 
ENaC-β to levels higher than that of oestrogen alone.        
In the presence of oestradiol, toremifene demonstrated a considerable increase 
in ENaC-β expression and did not block the effects of oestrogen in EFM-19 
cells (Figure 6.13B). Nevertheless, bazedoxifene, raloxifene and lasofoxifene 
largely antagonised the effects of oestrogen. Raloxifene was the most 
antagonistic as it decreased the oestrogen-induced ENaC-β expression by 
about 2.5-times that of oestrogen alone.    
In EFF-3 cells, there was no significant difference in ENaC-β expression 
between untreated and oestrogen-treated cells, therefore it was difficult to test 
the antagonistic effects of these anti-oestrogens. This experiment requires 
further validation. 
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Figure 6.13 Antagonist activity of anti-oestrogens BZA, TOR, RAL, LAS on ENaC-β 
expression. MCF-7, EFM-19 (50,000 per well) and EFF-3 (100,000 per well) cells were plated 
onto a 24-well plate. Cells were steroid deprived by culturing in phenol-red-free media 
containing 10% dextran-coated charcoal treated serum and 1 µg/ml insulin, for 5 days and then 
cultured in withdrawal medium alone (utr) or treated with 10-9 M, 2x10-10 M 17β-oestradiol alone, 
or 10-7 M Bazedoxifene (BZA), 10-7 M Toremifene (TOR), 10-7 M Raloxifene (RAL), 10-8 M 
Lasofoxifene (LAS) in combination with 2x10-10 M 17β-oestradiol for 8 days. Cells were lysed 
and protein extracts were prepared. Protein aliquots of 10 µg were separated by 12% 
polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. The 
membranes were incubated with anti-ENaC-β antibody (dilution 1:100) overnight at 4 oC, 
followed by horseradish peroxidase conjugated horse-anti-mouse secondary antibody for 1 hour 
at 37 oC. Proteins were visualised by enhanced chemiluminescence with SuperSignal West 
Dura Extended Duration Substrate. A, B, C. The protein expression of ENaC-β in MCF-7, EFM-
19 and EFF-3 cells treated with anti-oestrogens, comparing serum withdrawn (-E2 ) samples 
with oestrogen-stimulated (+E2 ) samples. The image shown is representative of an 
experiment which has been replicated twice. D, E, F. Quantification of ENaC-β normalised 
against the corresponding GAPDH signal, *p < 0.05 and **p < 0.001 by ANOVA, compared with 
2x10-10 M oestradiol treated cells. Error bars indicate SEM of triplicate measurements.  
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6.5 Discussion 
The effects of seven anti-oestrogens on the expression levels of the proteins 
NKCC1, NHERF3 and ENaC-β was studied. These proteins are encoded by the 
oestrogen-regulated genes SLC12A2, PDZK1 and SCNN1B, respectively. The 
agonist activity of the anti-oestrogens tamoxifen, 4-hydroxytamoxifen, 
fulvestrant, bazedoxifene, toremifene, raloxifene and lasofoxifene were tested in 
the absence of oestrogen. The antagonistic properties of the different anti-
oestrogens were investigated in the presence of 17β-oestradiol.     
6.5.1 Effect of anti-oestrogens on NKCC1 expression 
The anti-oestrogens tamoxifen, 4-hydroxytamoxifen, fulvestrant, toremifene, 
raloxifene and lasofoxifene in the absence of oestradiol did not exert any 
oestrogen-like agonistic effects on the expression of NKCC1 protein in any of 
the cell lines. Bazedoxifene on its own displayed very weak agonism in EFM-19 
cells only. In MCF-7 and EFF-3 cells, bazedoxifene alone showed no agonism. 
In the presence of oestrogen, tamoxifen completely reversed the negative effect 
of oestrogen on NKCC1 expression in MCF-7 and EFF-3 cells, but not in EFM-
19 cells. 4-hydroxytamoxifen acted as a partial antagonist of oestrogen in all 
three cell lines. The fully antagonistic activity of tamoxifen and the partial 
antagonistic activity of fulvestrant in MCF-7 cells are interesting as generally 
tamoxifen and fulvestrant are known to be partially and fully anti-oestrogenic, 
respectively. Bazedoxifene, raloxifene and lasofoxifene antagonised fully the 
effect of oestrogen in all three cell lines. The structurally similar anti-oestrogens 
bazedoxifene and raloxifene behaved in a similar manner; they both inhibited 
the reduction of NKCC1 expression by oestrogen. The inhibition of the effect of 
oestrogen on the protein expression of NKCC1 by the anti-oestrogen toremifene 
varied between cell lines. In MCF-7 and EFM-19 cells, partial inhibition was 
detected, whereas in EFF-3 cells there was complete inhibition. These results 
indicated that, although tamoxifen, 4-hydroxytamoxifen and toremifene are 
similar in structure, their functional ability to block the effects of oestrogen on 
NKCC1 expression is dissimilar.    
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6.5.2 Effect of anti-oestrogens on NHERF3 expression 
Tamoxifen alone at 10-7 M showed no agonism in MCF-7 and EFM-19 cells, but 
was a weak agonist for the expression of NHERF3 protein in EFF-3 cells. 
However, tamoxifen at a higher concentration of 5x10-6 M, was a weak agonist 
in MCF-7 cells but not in EFM-19 cells. In MCF-7 and EFM-19 cells, the 
tamoxifen derivative, 4-hydroxytamoxifen, did not have any oestrogen-like 
activity on the expression of NHERF3, with the exception of EFF-3 cells, where 
it showed partial agonist activity by inducing NHERF3 expression to levels 
higher than those of tamoxifen alone. The pure anti-oestrogen fulvestrant and 
two anti-oestrogens bazedoxifene and raloxifene showed no agonism in all 
three cell lines. Data from the current study are consistent with those of Englert 
et al. (2011) who showed that PDKZ1 mRNA expression in MCF-7 cells is not 
increased by treatment with raloxifene. However, in long-term oestrogen 
exposed (LTEE) MCF-7 cells, PDZK1 expression was increased by 7.8-fold and 
this induction was also shown to be abolished by exposure to raloxifene 
(Englert et al., 2011). As observed in this chapter, similarities in the effects of 
bazedoxifene and raloxifene on the expression of NHERF3 protein could 
possibly be explained by their structural and functional similarities. In contrast, 
toremifene and lasofoxifene exerted a weak agonistic activity on NHERF3 
expression in MCF-7 cells, but not in the other two cell lines EFM-19 and EFF-3. 
Both tamoxifen and 4-hydroxytamoxifen inhibited completely the oestrogen-
induced NHERF3 expression in EFM-19 cells, whereas in MCF-7 cells they only 
partially blocked the effects of oestrogen. Similar results have been reported 
previously in MCF-7 cells by Ghosh et al. (2000) who indicated by northern 
transfer analysis that tamoxifen inhibited the oestradiol-induced expression of 
PDZK1. However, in the present study, these two anti-oestrogens tamoxifen 
and 4-hydroxytamoxifen were unable to oppose the effects of oestrogen on the 
protein expression of NHERF3 in EFF-3 cells. Complete antagonism against the 
oestrogen-induced NHERF3 expression was achieved by fulvestrant, 
bazedoxifene and raloxifene. Although lasofoxifene completely inhibited the 
effects of oestrogen on NHERF3 expression in both MCF-7 and EFM-19 cells, it 
did not block the oestrogenic effects in EFF-3 cells. Toremifene has a 
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pharmacological profile similar to that of tamoxifen and has been shown to 
inhibit growth and proliferation of breast cancer cells (Robinson and Jordan, 
1989; Grenman et al., 1991).  In the current study, the oestrogen antagonist 
property of toremifene varied between the three cell lines. In MCF-7 cells, it was 
weakly antagonistic, whereas in EFM-19 and EFF-3 cells toremifene increased 
the expression of NHERF3 above the level induced by oestrogen alone. The 
mechanism by which this effect occurs is not understood well, but studies have 
suggested the possible existence of oestrogen receptor heteroligand dimer 
complexes, in which oestradiol can bind to one ER monomer of the dimer 
subunit whilst the anti-oestrogen binds to the other monomer (Liu et al., 2013). 
Therefore it is likely that in EFM-19 and EFF-3 cells, dimer complexes that 
contain both oestradiol and toremifene could cooperatively enhance the 
expression of NHERF3.  
6.5.3 Effect of anti-oestrogens on ENaC-β expression 
The effects of the different anti-oestrogens on the expression of ENaC-β were 
variable between the three cell lines as shown in section 6.4 of this chapter. 
Tamoxifen at a concentration of 10-7 M and 5x10-6 M did not show any agonist 
behaviour in MCF-7 and EFF-3 cells. However, 10-7 M tamoxifen in EFM-19 
cells showed oestrogen-like effects. Both 4-hydroxytamoxifen and fulvestrant 
were full agonists in MCF-7 cells, but not in EFM-19 and EFF-3 cells. In MCF-7 
and EFM-19 cells, none of the anti-oestrogens bazedoxifene, toremifene, 
raloxifene and lasofoxifene had any oestrogen-like activity on ENaC-β 
expression. The levels of ENaC-β expression were less affected by the anti-
oestrogens. Conversely, the treatment of EFF-3 cells with these four anti-
oestrogens alone resulted in a significant decline in ENaC-β protein expression 
in comparison to the untreated cells. The results for tamoxifen and its active 
metabolite 4-hydroxytamoxifen are inconsistent. The mechanism of action is 
similar in both tamoxifen and 4-hydroxytamoxifen (Coezy et al., 1982; DeFriend 
et al., 1994a; Kiyotani et al., 2012) therefore it is not clear why 4-
hydroxytamoxifen induced the expression of ENaC-β whereas tamoxifen did not. 
The agonist activity of fulvestrant in MCF-7 cells is surprising, as it is considered 
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to be a pure anti-oestrogen. Agonist activity of fulvestrant has been reported in 
oestrogen-responsive breast cancer cells. Hutcheson et al. (2011) and Morrison 
et al. (2013) demonstrated that fulvestrant induces protein expression of 
members of the epidermal growth factor receptor (EGFR) family, ErbB3 and 
ErbB4. Hutcheson et al. (2011) showed that despite cell growth inhibition by 
fulvestrant, it stimulated expression of proteins involved in cell proliferation and 
survival, through posttranslational modifications hence allowing tumour cells to 
develop resistance.  
When the antagonistic properties of tamoxifen was tested, results indicated that 
it was partially anti-oestrogenic in MCF-7 and EFF-3 cells and very weakly 
antagonistic in EFM-19 cells. The induction of ENaC-β protein expression by 
both 4-hydroxytamoxifen and fulvestrant was greater than that of oestradiol 
alone in MCF-7 cells only. In EFM-19 cells, 4-hydroxytamoxifen and fulvestrant 
were very weak antagonists, whilst in EFF-3 cells they effectively inhibited the 
oestrogen-induced ENaC-β expression. Bazedoxifene and lasofoxifene were 
antagonistic to the effects of oestrogen in both MCF-7 and EFM-19 cells, 
whereas raloxifene increased ENaC-β expression to levels higher than that of 
oestrogen in MCF-7 cells only. The level of induction of the expression of 
ENaC-β by toremifene was considerably higher than oestrogen alone in EFM-
19 cells.        
6.6 Conclusion 
The oestrogenicity of the anti-oestrogens for the repression of NKCC1 or 
induction of NHERF3 and ENaC-β were specific for each protein and were 
variable between the three cell lines. Notably, the antagonistic effects of 
toremifene for NHERF3 and ENaC-β expression were somewhat similar, as it 
induced protein expression to higher levels than oestradiol alone. Tamoxifen, 
bazedoxifene, raloxifene and lasofoxifene completely inhibited the effects of 
oestrogen on NKCC1 expression.  
This chapter has shown successfully the complexity of the differential effects 
anti-oestrogens might have on various genes regulated by oestrogen. These 
results could potentially be translated into the clinics because such valuable 
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biomarkers might provide means for predicting or monitoring a patient’s 
response to endocrine therapy. It will be important to take into consideration the 
agonist activity of anti-oestrogens which might cause a limitation in their 
inhibitory anti-oestrogenic role and potentially lead to development of resistance 
or enhanced tumour progression.     
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Chapter 7.    General Discussion 
7.1 Discussion and Future work 
Breast cancer is currently the most commonly diagnosed cancer in the UK and 
has the second highest incidence throughout the world. Despite early detection 
screening and advances in treatment procedures, a large proportion of women 
die from breast cancer every year. In the UK, the number of deaths caused by 
breast cancer in females is second only to lung cancer. Therefore there is a 
necessity to identify prognostic biomarkers which may aid in an effective 
diagnosis. Also it would be clinically beneficial to patients because such 
predictive biomarkers would enable accurate forecasting of the response to 
individual therapies. Additionally potential therapeutic targets could be identified 
in order to maximise the rate of response as well as to overcome the problems 
associated with resistance to drugs.          
During recent years, ion transporters have been implicated in many 
characteristic features of cancer pathogenesis such as uncontrolled growth, 
migration, invasion and metastasis (Kunzelmann, 2005; Prevarskaya et al., 
2010; Li and Xiong, 2011). Therefore ion transporters are being identified as 
possible additional targets for combined therapies in cancer. Oestrogen is well 
known to play a major role in the progression and development of breast cancer. 
Previously, numerous genes that are regulated by oestrogen have been 
identified by our group (Westley and May, 2006; Wright et al., 2009). The 
recognition of genes involved in exocytosis and vesicle transport thought to be 
associated with breast tumorigenesis, has led to the discovery of new avenues 
for further investigation. Understanding the role of oestrogen in altering the 
secretory phenotype and mediating polarised ion transport is of vital importance. 
Out of the many genes identified, the roles of three oestrogen-regulated genes 
SLC12A2, PDZK1 and SCNN1B were studied in detail in this study. The 
regulation of the genes SLC12A2 and SCNN1B by oestrogen was novel, 
whereas PDZK1 was previously recognised as an oestrogen-regulated gene in 
breast cancer cells.  
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The expression of the proteins NKCC1, NHERF3 and ENaC-β which are 
encoded by the genes SLC12A2, PDZK1 and SCNN1B were measured. The 
expression of these proteins was investigated initially in a panel of oestrogen-
responsive and oestrogen-unresponsive breast cancer cell lines. The 
expression of NKCC1 varied between cell lines and the highest expression was 
in the oestrogen-responsive ZR-75 cells and the oestrogen-unresponsive in 
Hs578T cells. All other cell lines investigated, with the exception of SKBR3, BT-
20 and T47-D, expressed moderate amounts of NKCC1 protein. The total 
protein expression of NHERF3 was highest in ZR-75 cells, but MCF-7, EFM-19 
and T47-D cells also expressed NHERF3. It is important to note that there was 
no expression of NHERF3 in any of the oestrogen-unresponsive cell lines. 
Similar to NKCC1, some oestrogen-responsive and some oestrogen-
unresponsive cell lines expressed ENaC-β protein. Out of the oestrogen-
responsive cell lines, EFF-3 cells expressed highest levels of ENaC-β followed 
by BT-474, EFM-19 and MCF-7 cells. In the oestrogen-unresponsive cell lines, 
SKBR3, MDA-MB-231 and Hs578T cells expressed ENaC-β protein. The 
regulation of these proteins by oestradiol in three oestrogen-responsive breast 
cancer cell lines MCF-7, EFM-19 and EFF-3 was studied. Results obtained 
were consistent with the gene expression analysis, as NKCC1 expression was 
shown to decrease in response to oestradiol, whereas the expression of the 
proteins NHERF3 and ENaC-β were increased when stimulated with oestradiol. 
Furthermore, investigations showed that the regulation of these proteins by 
oestradiol was concentration dependent. The cellular localisation of these 
proteins was also evaluated by immunofluorescence and evidence showed that 
NKCC1 was clearly expressed in the cell membranes, whereas NHERF3 and 
ENaC-β were detected mainly in the cytoplasm. Investigation of the effects of 
oestrogen on the protein expression of NKCC1 showed a marked decrease 
whilst the expression of NHERF3 increased. These immunofluorescence results 
were consistent with the results from western transfer analysis. There was no 
expression of ENaC-β at the cell membrane therefore we were not so confident 
about the reliability of this immunofluorescent detection of ENaC-β. Future 
immunofluorescence experiments could include testing different commercially 
available antibodies against ENaC-β to identify its localisation within the cell. It 
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will be interesting to investigate any possible relocation of ENaC-β to the cell 
membrane through vesicular transport and also to explore and evaluate any 
changes in expression or localisation of ENaC-β in response to oestrogen 
stimulation.  
NKCC1 and ENaC-β protein was expressed in oestrogen-unresponsive cell 
lines which lack the oestrogen receptor. Therefore it would be desirable to 
extend a similar study to other breast cancer cell lines, particularly the 
oestrogen-unresponsive cell lines, in order to determine whether there are any 
additional mechanisms of regulation of genes and their proteins such as 
NKCC1 and ENaC-β other than through the oestrogen receptor. The regulation 
of NHERF3 expression by oestrogen in ZR-75 cells could also be explored, 
because ZR-75 expressed high amounts of NHERF3 protein. 
The functional activity of NKCC1 was assessed in the current study. 
Experiments with the 86Rb (K+) influx assay revealed lower activity of NKCC1 in 
comparison to Na+/K+ ATPase in both MCF-7 and EFM-19 cells cultured in full 
medium as the ouabain-sensitive influx was much greater than the loop-diuretic 
sensitive influx. Future work could include investigation of the expression and 
oestrogen regulation of Na+/K+ ATPase in the three breast cancer cell lines. In 
the present study, further experimentation in MCF-7 and EFM-19 cells grown in 
full media confirmed that NKCC1 is activated in response to cell shrinkage as 
induced by hypertonic mannitol and that NKCC1 is involved in the regulation of 
cell volume (Russell, 2000; Hebert et al., 2004). Although the effect of 
oestrogen on NKCC1 protein expression clearly demonstrated a significant 
decrease, the results from the influx assay do not show such a dramatic 
reduction on the functional activity of NKCC1. We also determined that NKCC1 
was activated in response to hypertonic stimulation by mannitol in both steroid 
withdrawn and in oestrogen stimulated cells. However, EFM-19 cells were 
significantly more responsive than MCF-7 cells, to both the effect of 
hypertonicity and also to the effect of oestrogen. This variability in the effects 
between the two cell lines is not understood and requires further clarification. 
Moreover, it would be useful to explore and compare the functional roles of 
NKCC1 present in cells that are treated with anti-oestrogens in the absence and 
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presence of oestrogen, to determine if the functional activity corresponds with 
the changes in expression induced by the anti-oestrogens shown in the current 
study. 
In the present study, the intracellular pH of breast cancer cells was measured 
as means of investigating the activity of Na+/H+ exchangers, whose organisation 
and anchorage at the surface of the plasma membrane is determined by the 
oestrogen-regulated NHERF3. Results showed that MCF-7 and EFM-19 cells 
are subject to pHi perturbations when exposed to highly acidic external pH. 
Since the inverse Na+ ion gradient is higher than the gradient of H+ ions, the 
Na+/H+ exchangers are unable to pump H+ ions out, therefore the pHi is not 
maintained at physiological values when the external pH is 6.0. The oestrogen-
stimulated EFM-19 cells were shown to have an increased buffering capacity in 
comparison to the unstimulated cells, as the pHi increased in response to 
oestrogen. This increase in buffering capacity coincides with the increase in 
NHERF3 protein. We have shown evidence for activation of Na+/H+ exchangers 
by the induction of hypertonicity with mannitol in both these breast cancer cell 
lines grown in full media. The effect of hypertonicity on untreated and 
oestrogen-treated cells was not consistent with the results from cells cultured in 
full media. At an external pH 6.0, the untreated MCF-7 and EFM-19 cells were 
unable to maintain pHi under hypertonic conditions, which was even worsened 
in oestrogen-stimulated MCF-7 cells. However, oestrogen-treated EFM-19 cells 
show increased capacity to regulate pHi. The ability of breast cancer cells to 
recover a physiological internal pH following an acidic pulse with the addition of 
NH4Cl was explored. At external pH 7.4, the removal of NH4Cl causes cytosolic 
acidification which then recovers slowly by the activity of Na+/H+ exchangers, 
but in an external pH 6.0, cells do not have the capacity to aid in recovering pHi. 
Another study in MCF-7 cells has investigated the involvement of NHE1 in the 
recovery of pHi in response to an acid pulse (Friday et al., 2007). We 
hypothesised that, in comparison to the untreated cells, oestrogen-stimulated 
cells would have an enhancement in their rate of recovery by Na+/H+ exchange 
because NHERF3 protein expression is increased in cells treated with 
oestrogen. Nevertheless, current data showed no such enhancement in the pHi 
regulatory capacity in oestrogen-treated MCF-7 and EFM-19 cells. To the best 
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of our knowledge this is the first study to demonstrate pHi regulation in EFM-19 
cells. Future experimentation could potentially involve siRNA knockdown of 
PDZK1 in breast cancer cell lines which would enable understanding of the role 
played by NHERF3 in modulating the linkage and regulation of Na+/H+ 
exchangers associated with pHi regulation. This study could be extended to 
measure the protein expression and the oestrogen-regulation of the different 
Na+/H+ exchangers in MCF-7, EFM-19 and EFF-3 breast cancer cells. The data 
obtained from the present study encourage further experimentation with the 
BCECF-AM assay, as it would be beneficial to include inhibitors of Na+/H+ 
exchangers such as ethyl-isopropyl-amiloride (EIPA) to evaluate the effects of 
oestrogen in mediating ion transport through upregulation of PDZK1.  
The effects of anti-oestrogens on the expression of NKCC1, NHERF3 and 
ENaC-β protein was evaluated. It was evident that the agonistic and 
antagonistic effects of different anti-oestrogens on each of the three proteins 
were complex and there was variability between cell lines. Overall, none of the 
anti-oestrogens displayed oestrogen-like activity towards the expression of 
NKCC1, apart from bazedoxifene in EFM-19 cells. Tamoxifen, 4-
hydroxytamoxifen, toremifene and lasofoxifene were partially agonistic to 
varying degrees for the expression of NHERF3 protein in MCF-7 and EFF-3 
cells. The agonist effect of fulvestrant on increased expression of ENaC-β in 
MCF-7 cells was particularly surprising because this pure anti-oestrogen is a 
selective downregulator of the oestrogen receptor. In the three cell lines, all 
anti-oestrogens either partially or completely antagonised the effects of 
oestrogen for the expression of NKCC1 protein. The effect of oestrogen on the 
expression of NHERF3 was also reversed partially or completely by most of the 
anti-oestrogens, excluding toremifene in EFM-19 cells. In EFF-3 cells treated 
with tamoxifen, 4-hydroxytamoxifen, toremifene and lasofoxifene in the 
presence of oestrogen, no inhibition of the effect of oestrogen was observed. 
The antagonistic properties of the anti-oestrogens for the expression of ENaC-β 
were very variable between cell lines. In MCF-7 cells, 4-hydroxytamoxifen, 
fulvestrant, toremifene and raloxifene were unable to block the effects of 
oestrogen, whereas in EFM-19 cells toremifene was unable to inhibit the 
increased expression induced by oestrogen. The oestrogen-induced protein 
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expression of ENaC-β was almost completely inhibited by tamoxifen, 4-
hydroxytamoxifen and fulvestrant in the EFF-3 cell line.  
Differences in response of genes to anti-oestrogens could perhaps be 
accounted for by differences in genetic mutations between the cell lines. 
Analysis from the Catalogue Of Somatic Mutations In Cancer database, 
highlighted mutations in PIK3CA in both MCF-7 and EFM-19 cell lines 
(COSMIC). The mutation in PIK3CA in MCF-7 cells is a heterozygous, 
missense substitution, whereas in EFM-19 cells it is a homozygous missense 
substitution. It has been reported that oestradiol blocks apoptosis and promotes 
survival through activation of the PI3K and MAPK pathways (Fernando and 
Wimalasena, 2004). Activation of the PI3K/AKT pathway and the MAPK/ERK 
pathway have been reported to contribute to the development of resistance to 
endocrine therapy (Zhang et al., 2011). In collecting duct cells, the regulation of 
ENaC activity by hormones such as oestrogen, aldosterone and insulin is 
mediated via a PI3K dependent mechanism which includes phosphorylation of 
SGK1 (Wang et al., 2008; Baines, 2013). Moreover, in cortical collecting duct 
cells, the inhibition of PI3K by LY294002, prevented transepithelial transport of 
Na+ ions that was previously induced by aldosterone (Zhou et al., 2014). The 
phosphorylation of NKCC1 is suggested to be mediated via a PI3K-dependant 
mechanism, which in turn leads to an enhancement in migration of glioma cells 
(Garzon-Muvdi et al., 2012). In addition to PIK3CA, the transcription factor 
GATA3 is mutated in MCF-7 cells only (Usary et al., 2004). This is an insertional 
frameshift mutation at amino acid position D336, resulting from an insertion of a 
guanine nucleotide. The FGFR2 and TP53 genes are mutated in EFM-19 cells. 
The gene FGFR2 identified previously by genome wide association studies is 
associated with breast cancer risk (Easton et al., 2007). The mutations 
identified are unlikely to account for the differential responses of the cells to 
anti-oestrogens. 
In order to determine the clinical relevance of the three genes, I evaluated the 
supplementary data from a number of published studies that explored agonist 
and antagonist effects of anti-oestrogens and aromatase inhibitors on the 
expression of oestrogen regulated genes. The gene PDZK1 whose expression 
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is known to be increased by oestrogen has been shown previously to be 
decreased by treatment of MCF-7 cells with 1 µM of the anti-oestrogens, 
fulvestrant and raloxifene (Frasor et al., 2004). In two clinical studies, in which 
breast tumours were isolated from postmenopausal women who had previously 
been treated for 14 days with the aromatase inhibitors; anastrozole and 
letrozole, the expression of PDZK1 was consistently downregulated in response 
to treatment (Mackay et al., 2007; Miller et al., 2007). The other two genes 
SLC12A2 and SCNN1B were not detected in any of these clinical studies. 
Furthermore, future directions including immunohistochemical studies would 
provide valuable analysis of the expression and localisation of the proteins 
NKCC1, NHERF3 and ENaC-β in breast tumours isolated from patients. 
Investigations could be extended to evaluate expression of the three proteins in 
xenograft models and patient derived breast cancer samples that retain 
characteristics of the original tumour. Such models would enable greater 
understanding of clinically-relevant prognostic and predictive information for the 
potential development of personalised therapeutic strategies. The generation of 
3D spheroids and organoids may provide a close resemblance to the 
physiology of cancer cells in vivo. These 3D cultures can form well-organised 
epithelial structures, complete with cell polarity and formation of tight junctions.     
The role of oestrogen in altering the expression and activity of proteins involved 
in ion transport was confirmed. Modification of this cell phenotype may favour 
breast cancer progression. The results from this study, particularly NKCC1 and 
NHERF3 will be of great benefit in terms of identifying suitable treatment 
conditions and to forecast disease progression.       
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Abbreviations  
µM Micro molar 
µm Micro metre 
17β-HSD1 17β-hydroxysteroid dehydrogenase type 1 
4OHT 4-hydroxytamoxifen 
ADP  Adenosine diphosphate  
AF-1 Activation function domain 1 
AF-2 Activation function domain 2 
AFF2 AF4/FMR2 family member 2 
ANKLE1 Ankyrin repeat and LEM domain containing 1 
ANOVA  Analysis of variance  
APS  Ammonium Persulphate  
ATCC  American Type Culture Collection  
ATM Ataxia-telangiectasia mutated  
BABAM1 BRISC and BRCA1 A complex member 1 
BCA  Bicinchoninic Acid  
BCECF-AM 2',7'-bis-(2-carboxyethyl)-5-(and-6)-
carboxyfluorescein acetoxymethyl ester 
bp  base pair  
BRCA (1, 2)  Breast Cancer Associated (susceptibility gene 
1 and 2)  
BSA  Bovine Serum Albumin  
BZA Bazedoxifene 
CaCl2 Calcium chloride 
cAMP Cyclic adenosine monophosphate 
CASC16 Cancer susceptibility candidate 16 
CASC21 Cancer susceptibility candidate 21 
CASC8 Cancer susceptibility candidate 8  
CCND1 Cyclin D1 
CCND3 Cyclin D3 
CDK4 Cyclin-dependent kinase 4 
CDK6 Cyclin-dependent kinase 6 
cDNA  Complementary deoxyribonucleic acid  
CFTR Chloride transport receptor 
CNA Copy number aberrations 
COMT Catechol-o-methyltransferase 
COSMIC Catalogue of somatic mutations in cancer 
CPM Counts per minute 
CRUK  Cancer Research United Kingdom  
Cu+ Cuprous ion 
Cu2+ Cupric ion 
CYP2C19 Cytochrome P450, family 2, subfamily C, 
polypeptide 19  
DAPI  4',6-diamidino-2-phenylindole  
DBD  DNA Binding Domain 
DCC-CS  Dextran-Coated Charcoal-treated Calf Serum 
DCIS  Ductal Carcinoma In Situ  
DMEM  Dulbecco's modified eagles medium  
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DMSO  Di-Methyl Sulphoxide  
DNA  Deoxyribo Nucleic Acid  
DNA-PK DNA-Protein Kinase 
E1 oestrone 
E2 oestradiol 
E3 oestriol 
EDTA  Ethylene Diamine Tetra Acetic Acid  
EGF  Epidermal Growth Factor  
EGFR  Epidermal Growth Factor Receptor  
EIPA ethyl-isopropyl-amiloride 
ELISA  Enzyme Linked Immunosorbant Assay  
EMSY EMSY, BRCA2-interacting transcriptional 
repressor  
ENaC Epithelial sodium channel 
ENaC-α Epithelial sodium channel alpha subunit 
ENaC-β Epithelial sodium channel beta subunit 
ENaC-γ Epithelial sodium channel gamma subunit 
ENaC-δ Epithelial sodium channel delta subunit 
ERE  Oestrogen Response Elements 
ERs Oestrogen Receptors 
ERα  Oestrogen receptor alpha 
ERβ  Oestrogen receptor beta 
FACS  Flow activated cell sorting  
FAK Focal adhesion kinase  
FBS  Foetal Bovine Serum  
FDA   Food and Drug Administration 
FGFR2 Fibroblast growth factor receptor 2 
Fig.  Figure  
FISH  Fluorescent in situ hybridisation  
FTO Fat mass and obesity associated 
FUL Fulvestrant 
G1/S Gap 1 / Synthesis 
GAPDH  Glyceraldehyde 3-Phosphate Dehydrogenase 
GATA3 GATA binding protein 3 
GWAS Genome wide association studies 
HCl  Hydrochloric acid  
HEPES N-2  hydroxyethylpiperazine-N’-2-ethanesulfonic 
acid 
HER2  Human Epidermal Growth Factor Receptor 2  
HRP  Horse Radish Peroxidase 
IDC  Invasive Ductal Carcinoma  
IGF-1  Insulin-like Growth Factor 1 
IGF-IR  Type I IGF receptor 
IHC  Immunohistochemistry  
ILC  Invasive Lobular Carcinoma  
IntClust Integrative Cluster 
IP3 Inositol-1,4,5 triphosphate 
IR Insulin receptor 
K2HPO4 Dipotassium hydrogen orthophosphate 
Kb  Kilobase  
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KCl Potassium chloride 
kDa  KiloDalton  
KH2PO4 Potassium dihydrogen phosphate 
KHH Krebs’ Henseleit HEPES-buffered solution 
LAS Lasofoxifene 
LBD  Ligand Binding Domain 
LCIS  Lobular Carcinoma In Situ  
LGR6 Leucine-rich repeat containing G-protein 
coupled receptor 6 
LSP1 Lymphocyte specific protein 1 
M Molar 
mA  Milliamps  
MAP17 Membrane-associated protein 17 
MAP2K4 Mitogen activated protein kinase kinase 4 
MAP3K1 Mitogen activated protein kinase kinase 
kinase 1 
MAPK  Mitogen Activated Protein Kinase 
Mb  Megabase  
MDM4 Mouse Double Minute 4, p53 regulator 
MEK Mitogen activated protein kinase kinase 
MES hydrate 2-(N-morpholino)ethanesulfonic hydrate 
MgCl2 Magnesium chloride 
MgSO4 Magnesium sulphate 
mM Milli molar 
mm Milli metre 
mRNA  Messenger RNA  
mTOR Mammalian target of rapamycin 
NaCl Sodium chloride 
NaH2PO4 Sodium dihydrogen phosphate 
NCS  New-born Calf Serum 
NF1 Neurofibromin 1 
NHE Sodium hydrogen exchanger   
NHERF Sodium hydrogen exchange regulatory co-
factor 
NKCC1 Sodium potassium chloride co-transporter 1 
NKCC2 Sodium potassium chloride co-transporter 2 
nM Nano molar 
NP-40  Nonylphenoxy Polyethoxy Ethanol  
NRIP1 Nuclear receptor interacting protein 1 
NTD N-terminal domain 
OH  Hydroxyl  
OSR1 Oxidative stress-responsive kinase 1 
PBS  Phosphate Buffered Saline  
PCR  Polymerase Chain Reaction  
PDVF  Polyvinylidene Difluoride  
pHi Intracellular pH 
PI  Propidium iodide  
PI3K  Phosphatidyl Inositol 3-Kinase related 
Kinases 
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-
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kinase catalytic subunit alpha 
PMSF  Phenylemethoxysulphonyl Fluoride  
PO4 Phosphate 
PR  Progesterone receptor  
PRF  Phenol red free  
PTEN  Phosphatase and Tensin homologue  
PTFE polytetrafluoroethylene 
PTHLH Parathyroid hormone-like hormone 
PTPN22 Protein tyrosine phosphatase non-receptor 
type 22 
qRT PCR  Quantitative Real Time Reverse Transcription 
Polymerase Chain Reaction 
RAL Raloxifene 
RALY RALY heterogeneous nuclear 
ribonucleoprotein 
RIPA  Radioimmunoprecipitation assay  
RNA  Ribo Nucleic Acid  
RPM  Revolutions per minute  
RUNX1 Runt-related transcription factor 1 
SDS  Sodium Dodecyl Sulphate  
SDW  Sterile Distilled Water 
SEM  Standard error of the mean  
SERD Selective oestrogen receptor downregulator 
SERM Selective oestrogen receptor modulator 
SGK Serum glucocorticoid kinase 
SHC Src homology domain containing protein 
siRNA  Small interfering RNA 
SLC Solute carrier family 
SNP Single nucleotide polymorphisms 
SPAK SPS1-related proline/alanine-rich kinase 
TAM Tamoxifen 
TBS  Tris-Buffered Saline  
TBST  Tris-Buffered Saline/Tween 20  
TBX3 T-box 3  
TCGA The cancer genome atlas 
TE  Tris-HCl EDTA 
TEMED  Tetramethylethylenediamine  
TERT Telomerase reverse transcriptase 
TM Transmembrane 
TNF  Tumour Necrosis Factor 
TNM  Tumour, node, metastasis 
TNRC9 Trinucleotide repeat containing 9 
TOR Toremifene 
TP53 Tumour protein 53 gene  
UV  Ultra-violet  
UV-light  Ultra Violet Light  
v/v  volume / volume  
VEGF  Vascular Endothelial Growth Factor  
w/v  weight / volume  
w/w  weight / weight  
188 
 
WHO  World Health Organisation  
WNK With no lysine kinase 
x g  Gravity  
γ-ray Gamma-Ray 
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